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Abstract 
In this thesis, the beneficial effect of ultrasound (US) energy is utilized for 
accelerating thrombolysis efficacy through non-thermal mechanisms. The outcome of the 
research, can be applied in the future for clinical use, providing alternative techniques 
(either noninvasive or invasive), for treating ischaemic stroke under MR guidance. 
To study the effect of US on thrombolysis efficacy, three different in vitro 
circulating flow clot models were developed. Fully retracted porcine blood clots were 
treated with US waves as an adjunct to thrombolytic drug tenecteplase (TNK-tPA), in the 
presence or absence of microbubbles (MBs). Each one of the flow clot models used, was 
designed to reproduce a different physiologic situation of middle cerebral artery (MCA) 
occlusion, since it is the most common cause of stroke. In all the proposed treatment 
protocols, temperature elevation at beam focus never exceeded 1 0C, providing that the 
contribution of thermal mechanisms to clot lysis was negligible. 
The first model, was reproducing a deep-seated MCA occlusion in a brain tissue. 
To provide a more realistic clinical environment, the study was conducted into a brain 
tissue mimicking phantom. Flow rate was set to 20 % of the maximum value occur in an 
open MCA and TNK-tPA dose was not exceeding the 30 % of the average maximum 
concentration in blood. Using 1.18 MHz focused US (FUS) waves, various experimental 
parameters that influence thrombolysis efficacy, were optimized.  Maximum 
thrombolysis efficacy was observed when FUS pulses were used as an adjunct to 
thrombolytic drug in the presence of MBs. With this technique, 370 mg of clot mass was 
removed in 30 min, which may not be enough to achieve significant clinical benefits. 
However, further improvement was done (increase of flow rate and TNK-tPA 
concentration), to enhance thrombolysis efficacy. 
The second model, was reproducing a MCA occlusion occurred superficially.  
Flow rate was increased four times and TNK-tPA concentration was doubled. The 
optimum operating mode parameters obtained before, were employed in this study in 
order to investigate the impact of frequency and acoustic intensity on thrombolysis 
efficacy. Study findings established that higher FUS frequencies (1.18 MHz), are 
associated with enhanced thrombolysis compared to lower frequencies (0.6 MHz). Also, 
a linear increasing dependence between acoustic intensity and thrombolysis efficacy was 
observed. After 30 min of treatment with 1.18 MHz FUS exposures in synergy with TNK-
tPA and MBs, 1050 mg of clot mass was removed, which should be sufficient for timely 
recanalization of an occluded cerebral artery. 
The third model, was reproducing a MCA occlusion, treated invasively with a 
catheter-directed US device. The efficacy of two small planar ultrasonic transducers 
(operating at frequencies 3.7 and 5.2 MHz respectively), on clot lysis was evaluated. The 
values of flow rate and TNK-tPA concentration were kept the same with those used in 
the previous study. Using 3.7 MHz US waves in association with TNK-tPA and MBs for 
30 min, 700 mg of clot mass was removed, showing that potentially, intravascular 
sonothrombolysis with such a transducer can be an effective method for treating stroke.  
Finally, the knowledge gained in vitro for enhancing TNK-tPA induced 
thrombolysis, was translated in vivo using an animal model. A blood clot was artificially 
formed into the right carotid artery of a rabbit, mimicking a MCA occlusion in humans. 
The complete flow blockage as well as the recanalization procedure were monitored using 
a 3D time of flight MR angiography. This novel technique, clearly demonstrated that the 
combination of 1.18 MHz FUS pulses with MBs, strongly accelerated the action of TNK-
tPA, leading through non-thermal mechanisms to full artery recanalization within 19 min. 
Keywords: ultrasound, stroke, clot, TNK-tPA, MBs, agar, intravascular, MRgFUS.
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 Introduction   
 Stroke 
Stroke is an important public health concern, since is one of the most frequent 
cause of mortality, morbidity and disability of population in developed countries [1-2]. 
According to World Health Organization (WHO), stroke is the number two cause of death 
worldwide after heart disease [3]. It is estimated, that 15 million people suffer from stroke 
worldwide each year [4] and of these, nearly six million die and another 5 million are left 
permanently disabled [5]. In 2012, stroke killed 6.7 million people out of an estimated of 
56 million deaths worldwide, making it roughly responsible for one-ninth of all global 
deaths [6]. Stroke is the leading cause of long-term disability in adults causing a 
tremendous burden on the healthcare system of each country, as it is associated with 
expensive long-term rehabilitation care [7]. Each year, millions of stroke survivors have 
to adapt on a new way of life with severe limitations on their daily living activities.  
Stroke, sometimes called “brain attack”, is caused when there is a blood flow 
disturbance to a part of the brain due to an occluded blood vessel. As a result, the blood 
supply is interrupted or severely reduced, known as ischemia. Therefore, the resupply of 
blood flow to the affected area is crucial, since the lack of oxygen to the affected part of 
the brain can lead within minutes to brain cells death (tissue necrosis) and brain damage. 
The effects of a stroke depend on which part of the brain occurs and how severely affects 
it. The longer the time that area remains without blood supply, the less chance to survive 
or function properly, as tissue necrosis increases with the duration of occlusion and 
ischemia. If this part of the brain is severely injured, sudden death can be caused. In 2014, 
Meretoja et al. [8], estimated 1.8 days of added healthy life benefit for each minute 
reduction in time to treatment.  
In a patient affected by an ischemic stroke it is possible to distinguish the three 
types of tissue with abnormal blood flow, as presented in figure 1.1: 
1. The core, which is a zone of death cells due to under-perfusion, where dense ischemia 
early infarction occurs.  
2. The penumbra, which is a zone with hypo-perfused tissue surrounding core, where 
moderate ischemia and delay infarction occurs. Penumbra remains salvageable if 
revascularisation occurs in a timely manner [9]. 
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3. The benign oligemia, which is a zone between the unaffected area and the ischemic 
penumbra, where blood flows below normal range but not at risk of infarction. Even 
without prompt reperfusion, tissue in this zone usually survives the ischemic insult [10]. 
Consequently, the most vital factor for the recovery of a stroke patient, is to 
resupply blood flow to the penumbra region of stroke before brain cells begin to die. 
 
Figure 1.1: The concentric, four-compartment, brain ischemia model. The core represents a tissue 
compartment that is irreversibly damaged, surrounded by the penumbra that is at risk of infarction. 
Between the unaffected area and the penumbra, there is an area of benign oligemia that usually survives 
the ischemic insult, even without prompt reperfusion [10]. 
The pathological background for stroke may be either due to ischemic or 
haemorrhagic disturbances of the cerebral blood circulation (figure 1.2). Ischemic stroke 
or cerebral infarction occurs when the blood supply to part of the brain is interrupted or 
severely reduced due to full or partial occlusion of a blood vessel, typically caused from 
a blood clot (thrombus). Haemorrhagic stroke occurs when a weakened blood vessel in 
the brain ruptures, causing blood leakage either within the brain, or into the space 
surrounding it. Bleeding into the space surrounding the brain is called a subarachnoid 
haemorrhage (SAH) and can be caused by a ruptured aneurysm.  Bleeding within the 
brain tissue itself is called an intracerebral haemorrhage and is primarily caused by 
hypertension.  About 87% of strokes are caused by ischemia and the remaining roughly 
13 % by haemorrhage [11].  
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Figure 1.2: The two types of stroke, the ischemic and hemorrhagic stroke [12].  
There are two types of ischemic stroke due to a blood clot (thrombus) occlusion, 
thrombotic stroke and embolic stroke: 
1. A thrombotic stroke occurs when a stationary thrombus or blood clot formed in one of 
the arteries supplying blood to the brain (cerebral arteries), blocks the blood flow, 
causing thrombotic stroke. 
2. An embolic stroke occurs when a blood clot formed in a part of the body other than the 
brain (usually the heart), breaks off and a part of it travels through the bloodstream to the 
brain until it reaches a brain vessel small enough to deny its passage and thus becomes 
lodged. This trapped clot, also known as embolus, blocks the blood flow causing embolic 
stroke. 
Thus, the critical need of an occluded cerebral vessel due to a blood clot, either local 
(thrombotic) or after migration (embolic), is to relieve ischemia as quickly as possible. 
Each type of stroke demands different treatment course. For haemorrhagic stroke, the 
treatment is focused to control the bleeding, to reduce the pressure on the brain and to 
stabilize blood pressure. For ischemic stroke, the treatment is focused to restore the blood 
flow to the brain by intravenous (iv) therapy, i.e. the use thrombolytic drugs (clot 
dissolving), to break up the thrombus [13].  
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 Thrombolytic therapy 
Healthy endothelial cells secrete tissue plasminogen activator, an enzyme that 
converts proenzyme plasminogen (circulates in the blood) into thrombolytic enzyme 
plasmin. Plasmin is a serine protease that is capable of breaking down (hydrolyses) the 
fibrin molecules of blood clots (thrombi) to fibrin degradation products (FDP), leading to 
clot dissolution [14].  
Consequently, thrombolytic drugs are plasminogen activators (PAs), of either human 
origin, which are identical to the naturally occurring endogenous fibrinolytic enzyme 
tissue-type PA (tPA), found in vascular endothelial cells in humans [15], or urokinase-
type PA (UK) [15], or bacterial products such as streptokinase (SK ) [16]. Since a blood 
clot consists of a structural matrix of fibrin fibres with entrapped platelets and red blood 
cells, thrombolytic drugs activate fibrin-bound plasminogen on the surface of the clot, 
improve plasmin formation and hence enhance thrombolysis. Of course, it is important to 
note that PAs sometimes referred as "fibrinolytic agents", also activate circulating 
plasminogen in plasma and the releasing plasmin can cause an unwanted systemic 
fibrinolytic state that can lead to undesirable bleeding problems. Although all PAs 
enhance the endogenous formation of fibrinolytic enzyme plasmin, they differ in fibrin 
specificity (selectivity) and for that reason are classified into fibrin selective such as tPA 
and non-fibrin selective such as SK and UK [14]. For instance, the affinity of tPA for 
plasminogen is significantly increased in the presence of fibrin, so plasmin formation on 
the clot surface is higher compared to that in the plasma. Despite its affinity for fibrin, 
tPA still activates circulating plasminogen, leading to undesirable bleeding (fibrin 
selectivity of tPA is relative not absolute). However, the low affinity for circulating 
plasminogen, makes the family of tPA a more desirable thrombolytic drug than SK and 
UK. So, are currently used clinically for breaking down the fibrin contained in a clot, for 
acute myocardial infarction, cerebrovascular thrombotic stroke and pulmonary embolism.  
Thrombolytic therapy has evolved from the first generation thrombolytics such as UK 
[17] and SK [18], to newer thrombolytics also known by specific chemical names such 
as the second generation alteplase [19], or the third generation reteplase [20] and 
tenecteplase [21]:  
1. Alteplase (Activase®; rt-PA) is a recombinant form of human tPA, commonly known 
as rt-PA, reflecting its method of manufacture. It has a short half-life (~5 min) and 
therefore is usually administered as an iv bolus followed by an infusion (second 
generation) [19]. 
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2. Reteplase (Retavase®) is a genetically engineered, smaller derivative of recombinant 
tPA that has increased potency and is faster acting than rt-PA. It is usually administered 
as iv bolus injections (third generation) [20].  
3. Tenecteplase (TNK-tPA) has a longer half-life and greater binding affinity for fibrin 
than rt-PA. Because of its longer half-life, it can be administered by iv bolus (third 
generation) [21].  
Although third generation thrombolytic agents offer pharmacokinetic and 
hemodynamic advantages over rt-PA, have not been approved yet by the United States 
Food and Drug Administration (FDA), for the treatment of acute ischaemic stroke (AIS). 
At present, rt-PA is the only thrombolytic treatment for AIS approved by the FDA [19] 
and is administered iv at a dose of 0.9mg/kg, with a maximum dose of 90 mg. Ten percent 
of the medication is given as a bolus and the remainder is infused over 60 min [22]. 
Nevertheless, there are severe restrictions in rt-PA administration. The most important is 
that according to the NINDS (National Institute of Neurological Disorders and Stroke) 
study, the drug should be administered within the first three hours of stroke’s onset in 
order to be beneficial [19]. However, in 2009, the European Cooperative Acute Stroke 
Study 3 (ECASS 3), demonstrated that patients treated with iv rt-PA in the 3–4.5 hour 
window, also showed improved outcome compared to placebo, with no increase in 
mortality. Although professional organisations in the United States and many regulatory 
agencies worldwide have recommended that the time requirement should be extended 
from 3 hours to 4.5 hours [23], the FDA has declined to approve this expanded time 
window.  
The most important to underline, is that not all the patients with ischemic stroke can 
be treated with thrombolytic drug rt-PA, due to protocol exclusion. Except form the time 
window restriction, patients that have taken heparin in the previous 48 hours, or had 
another stroke in the previous 3 months, or surgery within the past 14 days, or suffer from 
hypertension, should be excluded from thrombolytic therapy. It is estimated that less than 
5 % of patients with ischemic stroke receive iv rt-PA and of these, only 30 to 40 % achieve 
early recanalization. Furthermore, due to the low efficacy of thrombolytic therapy, the 
recanalization is complete and sustained in less than 20 % of the treated patients [24-25]. 
Moreover, many studies have shown that rt-PA administration leads to intracerebral 
haemorrhage [26-27]. As a result, even without any side effect, often cerebral vessels are 
still obstructed after the treatment [28]. Numerous studies have shown that in a significant 
number of patients, iv thrombolysis with rt-PA remains ineffective, with poor 
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recanalization rates, especially for large proximal vessels, as compared with distal smaller 
vessels [26]. More specifically, the recanalization rates achieved with iv administration 
of rt-PA for proximal, large-vessel arterial occlusion, range from only 10 % for internal 
carotid artery (ICA) occlusion to 30 % for MCA occlusion [27]. All these reasons have 
created the need for the development of new alternative methods for the treatment of 
stroke that would be less restrictive, more safe, easy to use and more efficient. 
 Sonothrombolysis 
Mathematical models of fibrinolysis predict that clot lysis occurs along a front 
where the concentrations of plasminogen activator generate a sufficient plasmin 
concentration [29]. As theoretically predicted by Zidansek and Blinc 1991 [30], Zidansek 
et al. 1993 [31], Diamond and Anand 1993 [32] and experimentally shown by Blinc et al. 
[33], clot lysis based solely on diffusion of fibrinolytic enzymes into the clot is a very 
slow process that could last for days instead of a few hours as required for successful 
thrombolytic therapy. Furthermore, Diamond and Anand 1993 [32] have shown in their 
theoretical model, that thrombolytic therapy is physically limited by diffusion as no 
“driving force” exists to promote drug permeation since blood flow is stagnant or absent 
near the clot surface. 
This “driving force” was found in the mid-70s to be the application of ultrasound 
(US) energy. Trübestein et al. 1976 [34], first reported that mechanical pressure waves 
produced by US energy enhance the efficacy of thrombolytic agents, a process known as 
US enhanced thrombolysis. Since then, the ability of US energy to increase thrombolysis 
has been investigated extensively both in vitro and in animal models by several 
investigators [35–39]. 
The use of US energy to enhance thrombolytic therapy, also referred as 
sonothrombolysis, represents a completely different approach with unique features. This 
new approach appears to be very attractive, since it could offer unique potential benefits 
for patients, such as faster and more complete clot dissolution as well as lower dose of 
thrombolytic agent with resulting reduction in associated bleeding risks [40]. Whether 
delivered through a catheter (intravascularly), or transcutaneously (noninvasively), the 
effects of US are limited to the insonified area. Catheter-based devices have the advantage 
of localizing treatment to the clot, without any interference with the tissue. By applying 
this therapeutic technique, more energy can be delivered to the clot and unnecessary side 
effects such as thermal heating can be avoided. On the other hand, intravascular 
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sonothrombolysis, is time delayed and carries an increased risk of bleeding due to damage 
of the vessel wall and infection [41].  
In 2004, Atar and Rosencschein [42], examined all available by that time, 
techniques and methods of US thrombolysis. According to their review, the potential 
advantages of noninvasive sonothrombolysis over catheter alternatives are significant 
because bleeding risks from catheters are eliminated and faster treatments may be 
achieved as the time delay to intervention could be dramatically decreased. 
 Effects of US on clot lysis 
The effects of US on thrombus dissolution vary with the energy level delivered, 
as described by Polak 2004 [43]. As it is shown in figure 1.3, at very low energies or 
intensities (< 0.5 MPa), US promotes the motion of fluid, an effect called microstreaming. 
It is possible that this effect agitates the blood close to the occluding clot and promotes 
the mixing of rt-PA. As a result, the concentration of the agent that is in contact with the 
thrombus is increasing effectively. At moderate energies or intensities (0.5-4 MPa), US 
increases permeation of rt-PA into clot and binding to fibrin mesh that forms the occlusive 
lesion. At high energies or intensities (> 4 MPa), the onset for cavitation activity is 
exceeded creating gaps in the fibrin mesh, that increases the permeation of rt-PA into clot. 
 
Figure 1.3: A) Low level US increases the concentration of the agent around clot due to microstreaming. 
B) Moderate level US increases drug’s permeation into clot and binding to fibrin. C) High level US disrupts 
the fibrin network in clot due to cavitation activity [43]. 
A 
B 
C 
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Similarly, Sakharov et al. 2000 [44], also showed in their study that acoustic 
streaming led to thrombolysis enhancement, which is equivalent to that induced by mild 
stirring of thrombolytic solution around the thrombus. If the streaming is significant, both 
in absolute terms and relative to the existing blood flow, it can act as a ‘mild stirrer’ 
enhancing the supply of a PA and plasminogen from outside the clot exterior, directly to 
the clot surface. 
Although the mechanism of action of sonothrombolysis is not fully understood, 
numerous studies demonstrated that exposure to US increases both the uptake and depth 
of penetration of the activator to fibrin, through mechanisms that improve drug 
transportation [43–45], causes reversible alteration of the fibrin structure [46–49] and 
increase the binding of thrombolytic agent to fibrin [50–52]. The mechanisms for US 
enhancement of clot lysis and the contribution of each one of these mechanisms to 
thrombolysis efficacy are well reviewed by Bader et al. 2016 [53]. 
Exposure to US can be used with any thrombolytic agent and at any site where 
the appropriate US field can be delivered. US enhances thrombolysis during pulsed 
(instead of continuous), exposure and over a wide range of frequencies and intensities. 
Choices of frequencies for the majority of therapeutic US reside in the range of 40 kHz-
2 MHz due to lower skull attenuation and are typically lower than those for diagnostic 
applications, which are normally in the range of 2-10 MHz. 
The influence of operating parameters on US induced thrombolysis was 
investigated extensively by Schäfer et al. 2005 [54]. Study results have shown that the 
thrombolytic efficiency of US is directly depended on intensity and inversely depended 
on frequency. Higher US frequencies lead to greater energy attenuation, while higher 
intensities are associated with increased thermal effects. For this reason, the majority of 
sonothrombolysis models so far (both in vitro and in vivo), were developed using low 
frequencies and low intensities. 
Due to the increased interest in sonothrombolysis, there are a lot of experimental 
studies focusing on the significant enhancement of enzymatic thrombolysis by the 
simultaneous application of US. For instance, Devcic-Kuhar et al. 2002 [55], examined 
the effects of standing and travelling US wave fields on thrombolysis enhancement and 
showed that the enhancement of clot dissolution is much more pronounced in travelling 
than in standing acoustic waves. Another experimental study published by Pfaffenberger 
et al. 2003 [56], also suggested that an intermittent  (pulsed instead of continuous) 
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application of a 2 MHz high frequency US using a travelling wave field would be the 
most potent application for lysing blood clots. 
In chapter three, several published reports in the field of sonothrombolysis are 
summarised in three tables (in vitro, in vivo and clinical), since 1992. This comprehensive 
review, provides an overview of the different protocols applied so far by researchers on 
US thrombolysis studies. 
 In vitro and in vivo studies 
In the past two decades, increased evidence of US ability to accelerate 
thrombolysis rate with adjunctive PAs in vitro, have been reported [57–59]. Kimura et al. 
1994 [57], Spengos et al. 2000 [58] and Holland et al. 2008 [59], showed that external 
application of US increased thrombolysis in vitro. Kimura et al. 1994 clarified that the 
mechanism of clot lysis when subjected to a combination of thrombolytic drug and US 
leads to degradation of fibrin, allowing a quantitative measurement of the enhancement 
of clot lysis. 
Also, Spengos et al. 2000 suggested that transcranial application of 1 MHz pulsed-
wave US may accelerate reperfusion and recanalization rate of occluded intracerebral 
vessels, by enhancing rt-PA mediated thrombolysis. Holland et al. 2008 explored various 
US settings to determine the thrombolytic efficacy of US therapy with and without rt-PA 
administration. Using an in vitro model, they demonstrated that treatment with US as an 
adjuvant to rt-PA can significantly increase clot dissolution by as much as 104 % 
compared to rt-PA alone. 
Moreover, many in vivo studies like Lauer et al. 1992 [60], Kashyap et al.1994 
[61] and Suchkova et al. 2000 [62], have shown that the combination of thrombolytic 
drugs and US accelerates ﬁbrin degradation and causes a significant enhancement of 
thrombolysis. The study by Lauer et al. 1992, demonstrated that 1 MHz intermittent US 
enhances rt-PA induced clot lysis in a rabbit jugular vein thrombosis model. Similarly, 
Kashyap and colleagues showed in their study that noninvasive percutaneous application 
of 1 MHz pulse wave US significantly accelerated SK induced fibrinolysis, in a rabbit ear 
model of small vessel injury. Furthermore, Suchkova et al. 2000, showed that the 
combination of SK with low intensity 40-kHz US in a rabbit model, markedly accelerates 
fibrinolysis, improves tissue perfusion and reverses acidosis, effects that would be 
beneficial in the treatment of acute thrombosis. In the former studies, the range of 
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intensities varied from 0.2–2.0 W/cm2 (spatial peak, temporal average intensity-ISPTA), 
while the range of frequencies varied from 20 kHz to 2 MHz, using unfocused US. 
Another promising method for the treatment of vascular thrombosis is the targeted 
delivery of fibrinolytic agents to the site of occlusion such as the entrapment of rt-PA into 
liposomes. This method, provides a selective targeting to improve the efficacy of 
fibrinolytic agents [63-64]. Shaw et al. 2009 [63] have shown that the combination of 120 
kHz US with rt-PA-loaded echogenic liposomes, significantly enhanced lytic treatment 
efficacy. In another study, Laing et al. 2011 [64], using a rabbit aorta model, demonstrated 
that liposomes loaded with rt-PA in combination with Doppler US treatment, can 
significantly enhanced thrombolysis. 
 MBs enhanced sonothrombolysis  
In addition to thrombolytic drugs, US contrast agents (UCA) have been studied as 
a way to further enhance the effect of US, on the lysis of blood clots. UCA are micron-
sized gas bubbles widely used to improve the signal-to-noise ratio in US image 
acquisition. Beyond their routine diagnostic use as UCA, there is growing interest in the 
therapeutic potential of these MBs, since many studies have shown that may also improve 
the lytic efficacy of sonothrombolysis. The use of MBs to enhance thrombolysis, was first 
introduced by Tachibana and Tachibana 1995 [65]. The authors, demonstrated that the 
presence of albumin MBs can further accelerate fibrinolysis induced by 170 kHz US plus 
UK, in an in vitro human blood clot model. 
The administration of MBs in combination with US and rt-PA, may further 
improve thrombolysis as a result of cavitation mechanisms. Acoustic cavitation, is the 
formation of gas bubbles within US field that undergo oscillation and disruption. When 
oscillating under US exposure, MBs can increase rt-PA permeation inside the clot due to 
stable cavitation [66] or can cause directly a mechanical breakdown of the clot surface 
due to inertial cavitation [67]. 
The last 20 years, several in vitro and in vivo studies have presented that the 
effectiveness of thrombolytic drugs can be increased when combined with US and MBs 
[68-69]. Using either high [68] or low excitation frequencies [69], treatments combining 
US, MBs and rt-PA achieved greater mass loss than rt-PA alone or rt-PA with US. For 
instance, Cintas et al. 2004 [68], using an in vitro model found that the application of 
MBs, strongly accelerates rt-PA induced fibrinolysis of clots exposed to high excitation 
frequency (2 MHz US). In contrast, Datta et al. 2008 [69], exposed in vitro human blood 
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clots using low excitation frequency (120 kHz US). Study results showed that the greatest 
clot mass loss was also observed for clots treated with US plus rt-PA and MBs. 
Concerning the in vivo studies, Brown et al. 2011 [70], using a rabbit embolic 
stroke model, demonstrated that the combination of low-dose or no-dose rt-PA and US 
plus MBs, improved thrombolytic treatment with a strong trend to decrease infarct 
volumes and significantly decreased intracranial haemorrhage (ICH), outside the area of 
infarct.  
Another area of investigation was focused on clot lysis using only US in synergy 
with MBs, for patients that are ineligible for rt-PA administration. An in vitro study by 
Nishioka et al. 1997 [71], showed that US in combination with MBs can induced clot 
lysis without the use of thrombolytic drugs. Besides, Culp et al. 2011 [72], using a rabbit 
embolic stroke model, demonstrated that MBs sonothrombolysis with no exogenous rt-
PA, produces significant improvement in strokes without apparent side effect. Study 
results along with the results of a long series of animal studies conducted by the author in 
the past, have shown that human trials without rt-PA (for patients where rt-PA is 
contraindicated), were justified. 
As cavitation is an important mechanism of thrombolysis with US and MBs, 
specifically targeting bubbles may enhance this effect, through close proximity of the 
cavitating bubbles to the thrombus. A challenging option may be the formation of MBs, 
which can be attached to vascular thrombi by using ligands and receptors that are 
incorporated in bubble’s shell (figure 1.4). Studies have demonstrated that MBs can be 
concentrated at the surface of clot by attaching a glycoprotein receptor antagonist, which 
increases MBs proximity to blood clot, leading to enhanced thrombolysis [73-74]. 
 
 
 
 
 
 
 
Figure 1.4: A) MB can be attached to a target tissue by using ligands and receptors, which are 
incorporated in its shell. B) MB attached to a  target blood clot [67]. 
A B 
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 Role of FUS in clot lysis 
A relatively new approach to sonothrombolysis is the use of FUS from an external 
source. This novel, emerging, therapeutic modality has received attention lately as it can 
deposit energy into millimetre sized focal volumes within the body, without harming 
adjacent normal tissue. Many studies, either bench-top [75–77] or animal [78–80], have 
shown that the use of FUS for clot distraction is enhancing thrombolysis. In 2006, Frenkel 
et al. [75] evaluated the effect of FUS on clot destruction with and without rt-PA, using 
an in vitro human blood clot model. No significant increase in thrombolysis from FUS 
treatment alone was seen but they demonstrated that treatment with FUS in combination 
with rt-PA increases thrombolysis by 50 % compared to treatment with rt-PA alone. In 
2007, the same group conducted in vivo studies using a rabbit marginal ear vein thrombus 
model [78]. Once again, FUS treatment alone showed no significant increase in 
thrombolysis, but the group observed improved rates of clot reduction using pulsed FUS 
in synergy with rt-PA. 
Recently, the use of FUS has been proposed as a stand-alone method for clot lysis 
(in the absence of thrombolytic drugs). In the study by Hölscher et al. 2011 [81], human 
whole blood clots in vitro were ablated though the skull using pulsed FUS. The conclusion 
of the study was that even in the absence of thrombolytic drug, FUS alone can be utilized 
to destroy clots. In another study, Wright et al. 2012 [82], showed that FUS either in vitro 
or in vivo can cause clot lysis within minutes when used as a stand-alone method.  Even 
though this would eliminate side effects from thrombolytic drugs and hence reducing the 
risk of haemorrhage, the potential for bleeding with this approach requires further 
investigation. 
So far, none of the experimental studies on sonothrombolysis has claimed 
enzymatic clot lysis within minutes, based on non-thermal effects. To our knowledge, it 
is speculated that clot lysis within minutes should be probably due to thermal 
mechanisms. 
 MRgFUS 
In the last few years, an innovative new technology is emerging, which offers FUS 
treatments under magnetic resonance (MR), guidance and monitoring. This new quickly 
developing technology is commonly used by the term MR guided FUS (MRgFUS). The 
idea of using MRI to guide and monitor a real time non-invasive FUS treatment was 
originally introduced by Hynynen et al. in 1993 [83], who demonstrated that lesions 
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produced in dog's thigh muscle in vivo were clearly visible inside the gantry of an MRI. 
Studies followed this concept shown that the contrast between necrotic tissue and normal 
tissue is superior when compared with US technology, verifying that MRI is an excellent 
tool for FUS systems guidance [84-85]. Since then, MRI became the preferred monitoring 
tool because not only provides the possibility to monitor a therapeutic effect close to real 
time, but also to monitor temperature elevation as well as focus navigation based on MRI 
derived thermometry. This rapidly expanding technology has many applications across 
the spectrum of non-invasive FUS treatments, especially in the domain of oncology. 
Lately, the possibility of using MRgFUS for treating stroke has become an 
important area of investigation, since stroke is the primary focus of sonothrombolysis 
research due to the high mortality rate associated with it. In 2012, Burgess and colleagues, 
used MRgFUS for clot dissolution in a rabbit embolic stroke model [86]. Study results 
have shown that this technique could dramatically reduce restoration flow time, leading 
to a significant increase in the number of patients, which benefit from MRgFUS 
thrombolysis treatment. 
As MRgFUS sonothrombolysis relies on non-thermal mechanisms to achieve clot 
lysis, MR thermometry is not useful for treatment monitoring in real time. In 2013, Durst 
et al. [87], evaluated different imaging sequences in order to extract the optimal imaging 
sequence, for real time monitoring of in vitro clot sonothrombolysis by MRgFUS. Study 
findings have identified T2-weighted imaging as the optimum imaging sequence to verify 
that a clot had been lysed. 
A major limitation of all transcranial US techniques is the beam distortion due to 
the inhomogeneous thickness and density of the skull bone and the heating of the skull 
and near-field soft tissues caused by the acoustic signal absorption. As a result, the 
acoustic energy that reaches the deeply located lesions, decreases proportional. To 
overcome these limiting factors, an innovative MRgFUS head system, has been 
developed. This prototype helmet-type brain system (figure 1.5A), is equipped with a 
hemispheric multi-element array transducer that produces a sharp focus at the target 
lesion, while it simultaneously distributes heating across a larger surface area (Exablate 
4000, Insightec, Haifa, Israel). In addition, an active cooling system that circulates cold 
degassed water (about 15 0C), is placed between the patient’s head and transducer. The 
clinical set up is shown in figure 1.5B. 
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Figure 1.5: MRgFUS head system. A) The helmet-type hemispheric transducer with 1,000 single piezo 
elements. B) Patient set up prior to positioning inside the MRI scanner [88]. 
 Clinical trials using sonothrombolysis 
The enhancing effect of US on rt-PA mediated lytic efficacy, which have been 
demonstrated in many in vitro and in vivo studies, have led to clinical trials of 
Transcranial Sonothrombolysis in acute ischemic stroke (AIS) patients. In the last 10-15 
years, there have been some significant clinical trials concerning the application of 
therapeutic US in the treatment of stroke. Although preclinical studies have been very 
encouraging, the results from clinical trials have shown that further research in the field 
of sonothrombolysis has to be done. 
Two different approaches regarding sonothrombolysis for recanalization have 
been evaluated (figure 1.6): (1) a noninvasive transcranial approach using a Doppler in 
combination with rt-PA [89–93] and (2) an invasive endovascular approach using an US 
emitting catheter for simultaneous intra-arterial (ia) delivery of rt-PA and US [94–98]. 
 
Figure 1.6: A) Invasive approach using US assisted thrombolysis catheter. B) Noninvasive approach using 
transcranial Doppler [53]. 
Although low-frequency US (< 1 MHz) is a good choice for skull penetration [99], 
a clinical trial using transcranial 300 kHz US plus rt-PA, the TRanscranial low-frequency 
A B 
A B 
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Ultra-sound-Mediated thrombolysis in Brain Ischemia (TRUMBI) trial, was ended 
prematurely due to a significant increase (36 %), in symptomatic intracranial hemorrhage 
(sICH) within 3 days of treatment [89]. Since then, low frequency US has not been 
available for therapeutic purposes in clinical trials. 
One of the first clinical studies, using high frequency (2 MHz) low intensity 
Transcranial Doppler US (TCD), was the Combined Lysis of Thrombus in Brain Ischemia 
Using Transcranial US and Systemic rt-PA (CLOTBUST) trial, by Alexandrov et al. [90]. 
The purpose of this phase II randomized multi-center international clinical trial, was to 
evaluate the effects of TCD ultrasonography in conjunction with systemic administration 
of rt-PA in patients who had AIS due to occlusion of the MCA. After 2 hours of 
continuous TCD monitoring, increased recanalization rates were observed in 49 % of 
patients treated with TCD + rt-PA compared to 30 % of patients treated with rt-PA alone. 
Similarly, in another smaller clinical trial by Eggers et al [91], patients with acute 
proximal MCA occlusion were treated with 1.8 MHz transcranial color-coded duplex 
(TCCD) technology in association with rt-PA.  TCCD transducers generate multiple small 
beams at dual emitting frequencies, one for Doppler (1.8 MHz) and one for gray scale 
imaging (4 MHz). Study results, also demonstrated improved recanalization rates when 
TCCD was combined with rt-PA in patients with AIS, compared to patients treated with 
rt-PA alone. 
The last few years, sonothrombolysis clinical research has been focused on the 
boosting effect of MBs in clot dissolution. The safety and effectiveness of various types 
of MBs in combination with transcranial US and rt-PA have been clinically evaluated 
since 2006. 
Molina et al. [92], combined 2-MHz TCD with rt-PA and MBs in patients with 
AIS. The study showed promising results since the patients treated with the triple 
combination of 2 MHz TCD, rt-PA and MBs, exhibited higher recanalization rate 
compared with patients treated either with rt-PA plus TCD or rt-PA alone. 
Based on the encouraging results from the first study, Molina et al. [93], 
performed a second clinical trial, the Transcranial Ultrasound in Clinical 
Sonothrombolysis (TUCSON). In this study, stroke patients were treated with 2 MHz 
TCD in combination with rt-PA and continuous infusion of newly developed MBs, such 
as the C3F8 perfultren-lipid microspheres-“MRX-801” (ImaRx Therapeutics, Inc., 
Tucson, Arisona). Theoretically, the smaller size of these newer and more stable 
microspheres (1-2 μm), allows permeation through the thrombus, which may further 
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enhance recanalization process, when combined with iv administration of rt-PA plus TCD 
monitoring. Although at low dose of MBs, 50 % reperfusion enhancement was observed, 
when the dose was double, reperfusion enhancement was ceased and hemorrhaging 
occurred. As a result, the clinical trial terminated with the recommendation that the use 
of low doses MBs in sonothrombolysis may be safe, but higher doses when administered 
with rt-PA may increase sICH rate. 
Another series of clinical trials, investigated the safety and feasibility of 
endovascular sonothrombolysis for treating patients with AIS. The first experience with 
endovascular sonothrombolysis for patients with AIS, was published by Mahon et al. 
[94]. They used the EKOS Micro-Infusion Catheter, a novel technology for ia delivery of 
rt-PA along with low intensity US from the tip of the catheter, in order to accelerate 
thrombolysis. EKOS Infusion Catheter [100], consisted of a Drug Delivery Catheter 
(DDC) and an US Core (USC) (figure 1.6). The DDC had a pattern of holes to deliver 
uniform drug flow along and around the treatment zone and a central lumen to accept the 
USC and to deliver coolant fluid to the USC during operation. Six US transducer 
elements, each with dimensions 2.0 x 0.40 x 25 mm, were mounted at evenly spaced 1 
cm intervals along the USC to form the treatment zone. The combination of ia rt- PA 
administration with endovascular US, was applied continuously for 60 min. Partial or 
complete recanalization was detected in 57 % patients and no adverse effects were 
observed during the therapy. 
 
Figure 1.7: EKOS Infusion Catheter [100]. 
To bridge the gap between early initiation of iv therapy and faster recanalization 
of ia therapy, a combined iv/ia thrombolysis approach was designed to achieve higher 
rates of early and successful reperfusion. This approach was evaluated in the International 
Management of Stroke (IMS) I and II clinical trials, sponsored by the National Institute 
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of Health (NIH). The first phase of the study (IMS I) was completed in 2002 [95], 
followed by the second phase (IMS II), which was completed in 2005 [96]. Both studies 
have shown that this combined approach may be more effective in recanalization than 
standard iv rt-PA alone. 
Additionally,  in the IMS II trial, the feasibility and safety of intravascular 
sonothrombolysis for treating patients with AIS was investigated [96]. More than half of 
the patients in the IMS II study, were treated with the EKOS system along with ia infusion 
of rt-PA, in order to accelerate thrombolysis. The study showed that this combined 
approach may be more effective in recanalization than standard iv rt-PA alone.  
Based on the positive findings of IMS I and IMS II clinical trials, the NIH has 
sponsored in 2006 the largest interventional ischemic stroke clinical trial so far, called 
IMS III [97]. Nevertheless, IMS III trial was terminated prematurely in 2012 when the 
results shown no substantive difference in benefit between stroke patients receiving 
endovascular therapy after iv rt-PA, as compared with iv rt-PA alone. 
Another clinical study by Kuliha et al. [98], was also designed to confirm the 
safety and efficacy of intravascular sonothrombolysis for treating stroke patients. Study 
results demonstrated that complete or partial recanalization of brain artery was achieved 
in 77 % of the patients treated with the EKOS system along with ia infusion of rt-PA. 
Finally, a different focus for sonothrombolysis research concerns clinical trials for 
those stroke patients who are ineligible for rt-PA [101]. Based on both in vitro and in vivo 
studies, which have shown that US energy (with or without MBs) can induce clot lysis, 
the authors of this study evaluated the effects of TCD on patients with acute MCA 
occlusion and contraindications for rt-PA administration. Even though the results of the 
study were promising, need to be confirmed in larger clinical trials. 
 Aims and objectives 
The aims and objectives of the thesis are listed below: 
i. To review protocols used in sonothrombolysis studies aiming to give an overview 
of the different protocols used so far in the field of sonothrombolysis and to 
investigate the impact of several aspects involved, on thrombolysis outcome. 
ii. To use fully retracted blood clots, obtained by natural coagulation of fresh porcine 
blood, in order to study the effect of US energy on thrombolysis efficacy. 
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iii. To design circulating flow clot models, reproducing in vitro the physiological 
situation of a MCA occlusion occurred either deeply into a brain tissue mimicking 
phantom or superficially. 
iv. To measure thrombolysis efficacy the blood clots will be treated with US waves 
as an adjunct to thrombolytic drug TNK-tPA, in the presence or absence of MBs. 
v. To determine and evaluate various experimental parameters (acoustic and 
physical), that influence the thrombolytic efficacy of the 3rd generation 
thrombolytic drug TNK-tPA. 
vi. To establish an optimised treatment protocol that through non-thermal 
mechanisms maximises the thrombolytic activity of TNK-tPA leading to 
enhanced thrombolysis. 
vii. To evaluate the thrombolytic efficacy of two small planar ultrasonic transducers 
(operating at frequencies 3.7 and 5.2 MHz respectively). 
viii. To evaluate the thermal capabilities of a small flat rectangular ultrasonic 
transducer, operating at 4 MHz frequency, with the use of two different gel 
phantoms fabricated to mimic brain tissue. 
ix. To optimise treatment protocol obtained in vitro must be translated in vivo using 
a carotid artery model under MR monitoring. The aim of the study is the fast and 
complete recanalization of a fully occluded carotid artery of a rabbit, without 
excess heating.  
 Chapters outline 
This section gives an overview of each chapter. 
Chapter 2:  Physics of Ultrasound and Biological Tissue Effects 
This chapter covers the physics of US as well as the biological effects 
generated from the interaction of US waves with targeted tissue. It refers 
to the basic ultrasonic quantities, to the generation and the types of US 
waves and to image guidance. Also, it describes the FUS induced 
biological effects and their underlying thermal and non-thermal 
mechanisms, which are the foundation of FUS therapies such as 
hyperthermia, thermal ablation, sonoporation and sonothrombolysis. 
Chapter 3: Review of Protocols used in Ultrasound Thrombolysis 
This chapter focuses on the review of different protocols used so far in the 
field of sonothrombolysis. These protocols are summarised in three tables 
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(in vitro, in vivo and clinical), providing detailed information concerning 
clot model, thrombolytic drug, treatment mode, sonication parameters, 
evaluation method, thrombolysis outcome, side effects and conclusions. 
Chapter 4:  Determination of the Experimental Parameters that Influence 
         Ultrasound Induced Thrombolysis in Vitro 
In this chapter, various physical and acoustic properties that influence the 
thrombolytic activity of the 3rd generation thrombolytic drug TNK-tPA, 
are determined. In addition, the different circulating flow clot models used 
to evaluate in vitro the effect of US energy (either focused or unfocused), 
on clot lysis are also described.  
Chapter 5:  Focused Ultrasound Enhanced TNK-tPA Mediated Thrombolysis 
into a Brain Tissue Mimicking Phantom 
 In this chapter, an in vitro flow clot model is developed, reproducing the 
physiological situation of MCA occlusion, occurred 4 cm deep into a brain 
tissue. For this purpose, fully retracted porcine blood clots are embedded 
into a brain tissue mimicking phantom and treated with FUS pulses either 
alone or as an adjunct to TNK-tPA, in the presence or absence of MBs. 
The objective is to establish an optimized treatment protocol that 
maximizes the permeation and binding of thrombolytic drug into the clot, 
leading to increase degree of thrombolysis, without excess heating. 
Chapter 6:  The Enhancing Effect of Focused Ultrasound on TNK-Tissue 
Plasminogen Activator Induced Thrombolysis of a Superficial Target 
Using an in Vitro Circulating Flow Model 
In this chapter, an in vitro flow clot model is developed, reproducing a 
MCA occlusion occurred superficially. The optimized experimental 
parameters obtained in the previous chapter are employed in this one in 
order to investigate the impact of frequency and acoustic intensity on 
thrombolysis efficacy. 
Chapter 7:  Microbubble Based Sonothrombolysis using a Planar Rectangular 
        Ultrasound Transducer 
In this chapter, an in vitro flow clot model is developed, reproducing a 
MCA occlusion, treated invasively with a catheter-directed US device. 
The aim is to evaluate the efficacy of two small planar ultrasonic 
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transducers, operating at frequencies 3.7 and 5.2 MHz respectively, on clot 
lysis. 
Chapter 8:  Evaluation of a Small Flat Rectangular Therapeutic Ultrasonic 
        Transducer Indented for Intravascular Treatment of Atherosclerosis 
This chapter evaluates the thermal capabilities of a small flat rectangular, 
MRI compatible ultrasonic transducer, operating at a frequency of 4 MHz. 
Transducer’s efficacy is tested in two different gel phantoms fabricated to 
mimic tissue. A polyacrylamide hydrogel phantom is used to visualize the 
size and shape of the thermal lesion and an agarose based gel phantom is 
used to measure temperature elevation. 
Chapter 9:  MRI Guided Sonothrombolysis in Vivo Using a Rabbit Carotid 
Artery Model 
 In this chapter, the enhancing effect of 1.18 MHz FUS waves on TNK-
tPA induced thrombolysis in the presence of MBs, is evaluated in vivo 
under MR monitoring, using a carotid artery model. The aim of the study 
is the fast and complete opening of the occluded artery of the rabbit, 
without excess heating. 
Chapter 10:  Conclusions and Future Directions 
Conclusions and future direction are presented in this chapter. 
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 Physics of Ultrasound and Biological Tissue Effects  
 Introduction 
US biophysics studies the interactions between US waves and biological tissues. 
The type of each interaction such as transmission or reflection, specifies the way that 
biological tissues affect US waves and provides the basis for US applications (diagnostic 
or therapeutic). On the other hand, US can induce biological effects (bioffects), to tissues 
through mechanisms that are separated into thermal and non-thermal. If US waves can 
alter biological tissues in a controllable way, which means without any cause of 
undesirable side-effects, then can be used for many therapeutic applications. 
 Basic ultrasonic quantities 
US, are pressure waves that transport energy from one location to another, in a 
medium. As US waves propagate through a medium, apply pressure to its particles, 
causing them to oscillate back and forth around their rest position. Due to the bonding 
between the particles, the motion is transmitted to the neighbouring particles. If the 
particles are widely separated (gas), US propagation will be strongly reduced. When the 
particles get closer together, create wave fronts of compression (high or positive pressure) 
and when they separate, create wave fronts of rarefaction (low or negative pressure). As 
a result, US energy is propagated in a medium through these series of repeating 
compression and rarefaction regions. These mechanically pressure waves can be 
described through a sinusoidal function, which is characterized by the following 
properties (figure 2.1): 
Wavelength (λ): is the distance travelled by one oscillation (cycle), or is the distance 
between two consecutive maximal compressions or rarefactions. It is measured in meters 
(m). 
Frequency (f): is the number of times a particle oscillates per second. It is measured as 
cycles per second and the unit is hertz (Hz). 
Period (T): is the time occupied by one oscillation. It is expressed in seconds (s) and is 
the reciprocal of frequency: 
 
𝐓 =
𝟏
𝒇
 
                                       (2.1) 
Propagation Velocity (c): is the speed that sound waves propagate through a medium 
and depends on tissue density and compressibility (slower in gasses, faster in liquids, and 
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fastest in solids). Speed is the constant that relates wavelength (λ) to period (T) and is 
expressed by the Wave Equation: 
 𝐜 = 𝛌𝐟                                        (2.2) 
 
Figure 2.1: Physical parameters of US wave and their relations [102].  
For medical applications, the propagation velocity (c) in all soft tissue is assumed to be 
constant and equal to: 𝐜 = 𝟏𝟓𝟒𝟎 𝐦/𝐬. 
Amplitude: is the maximum distance a particle moves back or forth (displacement), i.e. 
the maximum height above or below the baseline value. It is expressed in decibels (dB), 
which is a logarithmic scale.  
Pressure amplitude (P): amplitude is also measured in units of pressure, which is 
described by the peak positive (Pp) and peak negative pressures (Pn).  
Acoustic Power (AP): is the amount of acoustic energy generated per unit time. Energy 
is measured in joules (J).  
Acoustic intensity (I): is the power flowing through a unit area. It is expressed in 
Watts/m2 or mW/cm2. For a sinusoidal wave, the instantaneous acoustic intensity I(t) is 
given by:  
 
𝑰(𝐭) =
𝐏(𝐭)𝟐
𝟐𝛒𝐜
 
                                       (2.3) 
where P(t) is the instantaneous pressure amplitude and 𝝆 is the physical density of the 
medium. 
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 Generation of US waves 
US waves are generated from small devices called transducers or probes, which are 
constructed of a piezoelectric crystal. Piezoelectric crystals have the property to convert 
electrical energy to mechanical energy and vice versa, a phenomenon known as the 
piezoelectric (“pressure electric”) effect. When an alternating current (AC) voltage is 
applied across the opposite surface of a piezoelectric crystal, its shape changes with 
polarity, causes the crystal to expand and contract (vibrate), at the same frequency (f) as 
that of the applied field. This leads to the generation of compressions and rarefactions of 
US pressure waves. The most commonly used piezoelectric crystal by all medical US 
transducers is lead zirconate titanate (PZT), because it exhibits strong piezoelectric effect 
and can be manufactured in almost any shape. The resonance frequency of a transducer, 
also referred to as the centre frequency (f), is determined by the thickness (d) of the 
crystal: 
 𝐟 =
𝐜
𝟐𝐝
                                        (2.4) 
Thus, thinner crystals generate higher frequencies, while thicker generate lower 
frequencies. 
To improve transducer’s efficiency, a matching layer is added to the external face of 
the crystal, providing acoustic coupling between the crystal and the patient. The thickness 
of this matching layer should be equal to a quarter of the US wavelength, to maximise 
energy transmission through the layer in both directions. 
With only air behind the crystal, the internal reverberations within the crystal due to 
US reflection would be very strong and would continue long after the end of the voltage 
pulse. This unwanted ringing can be much reduced by having a backing (damping) layer 
behind the PZT, made of a material with the ability to absorb US such as tungsten powder 
embedded in epoxy resign. 
 Focused transducer 
US beams can be either focused or unfocused depending on the curvature of the 
surface of the piezoelectric crystal. If the surface is flat, the beam will be unfocused. 
Using a curved surface piezoelectric crystal with a radius r, beam focusing is achieved, 
i.e. the beam becomes convergence and narrow in the point  which has the distance r to 
all points on the transducer surface [103]. The location where the beam reaches its 
minimum diameter is termed focus or focal point. The beam can be focused at a 
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predetermined distance from the transducer face, which is determined by both the 
frequency of US wave and the diameter (D) of the transducer. This predetermined 
distance, is termed focal depth or focal length. At focus, the beam has its maximum 
intensity (figure 2.2). With focused transducers, a great amount of energy is delivered to 
a precise location within the body without damaging the surrounding healthy tissues. 
For therapeutic applications such as brain treatments, a specially designed 
transducer has been developed, known as phased array. It comprised of a spherical 
transducer with multiple small piezoelectric crystals arranged with separate connections, 
which can be pulsed individually. This type of transducer offers versatility in beam 
steering and focusing, by applying variable delay time. 
 
Figure 2.2: Focused transducer [103]. 
 Phased-array transducer 
With the use of an array of small piezoelectric crystals, multiple pressure waves are 
generated each of which can be pulsed separately. The timing of firing of each crystal is 
electronically controlled in order to precisely steer and focus the beam (electronic beam 
steering), as it is shown in figure 2.3. The development of phased array transducers, make 
possible for transcranial FUS treatments, to overcome focal distortion of the target 
volume due to heterogeneity in skull thickness and density. 
 
Figure 2.3: Focusing and steering capabilities of phased arrays by controlling the phase and amplitude of 
the RF signal driving each crystal [103]. 
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 US wave types 
The classification of US waves is based on the direction the particles in the medium 
are oscillating, relative to the direction of energy transfer (propagation) and the material 
properties in which they travel. In other words, US waves are classified upon the way 
they travel and transfer their energy. Longitudinal waves occur when the particles 
oscillate along (back and forth) the direction of propagation (bungee cord). 
Shear waves occur when the particles oscillate transverse (vertically up and down) 
to the direction of propagation (guitar string) [104]. In general, longitudinal waves travel 
through all kinds of materials such as gases, liquids and soft tissue, while shear waves 
travel only through solid material such as bone. Shear waves are quickly attenuated in 
soft tissues because their attenuation is higher compare to that of longitudinal waves. At 
interfaces between different types of tissue, longitudinal waves may be converted into 
shear waves when the wave incidence is not normal to the interface, which is important 
at the interfaces between soft tissues and bones.  
Two types of modes are used to generate US waves for medical US: 
1. Continuous wave mode (CW) 
2. Pulse wave mode (PW) 
A continuous wave is produced when the US transducer is continuously excited at 
constant amplitude over time, containing an infinite number of maximum and minimum 
amplitude peaks with the same value, also called the Pp and Pn. Since in CW mode, US 
energy is produced all the time, US intensity is constant over time. A PW is produced 
when the US transducer is excited only for a short period of time (pulse “ON”)   followed 
by a pulse “OFF” period and both the “ON” and “OFF” pulses are repeated in succession 
throughout the sonication period.  
 Pulsed US intensities 
While a continuous US wave is sufficiently described by frequency (f), period (T), 
wavelength (λ) and propagation, for pulsed wave US several more terms are needed such 
as duty factor (DF), pulse duration (τ), and pulse repetition frequency (PRF). Pulse 
duration (τ), is the time length of a single pulse and is given by the number of cycles per 
pulse (N) times the period (T): 
 
𝛕 = 𝐍𝐓 =
𝐍
𝐟
 
                                       (2.5) 
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DF, is the fractional amount of time that the pulse is activated and is given by the ratio of 
the pulse duration to the pulse repetition period (PRP): 
 𝐃𝐅 =
𝛕
𝐏𝐑𝐏
= 𝛕𝐏𝐑𝐅                                        (2.6) 
where, pulse duration is the time from the beginning to the end of a pulse, PRP is the 
interval between pulses. The reciprocal of PRP is PRF, which is the number of pulses per 
unit of time.  
In pulsed mode operation, intensity may be calculated in several different ways, 
taking into account different power measurements and the spatial distribution of energy. 
Since pulsed wave intensity varies with time and distance across the beam, it can be 
expressed as peak or average intensity, either spatially (within a specified cross-sectional 
area) or temporally (within a specified exposure time). The temporal peak intensity (ITP) 
is the maximum value of intensity measured in a pulse and the temporal average intensity 
(ITA) is the measured average over the entire PRP. The spatial peak intensity (ISP) is the 
maximum value of intensity at a specific location in the US beam. The spatial average 
intensity (ISA), is the average value of intensity across the beam’s cross-sectional area. 
The pulse average intensity (IPA), is the measured average over pulse duration. Combining 
the above temporal and spatial considerations, the six intensities of importance are the 
following: 
1. Spatial average, temporal average (ISATA = ITA/beam area) 
2. Spatial peak, temporal average (ISPTA= ISATA x ISP/ISA) 
3. Spatial average, pulse average (ISAPA = ISATA/DF) 
4. Spatial peak, pulse average (ISPPA = ISATA x ISP/ISA) 
5. Spatial average, temporal peak (ISATP =ISP/beam area) 
6. Spatial peak, temporal peak (ISPTP) 
The lowest value of intensity is the spatial average, temporal average (ISATA), which 
is obtained by dividing the temporal average power by the area of the transducer face, i.e. 
it averages in space and time. The spatial peak, temporal peak intensity (ISPTP) is the 
highest value of the temporal peak intensity in the beam area (does not average either in 
space or time). The measurements which are most relevant to known bioeffects 
mechanisms are ISPTA and the ISPPA.  The spatial peak, temporal average intensity (ISPTA), 
is the time-averaged intensity at the position of the spatial peak, is used to estimate the 
thermal bioeffects of US and it is important in safety considerations. The spatial-peak, 
pulse-averaged intensity (ISPPA), is the intensity that exists during a pulse at the position 
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of the spatial peak and is related with the likelihood of mechanical bioeffects, such as 
cavitation.  
 Interaction of US with tissue 
As US beam propagates through different media of a body, encounters tissue types 
with varying physical and acoustic properties. Reflection occurs at a boundary between 
two different tissue types. At each boundary, an amount of US energy is reflected back 
and the remaining is transmitted, which means it continues deeper in the body. As an US 
wave travels deeper in the body, it becomes weaker, i.e. the amplitude of the wave 
decreases. 
For diagnostic applications, it is the detection of the reflections that forms an US 
image. For therapeutic applications, the goal is to minimize the reflected amount of 
energy, so the required amount of energy to cause the desired biological effect, to be 
transmitted to the target.  
Every medium has its own characteristic property, which is called the acoustic 
impedance (Z) and is the product of the speed of sound in the medium (c) and the physical 
density of the medium (ρ): 
 𝐙 =  𝛒𝐜                                        (2.7) 
The acoustic impedance (Z) is also defined as the ratio of acoustic pressure (P) at a 
point in the medium to the particle velocity (v) at the same point. Therefore, the particle 
velocity:  
 
𝒗 =
𝑷
𝒁
 
                            (2.8) 
The maximum displacement of the particles of a medium from their zero position 
with amplitude (ξmax) is defined as the ratio of the particle velocity (v) to the angular 
frequency of the wave (ω = 2πf):  
  𝛏𝐦𝐚𝐱 =
𝒗
𝝎
                                        (2.9) 
By combining equations 2.3, 2.7 and 2.8 with 2.9 the maximum particle 
displacement in a medium is given by: 
 
𝝃𝒎𝒂𝒙 =  
𝟏
𝝅𝒇
√
𝑰
𝟐𝝆𝒄
 
                                     (2.10) 
The amount of reflection depends on differences in acoustic impedance (z) between 
media. Maximum transmission occurs when the acoustic impedance on either side of a 
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boundary is equal. The greater the difference in impedance at a boundary, the greater the 
amount of US energy reflected and the less transmitted. This is the reason why US energy 
does not pass from air into water or vice versa. Due to that, is very critical for all FUS 
systems to have an appropriate acoustic interface between the transducer and the target in 
order to minimize the difference in impedance. The coupling media used for this purpose 
include various oils, gels or degassed water. Any bubbles filled with air or gas in the path 
of the US beam can cause reflection, which means that the transmission will not be 
effective. Therefore, bubbles should be removed during setup procedures. Acoustic 
impedance of some common types of human tissue in relation to density, sound 
propagation and absorption coefficient are shown in table 1 below [102]: 
Table 1: Values of acoustic impedance, density, sound propagation and absorption 
coefficient of some biological tissues 
Material Density  
( ρ) 
(kg.m-3) 
Propagation 
velocity (c) 
(m.s–1) 
Acoustic  
Impedance ( Z) 
(kg.m–2.s–1) 
Absorption  
coefficient (α) 
(dB.cm–1.MHz-1) 
Air 1.2 330 400 1.64 
Blood 1060 1570 1.61 × 106 0.18 
Skull 
Bone 
1810 3360 6.10 × 106 20 
Brain 1030 1560 1.55 × 106 0.85 
Liver 1060 1570 1.66 × 106 0.9 
Lung 400 650 0.26 × 106 40 
Muscle 1070 1580 1.70 × 106 1.2 
 
 Frequency as a function of depth and sharpness 
The amplitude of an US wave decreases with distance as it propagates into an 
attenuating medium such as tissue. This attenuation in intensity is either due to absorption 
or scattering. Absorption represents the part of US energy that is converted into heat, 
while scattering represents the part that changed direction. The intensity of an US wave 
is attenuating exponentially and is described by the following relationship: 
  𝐈 =  𝐈𝟎𝐞
−𝛍𝐱                                      (2.11) 
with I0 being the initial intensity and I the intensity at any point x along the propagation 
direction. The attenuation coefficient μ describes the loss in intensity per unit length x. 
The attenuation coefficient of tissue increases as a function of frequency (f) and is 
described by the following relationship: 
 𝛍 =  𝐚𝐟 𝐛                                      (2.12) 
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with 𝐚 and b, being constants dependent on tissue type 
From equation 2.12 is derived that as the US frequency increases, the absorption 
per unit length (heating) increases and hence the depth of penetration decreases. At a 
frequency of 1 MHz, the attenuation coefficient in soft tissue is approximately 0.7 dB/cm, 
whereas at 2 MHz, is double (1.4 dB/cm), indicating that is linearly related with 
frequency. The attenuation coefficient for soft tissue can be expressed mathematically by 
the value of 0.5 dB/cmMHz.  
The optimal frequency for therapeutic US systems varies by treatment and is a 
balance between depth of penetration and sharpness of the focus. As US frequency 
decreases, the penetration of the beam increases but the creation of a sharply defined 
thermal focus becomes difficult. For this purpose, most of sonothrombolysis models were 
developed using low frequencies in order to penetrate the skull.  
 Thermal energy transfer 
The thermal energy (heat) produced by the absorption of US energy, is transferred to 
biological tissue through the following two mechanisms: 
1. Relaxation absorption, which is the most important 
2. Classical absorption, which is less important  
Relaxation absorption is the mechanism of thermal energy transfer that is 
dominant in US clinical frequencies and is described by the following relationship: 
 
𝛃𝐫, 𝐭𝐢𝐬𝐬𝐮𝐞 ∝ ∑
𝐟𝟐
𝟏 + (
𝐟
𝐟𝐫, 𝐧)
𝟐
𝐧
 
                                  (2.13) 
where βr is the relaxation absorption coefficient, f is the operating frequency and fr,n are 
the various relaxation frequencies present in the tissue. The relaxation frequency (fr) of 
each type of tissue corresponds to a relaxation time (𝛕 =
𝟏
𝐟𝐫
), which is the time required 
for elastic forces within the tissue to return the particles to their equilibrium position after 
having been displaced (either compressed or rarefacted), by a pressure wave. If the elastic 
forces are moving the particles to their equilibrium position (left) at the same time the 
next compression wave arrives, which tries to move the particles to opposite direction 
(right), then the two forces applied to particles are destructive and the amount of energy 
extracted from the pressure wave is maximum. In contrast, if the elastic forces are moving 
the particles to their equilibrium position (left) at the same time the next rarefaction wave 
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arrives (left), then the two forces applied to particles are constructive and the amount of 
energy extracted from the pressure wave, is minimum.  
Classical absorption is the second mechanism of thermal energy transfer and is 
less important. Classical absorption occurs due to the friction between particles in the 
tissue. It is proportional to the square of the operating frequency and is described by the 
following relationship: 
 𝛃𝐜𝐥𝐚𝐬𝐬𝐢𝐜𝐚𝐥 ∝ 𝐟
𝟐                                      (2.14) 
The friction between particles in a biological tissue as they are displaced by the passage 
of a pressure wave converts the US energy into heat and thus is proportional to the 
viscosity of the medium. For thermal applications of therapeutic US such as tumour 
ablation where the key point is temperature elevation at the focus of the beam, classical 
absorption is the dominant mechanism for heating [105]. 
 Image guidance 
Image guidance is very crucial in FUS surgery in order to verify that the patient is 
correctly positioned and to ensure that the therapeutic target and surrounding structures 
have been identified and localized. Also, real-time image guidance can provide targeting 
feedback during treatment. A technique known as thermometry can be used in thermal 
therapies to ensure accurate targeting and to monitor temperature changes especially in 
sensitive structures such as the brain. 
Currently, FUS systems are using either US or MR technique for image guidance. 
US guided FUS, sometimes referred as USgFUS systems [106], rely on diagnostic US 
imaging for target localization and post procedure verification. MR guided FUS, 
sometimes referred as MRgFUS systems [106], use MR for target localization and post 
procedure imaging for verification as well as real time monitoring of temperature changes 
through a technique called MR-thermometry [107]. This is due to the fact that MR 
parameters such as longitudinal relaxation time T1, transverse relaxation time T2, proton 
density (PD), diffusion coefficient (D), and proton resonance frequency (PRF) are 
temperature dependent.  
In general, temperature has a larger effect on T1 than T2, while the temperature 
dependency of proton density is much weaker. Among all these MR parameters, PRF is 
the most reliable indicator of temperature change. The excellent linearity with field 
strength and good temperature dependence of PRF as well as its tissue type independence 
for most soft tissues has made this thermometry method the most commonly used. In PRF 
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thermometry technique, the temperature change is determined using phase changes in 
gradient echo (GRE) pulse sequences. Temperature change is relative to a baseline 
condition, so images acquired during treatment are subtracted from baseline images 
acquired prior to temperature elevation. The change in temperature is described with the 
following formula: 
 
𝚫𝚻 =
𝜟𝝋 (𝑻 − 𝐓𝟎)
𝜸𝜶 𝑩𝟎𝑻𝑬
 
                                     (2.15) 
where, Δϕ is the absolute phase change of the MR signal at a starting and final 
temperature T and Τ0 respectively, γ is the gyromagnetic ratio, B0 is the main magnetic 
field, TE is the echo time and α is the PRF change coefficient. 
MR-thermometry based on PRF phase mapping method, can provide quantitative 
temperature measurements over the temperature range of interest used in FUS treatments, 
which are independent of tissue type and can be acquired at almost real-time using 
customized gradient echo (GRE) pulse sequences. PRF thermometry works best when the 
baseline and treatment images are perfectly aligned [107]. Any misalignment, caused by 
patient movement or internal organ motion, edema, structural changes and deformation 
of the treated tissue due to thermal coagulation, might cause artifacts in the resulting 
thermal map. Additionally, PRF phase mapping cannot be used to measure temperature 
within fatty tissue (e.g. breast), as the phase dependence of fat is almost independent of 
temperature [107]. 
 Biological effects of FUS 
The interaction of US waves with the targeted tissue can produce a variety of 
biological effects (bioeffects) that can be beneficial in a wide range of therapeutic 
applications. Bioeffects are classified into: 
1. Thermal effects (continuous wave exposure), cause changes related with temperature 
elevation as a direct result of US energy absorption in tissue. Thermal effects occur when 
tissue is damaged due to heating such as thermal ablation treatment. 
2. Non-thermal or mechanical effects (pulsed wave exposure), cause changes related with 
the mechanical interactions between US energy and tissue. Non thermal effects occur 
when tissue is damaged due to mechanical forces and can be categorized as primary 
mechanical effects such as acoustic radiation force (ARF) or secondary mechanical 
effects such as acoustic cavitation. ARF refers to the transfer of momentum from the 
propagating US wave in an attenuating medium. ARF can induce displacement in tissue 
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and motion in fluids. Cavitation activity refers to both bubble formation and oscillation 
due to an acoustic pressure and is divided into stable and inertial cavitation. Stable 
cavitation due to sustained bubbles motion generates microstreaming of the surrounding 
fluid, while inertial cavitation due to violent collapse of bubbles is associated with effects 
such as shock waves and liquid microjets. The non-thermal mechanisms underlying the 
biological effects induced when MBs are excited by FUS energy, are well presented in 
figure 2.4.  
 
Figure 2.4: In stable cavitation, radiation forces, microstreaming and shear stresses resulting from bubble 
oscillation can cause localized micron sized stretching of cells membrane, leading to increased cell 
permeability. In inertial cavitation, shock waves from violent bubble implosion, cause cell membrane 
disruption  [88], [108]. 
 Thermal effects 
US absorption in tissue causes microscopic-scale frictional heating, generated by 
shearing due to longitudinal compression and rarefraction pressure variations of the US. 
The friction between the molecules causes temperature elevation. The amount of 
temperature increase, which can be measured with techniques such as MR thermometry, 
depends on DF, intensity, frequency, type of tissue etc. It should be noted that when used 
for tissue ablation, FUS thermal effects are significantly different from traditional 
hyperthermia therapies as used in oncologic settings. Ablative FUS achieves much higher 
temperatures in a much shorter amount of time, and in a more localized area of tissue. 
Thermal effects causing ablation of tissue are currently the primary effects used in FUS. 
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 Non thermal effects 
 Acoustic radiation force 
Is a physical phenomenon associated with the interaction of a propagating US 
wave with a biological tissue. As a result, the medium is subjected to a mechanical force, 
which has the ability to deform it (tissue), or to set it in motion in the direction of 
propagation (fluid) [53]. Even though this tissue displacement induced by radiation force 
is small, is detectable and can be used in Magnetic Resonance Acoustic Radiation Force 
Imaging (MR-ARFI). This imaging technique uses highly motion sensitized gradients to 
measure tissue displacement within a resolution of micrometre (μm) and thus the position 
of the focal point of an US beam can be detected in MRI without significant tissue heating. 
The acoustic radiation force (ARF) generated in tissue due to the transfer of momentum 
from the propagating FUS wave, can be written in terms of the absorption coefficient of 
the medium (α), transmitted frequency (f), intensity at beam focus (I) and speed of sound 
in medium (c): 
 
𝑨𝑹𝑭 =
𝟐𝛂𝒇𝑰
𝒄
 
                                     (2.16) 
 Acoustic streaming 
As US waves propagate through a fluid, can transfer momentum to the fluid upon 
interaction, thus creating a force, which depends on viscosity, absorption coefficient and 
US energy. This force is set the fluid in motion, creating a circular flow along the 
propagation of US wave. Acoustic streaming can induce high velocity gradients at the 
boundary between fluid and more rigid structures such as thrombi, which in turn causes 
shearing stresses, promoting the exposure of the fibrin network to vigorous drugs [55]. 
The shear stress associated with a velocity gradient (grad V) is given by: 
 𝐒 = 𝐧𝐠𝐫𝐚𝐝(𝐕)                                      (2.17) 
where 𝐧 is the viscosity of water at 37 °C  
 Acoustic cavitation 
Is the interaction of US waves with microscopic gas bubbles, commonly known 
as MBs. In order for cavitation to occur in a medium, the presence of pockets containing 
gas at locations termed cavitation sites is required. When the negative pressure of the 
rarefaction cycle is high enough to exceed the tensile strength of medium, the particles 
are pulled apart and gas is drawn out from the cavitation sites, forming bubbles. Once a 
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bubble is formed, oscillates in phase with the applied US field and grows with time until 
it reaches unstable size and collapses [109]. A graphical summary of the of bubble 
formation, growth and collapse over several cycles is shown in figure 2.5. 
 
Two possible cavitation phenomena may occur, which are triggered above a certain 
threshold value, depending on the frequency of the US wave (figure 2.6): 
1. Stable cavitation: At low acoustic pressures, bubbles oscillate at, or near their 
resonance size for a long period of time. 
2. Unstable or inertial cavitation: At higher acoustic pressures, bubbles rapidly expand, 
become unstable and collapse violently during the compression cycle of US wave over a 
very short period of time. 
 
Figure 2.6: Effect of acoustic pressure on MBs oscillation and explosion [108], [110]. 
 
A simple relationship that can relate the resonance size of the bubble with the 
frequency is given by equation:  
 𝐅 𝐱 𝐑 ≈ 𝟑                                      (2.18) 
Figure 2.5: Bubble forms, oscillates in phase with the applied US field, grows with time and collapses 
when it reaches unstable size [109]. 
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where, F is the frequency in Hz and R is the bubble radius in m. Note that this equation 
gives only a very approximate theoretical resonance size [111]. 
The pressure amplitude required to initiate stable oscillations is always lower than 
that required for inertial cavitation. Therefore, the threshold for the onset of inertial 
cavitation is reached with a small increase in the pressure amplitude of stable cavitation.  
The ability of an US wave to induce cavitation is given by the Mechanical Index 
(MI), which is an estimation of the biological effects induced by an US wave. MI is 
defined as the Pn (MPa), divided by the square root of the US transmitted frequency f 
(MHz): 
 
𝐌𝐈 =
𝐏𝐧
√𝐟
 
                                     (2.19) 
 Microstreaming 
Is a phenomenon that occurs in fluids when a gas bubble undergoes direct 
oscillation due to US exposure. During oscillation, the gas bubbles displace small amount 
of fluid surrounding them, causing rapidly moving streams around their surfaces (eddying 
circular currents), termed microstreams. The fluid velocity is greatest near the bubble 
surface and decreases with distance from the bubble. Due to this velocity changes, a 
gradient exists in the vicinity of fluid around the oscillating bubble. Strong velocity 
gradients, form shear forces on the side of the cell near the bubble, which can damage 
cell membrane [112]. Therefore, shearing forces resulting from oscillating gas bubbles 
close to a rigid structure (thrombus or brain barrier), may disrupt or tear biological tissues 
[113].  
 Shock waves and liquid microjets 
At high enough acoustical pressures, bubbles oscillations become highly 
nonlinear, the bubbles expand to a certain size (unstable) and then, their radius decrease 
rapidly and collapse violently [88]. The stored energy is released in the form of shock 
waves within the bubbles and surrounding fluid. This violent collapse also produces high 
velocity liquid microjets. Biological tissues exposed to shock waves and high velocity 
microjets, experienced stresses large enough to damage them (cell membrane disruption) 
[67], [88]. 
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 Therapeutic applications of FUS 
The interaction of FUS with the targeted tissue can induce different biological effects 
as a result of either thermal or non-thermal mechanisms. These localised biological effects 
are determined by the type of tissue and the acoustic parameters such as power, exposure 
time, and mode (continuous or pulsed). By using either thermal energy to destruct tissue 
(thermal ablation), or mechanical energy to increase the precise delivery of drugs to 
targets in the body (sonoporation) or to dissolve blood clots (sonothrombolysis), FUS can 
be applied to treat noninvasively a wide range of different diseases [114]. 
 Sonoporation 
Cell membranes often prevent large molecules such as drugs or genes to pass into the 
cells and take effect. Low intensity US, alters temporarily cell membrane permeability 
and enhance the absorption of these molecules. When non thermal mechanisms such as 
stable cavitation occur at the boundary of cell membrane, have sufficient strength to 
modify the permeability of cell membranes by creating pores, allowing the therapeutic 
molecules to enter into the cell (figure 2.6). Additionally, the microstreaming produced, 
increases the flow of fluid in cell’s environment enhancing cellular uptake. This effect, 
known as sonoporation can increase the efficacy of drugs and genes in precise areas in 
the body. Potential applications taking advantage of this effect include drug delivery, gene 
therapy and selective opening of the blood-brain-barrier (BBB). 
 
Figure 2.7: FUS alters temporarily cell membrane permeability allowing large therapeutic molecules such 
as drugs to pass into the cells  [114]. 
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 Sonothrombolysis 
FUS, either alone, or as an adjunct to thrombolytic agents and/or in combination 
with microbubbles (MBs), has been shown to enhance thrombolysis and dissolve blood 
clots (figure 2.7). US energy is capable of accelerating clot breakdown via mechanisms 
that include thermal heating acoustic radiation force and cavitation. This could play a 
significant role in thrombolytic therapy such as the treatment of stroke, since there is a 
low risk of side effects outside the focal zone, although a high amount of energy is 
deposited at beam focus. 
 
Figure 2.8: FUS is capable of breaking down the fibrin matrix of blood clots [114] 
 
 
 
 
 
  
38 
 Review of protocols used in ultrasound thrombolysis  
 Introduction 
One of the early investigators who used US energy to accelerate the fibrinolytic 
activity of thrombolytic drugs in vitro, was Lauer et al. 1992 [60]. Later, more in vitro 
studies [59], [115], [116], have shown that US applications, improved thrombolysis 
induced by thrombolytic agents (sonothrombolysis). The knowledge on US thrombolysis 
was enhanced by performing experiments in animals [78], [117], [118]. When sufficient 
data were collected, this research was translated into clinical trials [91], [119], [120]. 
This chapter focuses on the review of protocols used in thrombolysis studies with 
US. The protocols of several published reports are summarised in three tables (in vitro, 
in vivo and clinical), providing detailed information concerning clot model, thrombolytic 
drug, treatment mode, sonication parameters, evaluation method, thrombolysis outcome, 
side effects and conclusions. 
 Aim of the review 
This review aims to give an overview of the different protocols used so far in the 
field of sonothrombolysis and to investigate the impact of several aspects involved, on 
thrombolysis outcome.The review provides information regarding: (1) the clot model 
used (human or animal for the in vitro studies and type of occlusion for the animal and 
clinical studies), (2) the US technique applied such as external or internal (catheter based) 
and focused or unfocused, (3) the use of flow system (only in vitro), (4) the temperature 
(only in vitro), (5) the type and concentration of thrombolytic drug used, (6) the treatment 
mode (US alone, drug alone, US + drug, US + MBs, and US + drug + MBs), (7) the 
sonication parameters applied, such as frequency, intensity or acoustic power or negative 
pressure, pulse repetition frequency (PRF), duty factor (DF) and treatment time, (8) the 
evaluation method used to estimate study’s outcome,  (9) the effect of treatment on clot 
lysis and (10) the main conclusions derived. 
 Methodology 
This review is divided into three categories (in vitro, in vivo and clinical) and 
provides a comprehensive compilation of protocols used during US thrombolysis studies 
with or without thrombolytic drugs and/or MBs, since 1992.  
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Published reports on thrombolysis with US that are available in PubMed 
(www.ncbi.nlm.nih.gov/pubmed), were collected. Information in several aspects of the 
protocols used in the studies examined, were also extracted. In animal studies as well as 
in clinical trials, the following info was needed: treatment time, evaluation method, 
treatment’s outcome, side effects and main conclusions.  In the in vitro compilation, the 
additional info needed was temperature. 
There is an absence in standardization about the necessary info collected from 
each study due to different methods/measuring units used by the investigators. For 
example, the output of US transducer is specified in different units (intensity, acoustic 
power, negative pressure etc.) and the treatment’s outcome is quantified by different 
evaluation methods such volume reduction, fibrin degradation products (FDP), lytic rate, 
recanalization rate, etc. Furthermore, in some cases experimental parameters like 
temperature, PRF and DF are not specified.  
 Analysis of results 
Table 1 lists the in vitro studies, which include info that describe the clot model 
used (human or animal clot, flow system, focused or unfocused US waves, external or 
internal US device, temperature, type and concentration of thrombolytic drug). Also, info 
is provided regarding the treatment mode (US, drug, MBs), along with the sonication 
parameters applied (frequency, output, PRF, DF and treatment time). Moreover, the 
evaluation method, the treatment’s outcome and the main conclusions are presented as 
well. 
Table 2 lists the in vivo studies, which include info that describe the clot model 
used (type of occlusion, focused or unfocused US waves, external or internal US device, 
type and concentration of thrombolytic drug). Also, info is provided regarding the 
treatment mode (US, drug, MBs) and the sonication parameters applied (frequency, 
output, PRF, DF and treatment time). Moreover, the evaluation method, the treatment’s 
outcome, the side effects and the main conclusions are also presented. 
Table 3 lists the clinical studies, which include info that describe the clot model 
used (type of occlusion, focused or unfocused US waves, external or internal US device, 
type and concentration of thrombolytic drug). Also, info is provided regarding the 
treatment mode (US, drug, MBs) and the sonication parameters applied (frequency, 
output, PRF, DF and treatment time). Moreover, the evaluation method, the treatment’s 
outcome, the side effects and the main conclusions are presented as well.
  
40 
 Review of protocols used in ultrasound thrombolysis 
Table 2: In vitro protocols used in US thrombolysis 
Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human rt-PA 
(3000 IU/mL) 
37  Yes       50 Measured 
volume 
reduction 
33 % [60] 
   Yes  1 MHz 1.75 W/cm2 
ISATA 
Intermittent 50 50 50 % 
  Yes       200 62 % 
   Yes  1 MHz 1.75 W/cm2 
ISATA 
Intermittent 50 200 91 % 
US combined with rt-PA 
caused a significant 
enhancement of 
thrombolysis compared 
with rt-PA alone. 
 
 
 
 
 
 
 
Human rt-PA 
(1 μg/mL) 
37  Yes       60 Measured 
volume 
reduction 
8 % [115] 
    Yes  27 kHz 1 W/cm2 70 10 60 17 % 
     Yes  40 kHz 1 W/cm2 70 10 60 20 % 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Yes  100 kHz 1 W/cm2 70 10 60 15 % 
US in the range of 27 to 
100 kHz is effective in 
accelerating fibrinolysis at 
intensities and pulsing 
conditions that minimize 
the probability of heating 
and cavitation. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human rt-PA 
(3000 IU/mL) 
36  Yes 
 
      60 Measured 
volume 
reduction 
22.7 % [56] 
    Yes  2 MHz 1.2 W/cm2 cw 100 60 49 % (travelling) 
    Yes  2 MHz 1.2 W/cm2 cw 100 60 34.8 % (standing) 
     Yes  2 MHz 1.2 W/cm2 1, 10, 100, 
1000 
50 60 46.4, 39.8, 44, 34 % 
Intermittent application 
of a 2 MHz high 
frequency US using a 
travelling wave field 
would be the most potent 
application for lysing 
blood clots. No effect of 
PRF on clot lysis. 
 
Human rt-PA 
(3000 IU/mL) 
37 Yes    1.95 MHz 1.2 W/cm2 
ISATA 
1 50 60 Measured 
volume 
reduction 
25.3 % [116] 
   Yes       60 19.9 % 
    Yes  1.95 MHz 1.75 W/cm
2 
ISATA 
1 50 60 35.2 % 
US enhances 
thrombolysis by affecting 
the distribution of rt-PA 
within the clot. 
 
Human rt-PA 
(3.15 μg/mL) 
37  Yes       30 Measured lytic 
rate 
0.5 μm/min [121] 
    Yes  120 kHz 0.35 MPa 1667 80 30 3.4 μm/min 
US treatment + rt-PA 
significantly enhanced the 
mean lytic rate (580% 
change), compared with 
rt-PA treatment alone. 
 
Human rt-PA 
(3.15 μg/mL) 
37  Yes       30 Measured lytic 
rate 
7 μm/min [122] 
    Yes  120 kHz 0.35 MPa 1667 10, 
20, 
50, 
80 
30 15, 25, 50, 65         
μm/min 
The lytic efficacy of clots 
exposed to rt-PA and US 
increases with increasing 
DF. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Porcine rt-PA 
(107 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
12 % [59] 
    Yes  120 kHz 0.35 MPa 1.7 k 80 30 19.1 % 
     Yes  1 MHz 0.35 MPa 1.7 k 100 30 25 % 
     Yes  1 MHz 0.35 MPa 1.7 k 10 30 22 % 
Both 120-kHz and 1-MHz 
pulsed and cw US 
enhanced rt-PA 
thrombolysis in a porcine 
whole blood clot model. 
 
Human rt-PA 
(10 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
16 % [123] 
    Yes  120 kHz 0.35 MPa 1667 50 30 31 % 
120-kHz US substantially 
increases the lytic efficacy 
of rt-PA for almost all rt-
PA concentrations. 
 
Human rt-PA 
(3.15 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
31 % [63] 
    Yes  120 kHz 0.35 MPa 1667 50 30 71 %  
   Yes  Yes 
(t-ELIP) 
    30 48 %  
     Yes Yes 
(t-ELIP) 
120 kHz 0.35 MPa 1667 50 30 89 % 
The addition of 120 kHz 
US with t-ELIP 
substantially increases 
the rate of lysis compared 
with either tPA or t-ELIP 
alone. 
 
 
Human rt-PA 
(0.5-3.15 
μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
38-44 % [124] 
    Yes  120 kHz 0.18 MPa 1667 50 30 50-70 % 
     Yes  2 MHz 0.47 MPa 10.5 k 13 30 52-58 % 
Combination treatment 
with rt-PA is more 
effective than rt-PA alone 
in human whole blood 
clots. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Fibrin 
gel 
rt-PA 
(0.1 μg/mL) 
25   Yes  1 MHz 2 W/cm2 100 50  Measured 
binding ratios 
US exposure accelerates 
rt-PA binding, alters 
binding affinity, and 
increases maximum 
binding to polymerized 
fibrin 
 
[125] 
          
            
Fibrin 
gel 
  Yes    1 MHz 4 W/cm2 c.w. 100 15 Measured 
fiber density 
Measured 
fiber diameter 
>  65 % 
 
[51] 
           < 27 % 
US exposure causes 
reversible disaggregation 
of uncrosslinked fibrin 
fibers into smaller fibers, 
an effect that may alter 
flow resistance and 
create additional binding 
sites for fibrinolytic 
components, improving 
fibrinolytic efficacy. 
Human rt-PA 
(0.1 μg/mL) 
37  Yes       240 Measured 
uptake rate 
 
8.2 % [46] 
    Yes  1 MHz 4 W/cm2 c.w. 100 240 15.5 % 
Exposure to US increases 
uptake of rt-PA into clots 
and also results in deeper 
penetration. 
 
Human rt-PA 
(2 μg/mL) 
  Yes       60 Measured 
fibrin 
degradation 
product, 
 D-dimer 
(FDP-DD) 
957 ng/mL [57] 
    Yes  300 kHz 0.07 W/cm2 c.w. 100 60 1669 ng/mL 
     Yes  1 MHz 0.4 W/cm2 c.w. 100 60 1727 ng/mL 
The combination of drug 
and US leads to 
degradation of fibrin, 
allowing a quantitative 
measurement of the 
enhancement of clot lysis. 
A high correlation was 
observed between the 
FDP-DD produced with 
the rate of decrease in 
clot weight. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human 
Flow 
system 
 
UK 
(400 U/mL) 
37  Yes       60 Measured 
volume 
reduction 
18.7 % [126] 
   Yes  1 MHz 2.5 W/cm2 c.w. 100 60 52.5 % 
C.W. US at 1 MHz and an 
intensity of 2.5 W/cm2 
accelerates urokinase-
induced thrombolysis and 
reperfusion. 
 
 
 
Human SK 
(5000 U/mL) 
37  Yes       65 Measured 
reperfusion 
rate 
100 % [127] 
    Yes  170 kHz 0.5 W/cm2 
(ISATA) 
c.w. 100 34 100 % 
    Yes       39 100 % 
     Yes  1 MHz 1 W/cm2 
(ISATA) 
c.w. 100 20  100 % 
US exposure of a type and 
intensity that may be 
transmitted 
transthoracically 
accelerates the 
thrombolytic process (for 
both frequencies used). 
 
 
Human 
HIFU 
rt-PA 
(10 μg/mL) 
37 Yes    1 MHz 60 W 1 10 30 Measured 
volume 
reduction 
33 % [75] 
  Yes       30 53.1 % 
    Yes  1 MHz 60 W 1 10 30 63.2 % 
The rate of tPA-mediated 
thrombolysis can be 
enhanced by using pulsed 
HIFU exposure. 
 
 
Human rt-PA 
(1.0 μg/mL) 
37  Yes       60 Measured 
volume 
reduction 
12.8 % [35] 
    Yes  1 MHz 1, 2, 4, 8 
W/cm2 
c.w. 100 60 18, 19.3, 22.8, 58.7 % 
US at 1 MHz potentiates 
enzymatic fibrinolysis by a 
non-thermal mechanism. 
Thrombolysis efficiency 
increases with intensity. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human  UK (200, 
2000, 5000 
μg/mL) 
room Yes    1 MHz 2.2 W/cm2 n/s n/s 30 Measured 
volume 
reduction 
18 % [128] 
  Yes       30 19, 44, 50 % 
   Yes  1 MHz 2.2 W/cm2 n/s n/s 30 41, 55, 61 % 
SK (50, 250, 
2000 μg/mL) 
 Yes    1 MHz 2.2 W/cm2 n/s n/s 30 26 % 
   Yes       30 37, 50. 62 % 
    Yes  1 MHz 2.2 W/cm2 n/s n/s 30 45, 61, 73 % 
The use of external US 
has the potential to 
increase both efficacy and 
rate of thrombolysis. 
Thrombolysis efficiency 
increases with drug dose. 
Thrombolytic activity of 
SK more effective than 
UK. 
 
 
Human rt-PA 
(1.0 μg/mL) 
37  Yes       60 Measured 
volume 
reduction 
23 % [129] 
    Yes  2.2 MHz 0.5, 1, 2, 4, 8 
W/cm2 
n/s n/s 60 31, 40, 48, 69, 88 % 
US accelerates enzymatic 
fibrinolysis by increasing 
transport of reactants 
through a cavitation-
related mechanism. 
Thrombolysis efficiency 
increases with intensity. 
 
            
Human rt-PA 
(66.7  μg/mL) 
37  Yes       25 Measured 
volume 
reduction 
7.24 % [126] 
   Yes  0.5 MHz 8 W/cm2 c.w. 100 25 26.7 % 
US waves accelerate rt-
PA-induced thrombolysis 
and reperfusion. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human rt-PA 
(1  μg/mL) 
37  Yes       60,120 Measured 
volume 
reduction 
13, 37 % [130] 
    Yes  40 kHz 0.25 W/cm2 c.w. 100 60,120  39, 93 % 
    Yes  40 kHz 0.75, 1, 1.5 
W/cm2 
c.w. 100 60 58. 75, 77 % 
40-kHz US significantly 
accelerates enzymatic 
fibrinolysis with excellent 
tissue penetration and 
minimal heating. 
Thrombolysis efficiency 
increases with intensity. 
 
 
Human rt-PA 
(3000 U/mL) 
37  Yes       60 Measured 
volume 
reduction 
23.8 % [55] 
    Yes  1 MHz 1.2 W/cm2 c.w. 100 60 34.8 (standing) 
    Yes       60 11.3 % 
     Yes  2 MHz 1.2 W/cm2 c.w. 100 60 24.5 % (travelling) 
Travelling US waves 
enhanced thrombolysis 
(116.8%), which is 
significantly more than 
standing US waves did  
(46 %). 
 
 
 
Human 
 
rt-PA 
(3 μg/mL) 
37 Yes    20 kHz 0.35 W/cm2 c.w. 100 10 Measured 
volume 
reduction 
41.8 % [131] 
  Yes       20 49.1 % 
     Yes  20 kHz 0.35 W/cm2 c.w. 100 10 65.8 % 
The use of low-frequency 
US alone, has the 
potential to induce 
thrombolysis. 
Combination of US with 
rt-PA is superior to either 
treatment alone. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human rt-PA 
(3.15 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
15.6 % [132] 
   Yes + Epf.       30 28 % 
    Yes  120 kHz 0.18 MPa 1667 80 30 44.4 % 
     Yes + Epf.  120 kHz 0.18 MPa 1667 80 30 30.3 % 
Although the addition of 
eptifibatide enhances the 
lytic efficacy of rt-PA 
alone, the efficacy of US 
and rt-PA is greater than 
that of combined US, rt-
PA and eptifibatide 
exposure. 
 
Human UK 
(2 mg/mL) 
37  Yes       720 Measured 
volume 
reduction 
43 % [133] 
    Yes  211.5 kHz 0.25 W/cm2 c.w. 100 720 61 % 
Low-frequency US 
transmits well through 
human temporal bone 
and enhances 
thrombolysis. 
 
 
Human 
Through 
skull 
rt-PA 
(100 μg/mL) 
37 Yes    33.3 kHz 0.5 W/cm2 n/s n/s 60, 
180 
Measured 
volume 
reduction 
39.96, 44.09 % [134] 
 
 Yes    71.4 kHz 3.4 W/cm2 n/s n/s 60, 
180 
32.24, 35.17 % 
   Yes       60, 
180 
46.55, 56.27 % 
    Yes  33.3 kHz 0.5 W/cm2 n/s n/s 60, 
180 
51.04, 67.89 % 
     Yes  71.4 kHz 3.4 W/cm2 n/s n/s 60, 
180 
46.23, 60.47 % 
Transcranial 
application of US can 
shorten the recanalization 
time of intracerebral 
vessel occlusion by 
increasing rt- 
PA-mediated 
thrombolysis. 
Thrombolysis efficiency 
increases with time. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human rt-PA 
(3.15 μg/mL) 
33, 37 Yes    120 kHz 3.2 W/cm2 1667 80 30 Measured 
volume 
reduction 
7.5, 7.2 % [135] 
   Yes       30 8.6, 12.4 % 
     Yes  120 kHz 3.2 W/cm2 1667 80 30 21.2, 22.7 % 
The efficacy of US 
enhanced thrombolysis 
decreases at 
temperatures below the 
body baseline 
temperature of 37 0C. 
 
Human 
Through 
temporal 
bone 
rt-PA 
(10 μg/mL) 
37 Yes    1.8 MHz 1.6 MI n/s n/s 60 Measured 
volume 
reduction 
41 % 
70.8 % 
[136] 
  Yes       60 78.7 % 
    Yes  1.8 MHz 1.6 MI n/s n/s 60 Diagnostic transcranial US 
with rt-PA, enhances 
thrombolysis. 
 
Human 
Through 
skull 
HIFU 
Flow 
system 
 
 n/s Yes    220 kHz 111 W/cm2 2.5 50 0.5 Measured 
volume 
reduction 
76.1 % (flow) [81] 
 n/s Yes    220 kHz 111 W/cm2 2.5 50 0.5 29.9 % (no flow) 
Transskull HIFU for 
immediate clot lysis 
without the need of 
further drugs and 
disregarding individual 
skull bone characteristics 
is feasible. 
Human UK 
(1200 IU) 
37  Yes       60 Measured 
volume 
reduction after 
incubation 
 
 
 
40.6 % [35] 
     Yes  48 kHz 5-6 kPa n/s n/s 60 59.2 % 
   Yes       60, 
120 
8.9, 46.7 % 
     Yes  225 kHz 30 mW/cm2 n/s n/s 60, 
120 
37.3, 61.1 % 
US energy enhanced 
fibrinolysis with UK, 
especially in the early 
phase of lysis. 
Thrombolysis efficiency 
increases with time and 
decreases with frequency. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Bovine 
Through 
skull 
Flow 
system 
rt-PA 
(100 μg/mL) 
37  Yes       29.3 Measured 
recanalization 
rate 
100 % [137] 
37   Yes  1 MHz 0.35 W/cm2 
(ISPTP) 
16 k 41.6 17.1 100 % 
    Yes  185 kHz 1.27 W/cm2 
(ISPTP) 
c.w. 100 14.1 100 % 
Transcranial application 
of low frequency, c.w. US 
may accelerate 
reperfusion and shorten 
the recanalization time. 
 
Bovine 
Through 
skull 
Flow 
system 
rt-PA 
(100 μg/mL) 
37  Yes       30 Measured 
recanalization 
rate 
30 % [58] 
   Yes  1 MHz 0.35 W/cm2 
(ISPTP) 
16000 41.6 30 90-100 % 
Transcranial application 
of 1 MHz US may 
accelerate reperfusion 
and recanalization rate of 
occluded intracerebral 
vessels. 
Human 
Through 
skull 
HIFU 
Flow 
system 
 24 Yes    220 kHz 
 
13.7, 
27.4, 
54.8, 
136.8 
W/cm2 
(ISPTA) 
0.5, 
5, 
50, 
500 
 
5, 
10, 
20, 
50 
0.5 Measured 
volume 
reduction 
10.3-27.2 % 
17.1-42.9 % 
30-59.6 % 
48.7-59.2 % 
Using transcranial HIFU, 
significant thrombolysis 
can be achieved within 
sec and without the use 
of lytic drugs. Longer DF 
in combination with 
longer pw seem to have 
the highest potential to 
optimize clot lysis 
efficacy. 
[138] 
Human 
FUS 
 n/s Yes    550 kHz 200 W 3.7 10 5 Measured 
volume 
reduction 
80 % [139] 
  Yes    535 and 
565 kHz 
110 W 3.7 10 5 80 % 
The power needed to 
achieve 80 % of 
thrombolysis with a 
monofrequency 
excitation is reduced by 
the half with a 
bifrequency excitation. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human 
 
rt-PA 
(60 kU/mL) 
37  Yes       60 Measured 
volume 
reduction 
36.7 % [140] 
    Yes  2 MHz 
TCCD 
0.179 W/cm2 n/s n/s 60 40.8 % 
     Yes  2 MHz 
TCD 
0.457 W/cm2 n/s n/s 60 40.4 % 
Although clot lysis rate 
after I h treatment with 
rt-PA alone was 
significant, a slight 
increase of weight loss 
was detected under the 
application of US + drug. 
 
Human 
HIFU 
 
 37 Yes    230 kHz 
 
1000 W 1000 10 0.5 Measured 
volume 
reduction 
82 % 
After sonication, the clot 
was nearly completely 
lysed. 
 
 
[87] 
Human 
Through 
skull 
HIFU 
Flow 
system 
 37 Yes    220 kHz 
 
29.71-193.24 
W/cm2 
(ISPTA) 
2,5 50 0.5 Measured 
volume 
reduction 
4.55-74.83 % 
Transcranial 
sonothrombolysis could 
be achieved within sec in 
the absence of rt-PA and 
without producing 
relevant clot 
fragmentation, using 
acoustic output powers of 
<400 W. 
 
[141] 
Bovine  n/s Yes    500 kHz ISPTA > 35 
W/cm2 
200 4 4 Measured 
volume 
reduction 
91 % 
External HIFU 
thrombolysis for periods 
of ≤ 5 min appears to be a 
safe and effective method 
to induce thrombolysis. 
 
 
[142] 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Rabbit 
Flow 
model 
 room Yes    1.51 MHz 185 W 1 0.1 0.33 Measured 
volume 
reduction 
99.2 % 
HIFU thrombolysis is 
feasible as a means of 
restoring partial blood 
flow in thrombus 
occluded arteries in the 
absence of thrombolytic 
agents. 
 
 
[82] 
Human 
 
rt-PA 
(10 μg/mL) 
37 Yes    1 MHz 4 W/cm2 
(ISATA) 
c.w. 100 60 Measured 
volume 
reduction 
6.8 % @ 0 atm [143] 
   Yes    
 
   60 21.8 % @ 0 atm 
     Yes  1 MHz 
 
4 W/cm2 
(ISATA) 
c.w. 100 60 39.3 % @ 0 atm 
US is ineffective in 
increasing fibrinolysis 
without a fibrinolytic 
agent present. An 80% 
increase in clot lysis 
occurs when US and 
agent are both present 
(no overpressure). 
 
 
Porcine rt-PA 
(107 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
13 % [144] 
 
 
    Yes  120 kHz 0.15 MPa 1667 80 30 13.7 % (< SC) 
     Yes  120 kHz 0.24 MPa 1667 80 30 26 % (SC) 
     Yes  120 kHz 0.36 MPa 1667 80 30 20.7 % (SC+ IC) 
Significant enhancement 
of thrombolysis correlates 
with presence of 
cavitation. Stable 
cavitation appears to play 
a more important role in 
the enhancement of 
thrombolysis. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human 
Catheter 
type 
Flow 
system 
rt-PA 
(300 μg/mL) 
37  Yes       10 Measured 
volume 
reduction 
13.6 % [145] 
   Yes  1.7 MHz 62.46 W/cm2 
(ISPPA) 
30 8.5 10 21.4 % 
     Yes  1.7 MHz 180.02 
W/cm2 
(ISPPA) 
40 4 10 46.1 % 
Thrombolysis efficiency 
increases with intensity. 
 
 
Human rt-PA 
(96 μg/mL) 
37 Yes   Yes 120 kHz 0.32 MPa 1667 80 30 Measured 
volume 
reduction 
6.3 % [69] 
   Yes       30 13.0 % 
     Yes  120 kHz 0.32 MPa 1667 80 30 16.0 % 
     Yes Yes 120 kHz 0.32 MPa 1667 80 30 26.2 % 
MBs administration 
further increases the 
effect of US on rt-PA 
induced thrombolysis. 
 
 
Bovine rt-PA 
(1000 IU/mL) 
37 Yes   Yes 500 kHz 0.7 W/cm2 c.w. 100 1 Measured 
volume 
reduction 
25.8 % [146] 
    Yes       1 24.2 % 
    Yes  500 kHz 0.7 W/cm2 c.w. 100 1 24.9 % 
     Yes Yes 500 kHz 0.7 W/cm2 c.w. 100 1 29.2 % 
MBs have slightly 
accelerated the 
thrombolytic effect of rt-
PA. 
 
 
Human 
Catheter 
type 
rt-PA 
(5000 IU/mL) 
37 Yes   Yes 1.7 MHz 4.9 W/cm2 
ISATA 
n/s n/s 30 Measured 
volume 
reduction 
0.95 % [66] 
 
  Yes       30 7.68 % 
   Yes  1.7 MHz 4.9 W/cm2 
ISATA 
n/s n/s 30 11.10 % 
     Yes Yes 1.7 MHz 4.9 W/cm2 
ISATA 
n/s n/s 30 14.41 % 
SC plays an important 
role in MB-enhanced US 
accelerated rt-PA 
mediated thrombolysis. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human 
Flow 
system 
rt-PA 
(20 μg/mL) 
37 Yes    2 MHz 455 mW/cm2 
ISPTA 
5000 n/s 30 Measured 
volume 
reduction 
6.1 % [68] 
 
  Yes   Yes  455 mW/cm2 
ISPTA 
5000 n/s 30 10.9 % 
     Yes  2 MHz 455 mW/cm2 
ISPTA 
5000 n/s 30 13.1 % 
     Yes Yes 2 MHz 455 mW/cm2 
ISPTA 
5000 n/s 30 30.7 % 
The application of MBs 
strongly accelerates lysis 
of clots exposed to low-
intensity US with 
rt-PA. 
Rabbit  25 Yes   Yes 
(3 μm)  
1 MHz 0.1 W/cm2 100 20 30 Measured 
volume 
reduction 
18 % [147] 
   Yes   Yes  
(1 μm) 
 
3 MHz 2 W/cm2 
 
100 20 30 18 % 
Sonothrombolysis efficacy 
was achieved at twenty-
fold lower intensity with 3 
μm MBs (0.1 W/cm2) 
than with 1 μm MBs (2.0 
W/cm2). 
 
Porcine 
Flow 
system 
 
rt-PA 
(7.1 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
29 % [148] 
  Yes  Yes 120 kHz 0.44 MPa c.w. 100 30 34 % 
    Yes Yes 120 kHz 0.44 MPa c.w. 100 30 83 % (SC) 
SC nucleated by an 
infusion of MBs enhances 
rt-PA thrombolysis 
without apparent 
treatment-related 
damage. 
 
Human 
Flow 
system 
 
rt-PA  
(3 μg/mL) 
37  Yes       60 Measured clot 
diameter loss 
 
6.6 μm/min [149] 
rt-PA  
(0.3 μg/mL) 
   Yes Yes 1.6 MHz 600 kPa 0.33 33 60 5.9 μm/min 
Τhe combination of US, 
MB and a low dose of rt-
PA (0.3 μg/mL) is as 
effective for thrombolysis 
as is a high dose of rt-PA 
(3 μg/mL) alone. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Porcine 
Flow 
system 
 
rt-PA 
(3 μg/mL) 
37  Yes       30 Measured 
volume 
reduction 
25.6% [150] 
   Yes Yes 1 MHz 1 MPa 0.2 0.002 30 55.7 % 
The US + MB + rt-PA 
treatment showed 
dramatically higher lytic 
efficacy than rt-PA 
treatment alone. 
 
Porcine 
Flow 
system 
 
rt-PA 
(1 μg/mL) 
37 Yes   Yes 1 MHz 1.5 MPa 0.34 0.17 20 Measured lytic 
efficacy 
In terms of 
pressure 
change 
(thrombotic 
occlusion = 40 
mm Hg) 
 
6 mm Hg [151] 
   Yes Yes 1 MHz 1 MPa 0.34 0.17 20 2 mm Hg 
Similar lytic efficacy was 
achieved at 1.5 MPa 
without rt-PA as was at 
1.0 MPa with rt-PA. 
Porcine 
Flow 
system 
 
  Yes   Yes 1.6 MHz 0.2 (MI) n/s n/s 10 Measured 
volume 
reduction 
54 % (20 μs PD) [152] 
  Yes   Yes 1.6 MHz 0.2 (MI) 
 
n/s n/s 10 33 % (5 μs PD) 
Slightly prolonging the 
pulse duration (PD) on a 
diagnostic transducer 
improves the degree of 
sonothrombolysis that 
can be achieved without 
fibrinolytic agents at a 
lower MI. 
 
 
Human 
Flow 
system 
 
rt-PA 
(0.32-3.15 
μg/mL) 
37.3  Yes       10 Measured lytic 
rate 
0.8-2 %/min [153] 
   Yes  120 kHz 0.44 MPa Inter. 62.5 30  0.8-2 %/min 
   Yes Yes 120 kHz 0.44 MPa Inter. 62.5 30  2-5.5 %/min 
MBs administration 
significantly enhanced 
lytic rate. Both SC and 
radiation force are 
mechanistically 
responsible for the 
process of clot lysis. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Human 
Flow 
system 
 
rt-PA 
(3 μg/mL) 
37  Yes       60 Measured 
fibrin 
degradation 
product (FDP) 
51.7 % [154] 
   Yes Yes 1 MHz 528 mW/cm2 
ISPTA 
0.8 40 60 53.2 % (SC) 
    Yes Yes 1 MHz 323 mW/cm2 
ISPTA 
0.8 8 60 57.2 % (SC+IC) 
     Yes Yes 1 MHz 3 mW/cm2 
ISPTA 
0.8 0.08 60 50.9 % (SC+IC) 
     Yes Yes 1 MHz 45 mW/cm2 
ISPTA 
0.8 0.08 60 66.3 % (IC) 
Both SC and IC, resulting 
from the 
US–MB interaction, 
increased the efficacy of 
rt-PA with respect to 
fibrin degradation. 
 
 
 
 
 
 
 
Porcine 
FUS 
Flow 
system 
 
rt-PA 
(3.5 μg/mL) 
37 Yes   Yes 1 MHz 20 W 100 10 30 Measured 
volume 
reduction 
31 % [76] 
  Yes       30 45%  
   Yes  1 MHz 20 W 100 10 30  56.2%  
   Yes Yes 1 MHz 20 W 100 10 30  69.5 % 
MBs administration 
further enhanced the 
beneficial effect of FUS on 
TNK-tPA mediated 
thrombolysis. 
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Clot 
model 
Drug Temp. 
(0C) 
Mode 
 
US alone   Drug alone  US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Ref. 
Porcine 
Flow 
system 
 
rt-PA 
(7 μg/mL) 
37  Yes       30 Measured  
volume 
reduction 
29.2 % [77] 
   Yes  0.6 MHz 60 W 100 10 30  45.8 %   
   Yes  1 MHz 20-60 W 100 10 30 39-62,5 %   
    Yes Yes 1 MHz 60 W 100 10 30 87.5 %   
            1 MHz FUS frequency is 
associated with enhanced 
thrombolysis compared 
to that of 0.6 MHz. An 
increase linear 
relationship between 
acoustic power and 
thrombolysis efficacy was 
exhibited. The 
combination of MBs + 
FUS strongly enhanced 
the thrombolytic efficacy 
of TNK-tPA. 
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Table 3: In vivo protocols used in US thrombolysis 
Clot 
model 
Drug Mode 
 
US alone    Drug alone   US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
conclusion 
Side 
effects 
Ref. 
Rat 
Jugular vein 
occlusion 
rt-PA (1 mg) 
 
 Yes 
 
      50, 200 Measured 
volume 
reduction 
20, 30 %  [60] 
   Yes  1 MHz 1.75 W/cm2 Intermittent 50 50, 200 41, 55 %   
rt-PA (2 mg)  Yes       50, 200 28, 40 %   
   Yes  1 MHz 1.75 W/cm2 
 
Intermittent 50 50, 200  45, 50 % 
Intermittent US 
administered during a 
200-min period showed 
a trend toward 
enhancement of rt-PA-
induced fibrinolysis 
without causing thermal 
changes or inducing 
tissue damage. 
Thrombolysis efficiency 
increased with drug 
dose. 
 
  
Rat 
MCA stroke  
rt-PA (10 
mg/kg) 
 Yes       60 Measured 
relative infarct 
volume 
reduction 
34 % 18 % ICH [155] 
 
rt-PA (5 
mg/kg) 
  Yes  25.6 kHz 0.6 W/cm2 
 
n/s 20 60 51 %  
rt-PA (10 
mg/kg) 
  Yes  25.6 kHz 0.6 W/cm2 n/s 20 60 68 % 
US treatment in 
addition to rt-PA is more 
effective than single rt-
PA treatment in 
reducing infarct volume 
and safe with regard to 
bleeding. Thrombolysis 
efficiency increased 
with drug dose. 
 
20 % ICH 
Rabbit 
Embolic 
stroke 
HIFU 
 Yes    1.5 MHz 255 W 1 0.1 0.33 Measured 
reperfusion 
rate 
0 % (0/3)  [86] 
 Yes    1.5 MHz 415 W 
 
1 0.1 0.33 50 %  (2/4)  
 Yes    1.5 MHz 550 W 1 0.1 0.33  70 % (5/7) 
HIFU, as a stand-alone 
method, can cause 
effective thrombolysis 
and does not damage 
the targeted vessels. 
 
 
 
20 % ICH 
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Clot 
model 
Drug Mode 
 
US alone    Drug alone   US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
conclusion 
Side 
effects 
Ref. 
Rabbit 
 MCA 
Stroke 
HIFU 
 Yes   Yes 1.5 MHz 88-137 W 1 0.1 0.33 Measured 
recanalization 
rate 
78 % (7/9) 22 % ICH [156] 
 Yes   Yes 1.5 MHz 88 W 
 
10 0.1 0.33 50 %  (1/2) 
Droplets reduce the IC 
threshold and enable IC-
mediated clot lysis to 
occur at lower power 
levels. 
 
Rabbit 
Femoral 
artery 
occlusion 
HIFU 
 
 Yes    1.51 MHz 185 W 1 0.1 0.33 Measured flow 
restoration 
rate 
0 % (0/5)  [82] 
 Yes    1.51 MHz 215 W 
 
1 0.1 0.33 50 % (1/2)  
 Yes    1.51 MHz 300 W 1 0.1 0.33 63 % (5/8) 
HIFU thrombolysis is 
feasible as a means of 
restoring partial blood 
flow in thrombus-
occluded arteries in the 
absence of thrombolytic 
agents. Increased power 
resulted in increased 
flow restoration rate. 
13 % ICH 
Rabbit 
Iliofemoral 
artery 
occlusion 
SK 
(25000 U/kg) 
  Yes  37 kHz 160 W 91 n/s 15 Measured 
recanalization 
rate 
40 % (6/15)  
 
[157] 
   Yes  37 kHz 160 W 91 n/s 30 67 % (10/15) 
  Yes  37 kHz 160 W 91 n/s 45 87 % (13/15) 
  Yes  37 kHz 160 W 91 n/s 60 100 % (15/15) 
Transcutaneous 
concentrated US which 
significantly enhances 
streptokinase induced 
thrombolysis in vivo can 
be delivered without 
concomitant tissue 
damage. Recanalization 
rate increases with 
treatment time. 
Rabbit 
Iliofemoral 
artery 
occlusion 
 Yes    37 kHz 160 W 91 n/s 60 Measured 
recanalization 
rate 
0 % (0/5)  [158] 
    Yes 37 kHz 160 W 91 n/s 60 0 % (0/10)  
 Yes   Yes 37 kHz 160 W 91 n/s 15 30 % (3/10)  
 Yes   Yes 37 kHz 160 W 91 n/s 30 50 % (5/10)  
 Yes   Yes 37 kHz 160 W 91 n/s 45  70 % (7/10)  
 Yes   Yes 37 kHz 160 W 91 n/s 60  100 % (10/10) 
In vivo arterial clot 
dissolution can be 
achieved with i.v. MBs 
and transcutaneous US. 
Recanalization rate 
increased with 
treatment time. 
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Clot 
model 
Drug Mode 
 
US alone    Drug alone   US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
conclusion 
Side 
effects 
Ref. 
 
Rabbit 
Marginal 
ear vein 
occlusion 
HIFU 
 
rt-PA 
(1 mg/kg) 
Yes    1 MHz 40 W 1 5 15 Measured 
relative clot 
size at 5 h post 
treatment 
 
90 %  [78] 
 Yes       15 78 %  
  Yes  1 MHz 40 W 1 5 15 4 % 
rt-PA mediated 
thrombolysis can be 
significantly enhanced 
when combined with 
non-invasive pulsed-
HIFU exposures. 
 
Rabbit 
Femoral 
artery 
occlusion 
SK 
(15000 U/kg) 
bolus 
followed by 
an infusion 
of 15,000 
U/kg per h. 
 Yes       120 Measured 
volume 
reduction 
 
13 % (2/15)  [117] 
  Yes  1 MHz 2 W/cm2 c.w.  120 53 % (9/17) 
Externally applied, low-
intensity US can 
significantly enhance 
thrombolysis in a rabbit 
arterial model. 
 
Rabbit 
Femoral 
artery 
occlusion 
rt-PA 
(200 μg/5 mg 
of lipid) 
Yes   Empty 
ELIP 
5.7 MHz 1.25 MPa 5 k n/s 2 Measured 
recanalization 
rate at 15 min 
post treatment 
27 %  [64] 
 Yes  rt-PA 
ELIP 
rt-PA 
ELIP 
    2 60 %  
   Yes 5.7 MHz 1.25 MPa 5 k n/s 2 100 % 
Doppler US treatment 
enhances the 
thrombolytic effect of 
rt-PA loaded ELIP, 
resulting in earlier and 
more complete 
recanalization rates. 
 
 
Rat 
MCA stroke  
rt-PA 
(1.2 
mg/animal) 
 Yes       32 Measured 
volume 
reduction 
 
45 % (9/20)  [118] 
   Yes  490 kHz 0.8 W/cm2 c.w. 100 32 76.2 % (16/21) 
Low frequency 
transcranial US under 
appropriate conditions 
could be an effective 
and safe method of 
treatment for ischemic 
stroke. 
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Clot 
model 
Drug Mode 
 
US alone    Drug alone   US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
conclusion 
Side 
effects 
Ref. 
 
Rabbit 
Femoral 
artery 
occlusion  
mt-PA 
(1.2 
mg/animal) 
 Yes       32 Measured 
recanalization 
rate 
16.7 % (2/12)  [159] 
   Yes  490 kHz 0.13 W/cm2 c.w. 100 32 66.7 % (6/9) 
Low frequency and low 
intensity transcranial US 
enhanced thrombolysis 
by mt-PA. 
 
Rabbit 
Femoral 
artery 
occlusion 
SK 
(15000 U/kg) 
as bolus 
followed by 
an infusion 
of 
15000 
U/kg/h 
Yes    40 kHz 0.75 W/cm2 c.w. 100 120 Measured 
reperfusion 
rate 
< 7 %  [62] 
 Yes       120 7 %  
  Yes  40 kHz 0.75 W/cm2 c.w. 100 120 83 % 
40-kHz US at low 
intensity markedly 
accelerates fibrinolysis 
and also improves tissue 
perfusion and reverses 
acidosis, effects that 
would be beneficial in 
treatment of acute 
thrombosis. 
 
 
Rabbit 
MCA stroke  
HIFU 
rt-PA 
(1.mg/ml/kg) 
 Yes       120 Measured 
recanalization 
rate 
100 %  [79] 
  Yes Yes 1 MHz 20 W/cm2 
(ISATA) 
10 10 70 100 % 
HIFU in combination 
with rt-PA dissolved 
clots. 
 
Rabbit 
MCA stroke  
HIFU 
rt-PA 
(1.mg/ml/kg) 
  Yes Yes 1 MHz 20 W/cm2 
(ISATA) 
10 10 70 Measured 
recanalization 
rate 
100 % 
Therapeutic US in 
synergy with rt-PA 
dissolve clots. 
 
 
 
 [80] 
Rabbit 
Hindlimb 
occlusion 
 Yes   Yes 1 MHz 0.031 
W/cm2 
(ISATA) 
0.33 0.17 10 Measured 
recanalization 
rate 
67 %  [160] 
 Yes   Yes 1 MHz 0.031 
W/cm2 
(ISATA) 
0.33 0.17 20 100 % 
Long-pulse-length US 
with MBs has a 
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Clot 
model 
Drug Mode 
 
US alone    Drug alone   US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
conclusion 
Side 
effects 
Ref. 
therapeutic effect on 
microvascular perfusion. 
Rabbit 
Femoral 
artery 
occlusion 
rt-PA 
(30 
μg/kg/min) 
 Yes       74 Measured 
initial reflow 
 
15-50 %  [161] 
  Yes  1 MHz 6.3 W/cm2 
ISPTA 
c.w. 100 33 15-50 % 
Although time to initial 
reflow was shortened 
by US, it was associated 
with less reperfusion 
and more reocclusion in 
this model. 
 
 
 
 
 
Rat 
MCA stroke 
rt-PA 
(10 mg/kg) 
Yes    1-3 MHz 1.7 (M.I.) n/s. n/s 60 Measured 
recanalization 
rate 
40 %  [162] 
Yes   Yes 1-3 MHz 1.7 (M.I.) n/s. n/s 60 59 %  
  Yes       60 77 %  
   Yes  1-3 MHz 1.7 (M.I.) n/s. n/s 60 88 %  
   Yes Yes 1-3 MHz 1.7 (M.I.) n/s. n/s 60 96 % 
Recanalization rate with 
rt-PA alone is better 
than US alone. 
Recanalization rate 
significantly increased 
with the combination of 
US + drug. 
Recanalization rate 
increased even more 
when US was combined 
with rt-PA + MBs. 
 
 
 
Rat 
Carotid 
artery 
occlusion 
 Yes    2 MHz 1.56 MPa 150 5 30 Measured 
plasma 
D-dimer 
concentrations 
1.70 μg/mL  [163] 
 Yes   Yes 
(Nsib) 
2 MHz 
 
1.56 MPa 150 5 30 2.31 μg/mL  
 Yes   Yes 
(Abib) 
2 MHz 1.56 MPa 150 5 30 3.91 μg/mL 
US in combination with 
abciximab 
immunobubbles (Abib) 
induces thrombolysis 
without lytic agents that 
is superior to insonation 
of non-specific 
immunobubbles (Nsib). 
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Clot 
model 
Drug Mode 
 
US alone    Drug alone   US + Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
conclusion 
Side 
effects 
Ref. 
 
Rabbit 
Embolic 
stroke 
rt-PA 
(0.8-0.9 
mg/kg) 
Yes    1 MHz 0.8 W/cm2 
(ISATA) 
100 20 60 Measured 
infarct volume 
1 % 56 % ICH [70] 
   Yes  1 MHz 0.8 W/cm2 
(ISATA) 
100 20 60  0.13 % 61 % ICH 
 Yes   Yes 1 MHz 0.8 W/cm2 
(ISATA) 
100 20 60  0.2 % 19 % ICH  
    Yes Yes 1 MHz 0.8 W/cm2 
(ISATA) 
100 20 60  0.09 % 
The ability of 
MBs to reduce rt-PA 
requirements may lead 
to lower rates of 
hemorrhage in human 
stroke treatment. 
26 % ICH  
Rabbit 
Embolic 
stroke  
rt-PA 
(0.9 mg/kg) 
 Yes       60 Measured 
infarct volume 
2.2 % 45 % ICH [164] 
  Yes  1 MHz 0.8 W/cm2 n/s 20 60 1.7 % 50 % ICH 
Yes   Yes 1 MHz 0.8 W/cm2 n/s 20 60 0.8 % 
Sonothrombolysis 
without rt-PA using MBs 
is effective in decreasing 
infarct volumes. 
36 % ICH  
Rabbit 
Embolic 
stroke 
rt-PA 
(0.9 mg/kg) 
Yes    1 MHz 0.8 W/cm2 n/s 20 60 Measured 
infarct volume 
0.97 % 56 % ICH [165] 
 Yes       60 0.14 % 48 % ICH 
  Yes  1 MHz 0.8 W/cm2 n/s 20 60 0.15 % 73 % ICH 
Yes   Yes 1 MHz 0.8 W/cm2 n/s 20 60 0.20 % 19 % ICH  
    Yes Yes 1 MHz 0.8 W/cm2 n/s 20 60  0.10 % 
Treatment with MB+US 
following embolization 
decreased the incidence 
of ICH and efficacy was 
similar to tPA in 
reducing infarct volume. 
36 % ICH  
Rabbit 
Iliofemoral 
artery 
occlusion 
SK 
(25000 
U/kg)) 
Yes    20 kHz 1.5 W/cm2 n/s n/s 60 Measured 
patency rate 
0 % (0/6)  [166] 
 Yes       60 6 % (1/17)  
  Yes  37 kHz 160 W n/s n/s 60 100 % (15/15)  
  Yes Yes 20 kHz 1.5 W/cm
2 n/s n/s 60 87 % (13/15)  
  Yes   Yes 20 kHz 1.5 W/cm2 n/s n/s 60  76 % (13/17)  
  Yes   Yes 37 kHz 160 W n/s n/s 60  Non-invasive 
transcutaneous US can 
greatly enhance the 
effect of clot dissolution  
with thrombolytic drugs 
and/or MBs. 
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Table 4: Clinical protocols used in US thrombolysis 
Clot 
Model 
No of 
subjects 
Drug Mode 
 
US alone  Drug alone  US + 
Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Side 
effects 
Ref. 
 
Stroke 
patients 
MCA 
occlusion 
12 rt-PA 
(0.9 mg/kg) 
  Yes (TCD) Yes 2 MHz n/s n/s n/s 120 Measured 
complete and 
partial  
recanalization 
rate 
50 % (6/12) 0 % sICH [167] 
          33 % (4/12) 
MBs reached and permeated 
beyond occlusions with no increase 
in sICH suggesting 
the feasibility of further studies 
 
0 % sICH 
Stroke 
patients 
MCA 
occlusion 
12  Yes 
(TCD) 
   2 MHz n/s n/s n/s 60 Measured 
complete 
recanalization 
rate 
30 % (4/12) 
Sonothrombolysis using 2 probes 
and bilateral monitoring is safe but 
not more effective than standard 
sonothrombolysis. 
 
0 % sICH [168] 
Stroke 
patients 
MCA 
occlusion 
6  Yes 
(TCCD) 
   2 MHz 415 
mW/cm2 
(ISPTA) 
n/s n/s 30 Measured 
partial 
recanalization 
rate 
83 % (5/6) 
High rate of early partial 
recanalization during continuous 
exposure to 2-MHz US without rt-
PA. 
 
0 % sICH [169] 
Stroke 
patients 
MCA 
occlusion 
111 rt-PA 
(0.9 mg/kg) 
 Yes       120 Measured 
complete 
recanalization 
rate 
24 % (9/36) 5.5 % sICH [92] 
   Yes (TCD)  2 MHz n/s n/s n/s 120 41 % (15/37) 2.7 % sICH 
    Yes (TCD) Yes 2 MHz n/s n/s n/s 120 55 % (21/38) 
MBs administration induces 
further acceleration of US-
enhanced thrombolysis. 
 
2.6 % sICH 
Stroke 
patients 
MCA 
occlusion 
26 rt-PA 
(0.9 mg/kg) 
  Yes (TCCD)  2 MHz 189 
mW/cm2 
 
n/s n/s 60 Measured 
complete 
recanalization 
rate 
53 % (8/15) 7 % sICH [170] 
   Yes (TCCD) Yes 2 MHz 189 
mW/cm2 
 
n/s n/s 60 64 % (7/11) 
MBs enhanced TCCD monitored rt-
PA thrombolysis lead to a greater 
immediate clinical improvement. 
 
 
9 % sICH 
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Clot 
Model 
No of 
subjects 
Drug Mode 
 
US alone  Drug alone  US + 
Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Side 
effects 
Ref. 
 
Stroke 
patients 
MCA 
occlusion 
 
 
 
25 rt-PA 
(0.9 mg/kg) 
 Yes     
 
  60 Measured 
complete and 
partial 
recanalization 
rate 
21.4 % (3/14-complete) 
0 % (0/14- partial) 
7 % sICH [91] 
    Yes (TCCD)  2-4 MHz 179 
mW/cm2 
 
n/s n/s 60 27.3 % (3/11-complete) 
18.2 % (2/11-partial) 
Transcranial TCCD with rt-PA 
showed a higher grade of 
recanalization compared with rt-PA 
alone. 
 
36 % sICH  
Stroke 
patients 
MCA 
occlusion 
126 rt-PA 
(0.9 mg/kg) 
 Yes       120 Measured 
complete 
recanalization 
rate 
30 % (19/63) 5 % sICH [171] 
    Yes (TCD)  2 MHz 750 
mW/cm2 
 
n/s n/s 120 49 % (31/63) 
Continuous TCD augments rt-PA 
induced arterial recanalization. 
 
 
5 % sICH  
Stroke 
patients 
MCA 
occlusion 
55 rt-PA 
(0.9 mg/kg) 
  Yes 
(TCD) 
 2 MHz n/s n/s n/s 120 Measured 
complete 
recanalization 
rate 
36 % (20/55) 
Complete recanalization within 2 
hours after rt-PA bolus is a feasible 
goal for thrombolysis given with 
TCD monitoring. 
 
6 % sICH [119] 
Stroke 
patients 
MCA 
occlusion 
37 rt-PA 
(0.9 mg/kg) 
 Yes       60 Measured 
complete and 
partial 
recanalization 
rate 
11.1 % (2/18-complete) 
11.1 % (2/18-partial) 
5.6 % sICH [172] 
    Yes (TCCD)  1.8 MHz 179 
mW/cm2 
 
n/s n/s 60 15.8 % (3/19-complete) 
42.1 % (8/19-partial) 
Transcranial US in combination 
with rt-PA accelerates 
recanalization in MCA occlusion, 
compared to rt-PA alone 
 
 
15.8%sICH 
Stroke 
patients 
MCA 
occlusion 
26 rt-PA 
(0.9 mg/kg) 
 Yes       90 Measured 
recanalization 
rate 
(both 
complete and 
partial) 
50 % (6/12) 
29 % (4/14) 
Low frequency US combined with 
rt-PA showed an increased rate of 
sICH. 
 
0 % sICH [89] 
   Yes  300 kHz 700 
mW/cm2 
(ISPTA) 
100 5 90 36 %  sICH 
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Clot 
Model 
No of 
subjects 
Drug Mode 
 
US alone  Drug alone  US + 
Drug 
MBs Freq. 
 
Output PRF 
(Hz) 
DF 
(%) 
Time 
(min) 
Evaluation 
method 
Main 
Conclusion 
Side 
effects 
Ref. 
 
Stroke 
patients 
Proximal 
intracranial 
occlusion 
35 rt-PA 
(0.9 mg/kg) 
 Yes       90 Measured 
complete and 
partial 
recanalization 
rate 
33 % (4/12-complete) 
25 % (3/12-partial) 
0 % sICH [93] 
    Yes (TCD) Yes 
(1.4 mL) 
2 MHz n/s n/s 100 90 67 % (8/12-complete) 
17 % (2/12-partial) 
0 % sICH  
    Yes (TCD) Yes 
(2.8 mL) 
2 MHz n/s n/s 100 90 45 % (5/11-complete) 
0 % (0/11-partial) 
MBs can be safely combined with 
systemic rt-PA and US at a dose of 
1.4mL. 
27 % sICH  
Stroke 
patients 
MCA 
occlusion 
52 rt-PA 
(0.9 mg/kg) 
Yes 
(TCCD) 
   2-4 MHz 208 
W/cm2 
(ISPPA) 
5 k 0.7 45 Measured 
complete and 
partial 
recanalization 
rate 
97 % (36/37-complete) 
0 % (0/37-partial) 
2.7 % sICH [173] 
   Yes       45 67 % (10/15-complete) 
7 % (1/15-partial) 
6.6 % sICH  
    Yes (TCCD)  
 
2-4 MHz 208 
W/cm2 
(ISPPA) 
5 k 0.7 45 80 % (12/15-complete) 
7 % (1/15-partial) 
Recanalization rate of continuous 
TCCD monitoring of MCA occlusion 
in combination with rt-PA was 
lower compared to that of TCCD 
monitoring alone. 
6.6 % sICH  
Stroke 
patients 
MCA 
occlusion 
Catheter type 
 
81 rt-PA 
(60 mg IV + 
22 mg IA 
infusion ) 
 Yes  
Y es 
  
1.7 MHz 
 
n/s 
 
n/s 
 
n/s 
120 
120 
Measured 
recanalization 
rate 
(both 
complete and 
partial) 
56 % (33/59) 
73 % (24/33) 
EKOS micro-infusion catheter is a 
reasonable and easy-to-use tool 
for re-opening occluded 
intracranial arteries. Additionally, 
the delivery of intra-arterial rt-PA 
or other thrombolytic drugs via a 
standard micro-catheter remains 
an excellent option.  
6.6 % sICH 
9.9 % sICH 
[174] 
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 Discussion 
This compilation is very useful since numerous aspects associated with the US 
protocols examined (in vitro, in vivo and clinical), that are used in thrombolysis, were 
investigated.  The review protocols are summarised in tables providing all necessary data 
in terms of clot model, treatment mode, sonication parameters, evaluation method, 
thrombolysis efficacy and side effects. In addition, the main conclusions derived from 
each study are presented as well. 
Although the mechanisms behind US enhanced thrombolysis are not very clear, it 
is evidenced that exposure to US increases the uptake and depth of penetration of 
thrombolytics into clots [46], causes additional binding sites due to reversible 
disaggregation of fibrin fibres [51] and increases the binding of thrombolytic agents to 
fibrin [125].  
The influence of temperature on clot lysis was only investigated in vitro. In most 
of the experimental studies, the temperature during sonication was kept constant at 37 0C, 
which sufficiently explains that clot lysis occurred through non-thermal mechanisms. In 
a few studies, the temperature at the target was not specified. It is well established that 
temperature plays an important role on clot lysis, since thrombolysis efficacy decreases 
at temperatures below the body baseline temperature of 37 0C [135]. Therefore, it will be 
useful in the future, for all the in vitro studies to be conducted at 37 0C. 
Different thrombolytics such as UK, SK, rt-PA, TNK-tPA, etc. in various 
concentrations have been investigated. Studies have shown that US energy can accelerate 
the thrombolytic activity of any thrombolytic used and that the extent of thrombolysis is 
dependent on drug’s concentration [128], [153]. The most common thrombolytic drug 
used by the researchers was rt-PA, since it is the only thrombolytic treatment approved 
for AIS. Although rt-PA was administered in various concentrations between 0.1-300 
μg/mL, the majority of the above mentioned studies were conducted at a concentration of 
3.15 μg /mL, which is the average concentration of the drug in human blood. 
The current review, shows that the thrombolytic efficacy of drug alone is better 
than that of US alone [75], [136], [175]. Therefore, we assume that US energy as a stand-
alone method for clot lysis is not effective and should be applied in synergy with 
thrombolytic drugs to enhance thrombolysis. However, a few studies [82], [87], [141], 
demonstrated that using US alone (in the absence of thrombolytic drug), can achieve 
almost complete clot lysis within seconds. Taking into consideration the very high level 
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of acoustic powers used in their studies, in association with the fact that the temperature 
elevation at the target was not specified in their results, we suspect that most likely the 
protocols applied have entered into thermal mechanisms of thrombolysis. This suspicion, 
is supported by the results of many other researchers [75], [136], [175], who exhibited 
reduced thrombolytic efficacy using US alone, although prolonged exposure times were 
used in their studies.  
Some other studies, focused their research on the effect of travelling vs. standing 
acoustic waves on clot lysis, demonstrating that travelling acoustic waves enhanced 
thrombolysis significantly more than standing waves did [55-56]. 
It is well known that US frequency in conjunction with acoustic intensity, exert a 
major effect on clot lysis. Different US frequencies ranged from 20 kHz to 5.0 MHz and 
intensities (either low or high), have been employed for sonothrombolysis studies. A 
number of studies indicated that lower US frequencies (in the kilohertz range), are more 
efficient in sonothrombolysis over higher frequencies (in the MHz range), since they 
exhibited improved tissue penetration and greater acceleration in fibrinolysis [35], [124], 
[137]. Considering that some other studies showed that thrombolysis efficacy increases 
as the level of acoustic intensity increases [129], [130], [176], it is reasonable to come to 
the conclusion that the thrombolytic efficacy of US waves is directly dependent on 
acoustic intensity and inversely dependent on frequency. 
There is enough evidence from in vitro [69], animal [162], and clinical [92] 
studies, indicating that the administration of MBs further enhance the effect of US on 
enzymatic thrombolysis induced by thrombolytic agents. The findings of this review 
demonstrated that the boosting effect of MBs in clot dissolution, correlates with the 
presence of cavitation mechanisms and most specifically with stable cavitation, which 
appears to play a more important role in MB mediated sonothrombolysis [66], [144], 
[148]. However, a study performed by Molina et al. [93], showed that there is a safe limit 
on the administered dose of MBs, which should not be exceeded since it is associated 
with an increased risk of sICH rate. Therefore, it is recommended that MBs should be 
administered in combination with rt-PA at low doses (1.4 mL), in order to enhance 
thrombolysis and avoid unnecessary adverse health effects, such as sICH. 
Animal studies, as well as clinical trials, have shown that the most common side 
effect of sonothrombolysis was sICH. Apart from the use of high dose of MBs, the 
application of low frequency US might increase the rate of sICH. The TRanscranial low-
frequency Ultrasound-Mediated thrombolysis in Brain Ischemia (TRUMBI) clinical trial 
  
68 
[89], which was designed to treat stroke patients with transcranial 300 kHz US plus rt-
PA, was ended prematurely due to a significant increase in sICH rate. Since then, low 
frequency US has not been available for therapeutic purposes in clinical trials. 
Additionally, our investigation showed that the risk of sICH rate increases with the 
concentration of thrombolytic drug [155] and the level of acoustic intensity [86], [156]. 
The effect of time is very critical on thrombolysis efficacy, since early 
recanalization is the key of therapeutic success in the treatment of vascular thrombosis. 
In this review, the exposure times used in the in vitro studies varied from 0.5 to 240 min. 
In the animal studies, the treatment times ranged from 0.5 to 120 min, while in the clinical 
trials the continuous monitoring of the patients was between 30 and 120 min. Several 
studies [60], [134], showed that most of the clot mass was removed within the first 60 
min of treatment and beyond that time the efficacy of thrombolytic treatment was 
decreased significantly. This phenomenon, might be caused due to the fact that the 
concentration of the thrombolytic drug in the blood after 60 min of treatment, decreases 
dramatically leading to a significant reduction on enzymatic fibrinolysis rate. Therefore, 
at least for the experimental studies, 60 min of treatment must be a sufficient exposure 
time and should not be exceeded. 
The most common protocol used in clinical trials so far for the treatment of 
patients with AIS due to MCA occlusion, was the continuous monitoring of the patients 
with high frequency (2 MHz) low intensity (< 750 mW/cm2) diagnostic transcranial US 
in combination with rt-PA [169-170]. Using this protocol, higher recanalization rates 
exhibited compared to those with rt-PA alone.  
 Conclusions 
Despite the absence in standardization, the heterogeneity and the limitations of 
the reviewed studies, useful information concerning the ability of US energy to enhance 
thrombolysis efficacy either alone or as an adjunct to thrombolytic drugs and/or in 
combination with US contrast agents, was extracted. Although preclinical studies have 
been very promising, the results from clinical trials have shown that further research in 
the field of sonothrombolysis has to be done, in order to improve recanalization rates and 
clinical outcomes. 
More specifically, this comprehensive review has provided strong evidence that 
sonothrombolysis research for the treatment of stroke should be focused in the field of 
therapeutic MRgFUS. Additionally, the prospect of co-administration of thrombolytic 
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drugs with MBs is especially encouraging and therefore for better outcomes adjuvant 
therapies should be developed for future clinical studies. Based on these findings, a fully-
characterised sonothrombolysis model must be produced dedicated to use: 
1. High intensity FUS pulses under MR guidance and monitoring for fast and accurate 
beam targeting, temperature monitoring, post therapy evaluation. 
2. Phased array technology in order to overcome problems such as beam defocusing due 
to the inhomogeneous thickness and density of the skull bone and skull/near-field soft 
tissues heating, caused by the acoustic signal absorption. 
3. Non thermal mechanisms to avoid the contribution of thermal mechanisms in clot lysis 
5. A 3rd generation thrombolytic drug with longer half-life and higher thrombolytic 
potency than rt-PA 
6.  Systemically administered MBs to further increase FUS enhanced sonothrombolysis 
 Summary 
A summary table providing the most important studies in sonothrombolysis related to 
my thesis (in vitro, in vivo and clinical), is shown below. The table presents the main 
experimental parameters applied in each study and identifies the aspects that influence 
thrombolysis efficacy and were not explored by the investigators. These aspects will be 
evaluated in this research.  
Table 5: Most important studies in sonothrombolysis and gaps in knowledge 
Most important  
studies 
Freq. 
(MHz) 
Mode Output 
(Intensity) 
Drug 
(rt-PA) 
MBs 
 
Identification of aspects that influence 
thrombolysis efficacy and were not explored 
In vitro Holland 
et al. 
2007 
1 US Low 
 
Yes No The contribution of thermal effects, high 
intensity, FUS pulses, flow rate, MBs 
administration and parametric studies on clot 
lysis. 
Flow 
model 
Cintas 
et al 
2004. 
2 US Low 
 
Yes Yes The contribution of thermal effects, high 
intensity, FUS pulses and parametric studies on 
clot lysis 
 Frenkel  
et al. 
2006 
1 FUS High  Yes No               The contribution of thermal effects, flow rate, 
MBs administration and parametric studies on 
clot lysis.  
Flow 
model 
 
Wright 
et al. 
2011 
1.5 FUS High   No No The contribution of thermal effects, 
thrombolytic drug, MBs administration and 
parametric studies on clot lysis. 
In vivo Stone  
et al. 
2007 
1  FUS High  
 
Yes No The contribution of thermal effects, MBs 
administration and parametric studies on clot 
lysis. 
MRgFUS Burgess  
et al. 
2012 
1.5  FUS High   No No The contribution of thermal effects, 
thrombolytic drug, MBs administration and 
parametric studies on clot lysis. 
Clinical Alexandrov 
et al. 
2004 
2  TCD Low 
 
Yes No The contribution of thermal effects, FUS waves, 
high intensity, MBs administration and 
parameters optimisation on clot lysis. 
 Molina  
et al. 
2009 
2  TCD Low 
 
Yes Yes The contribution of thermal effects, FUS waves, 
high intensity, MBs administration and 
parametric studies on clot lysis. 
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 Determination of the experimental parameters that 
influence ultrasound induced thrombolysis in vitro 
 Introduction 
In this chapter, the experimental parameters that influence US induced 
thrombolysis were determined. Using an in vitro flow model, fully retracted porcine blood 
clots were exposed to a realistic unidirectional circulating pulsatile flow and were treated 
with either focused or unfocused US waves, either alone or as an adjunct to thrombolytic 
agent TNK-tPA and in the presence or absence of MBs. The objective of the study was 
to establish the optimum treatment protocol that maximizes the uptake, the depth of 
penetration and the binding of the thrombolytic agent to the fibrin of the clot, leading to 
enhance thrombolysis, without excess heating. 
In order to succeed this, the impact of operating acoustic parameters such as 
frequency, acoustic power (AP), pulse length, PRF, DF and treatment time, on 
thrombolysis efficacy was investigated. Additionally, the effect of various physical 
parameters on thrombolysis efficacy, was also explored. These are, the US energy, the 
temperature, the TNK-tPA concentration, the flow-rate, the formation of standing or 
travelling acoustic waves, the acoustic properties of the medium and the administration 
of MBs 
 In vitro clot preparation 
Blood clots were obtained by natural coagulation of fresh porcine blood, collected 
from healthy pigs. Blood clots were prepared by aliquoting blood samples of the same 
volume into pre-weighed tubes, tubing or custom made containers (depending on the 
study). The blood aliquots were incubated in a 37 °C water bath for 3 hours before 
refrigerated at 5 °C for 72 h, to ensure maximal clot retraction [59].  
The decision to use or reject the formed clots was based on their appearance. 
Normally should be dark red in color, since venous thrombi are mainly composed of fibrin 
and red blood cells, known as “red thrombi”. In 2007, Holland et al. [59], demonstrated 
that aged clots (2–16 day old), exhibited significantly lower mass loss when exposed to 
rt-PA alone, compared to clots that were one day old. Thus, in all subsequent experimental 
studies, only clots that were one day old were used.  
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After clot formation, the produced serum was completely removed from each 
sample with great caution in order not to disturbed the formed clot. Then, each container 
comprising clot was weighed again to determine the net mass clot weight (CNW): 
 𝐂𝐍𝐖 =  𝐖𝐂 − 𝐖𝐓                                        (4.1) 
where, WC is the weight of the container plus the clot and WT is the weight of the container 
alone. When the treatment was terminated, clot’s residual was carefully removed from 
the container and was left to dry on a filter paper for 60 min before weighted again to 
obtain the mass clot removed due to thrombolysis. 
The efficacy of thrombolytic treatment (T), was measured either as the relative 
reduction in the mass of the clot before and after treatment: 
 
𝐓 =
𝐖𝐢𝐧 − 𝐖𝐟𝐢
𝐖𝐢𝐧
𝐗𝟏𝟎𝟎 
                                       (4.2) 
where, Win is the initial clot weight and Wfi is the final clot weight, or was measured in 
mg of mass clot removed: 
 𝐓 = 𝐖𝐢𝐧 − 𝐖𝐟𝐢                                        (4.3) 
In all experimental studies, the mass of the clot before and after treatment was measured 
on a precision digital balance (Scaletec, SM001, Heiligenstadt, Germany). 
 Preparation of TNK-tPA 
TNK-tPA (Boehringer, Ingelheim, Germany), is a 3rd generation modified tissue 
plasminogen activator that is more fibrin-specific and more resistant to plasminogen 
activator inhibitor. Due to higher thrombolytic potency and longer half-life than rt-PA, 
TNK-tPA can be administered as an iv bolus [21], [177]. TNK-tPA was obtained as 
powder, mixed with sterile water as per manufacturer’s instructions. Although this 
thrombolytic agent is an approved safe drug for acute myocardial infarction, due to its 
safe administration and ease of use, it can be a new choice for AIS treatment [178]. Figure 
4.1 shows the time-dependence of plasma concentrations of alteplase (rt-PA) and 
tenecteplase (TNK-tPA), at 30, 40 and 50 mg in a subset of patients from the 
Thrombolysis in Myocardial Infarction (TIMI) 10B trial. This trial included 886 patients 
and was designed to compare prospectively the efficacy and safety of rt-PA and TNK-
tPA. Systemic exposure to TNK-tPA at all of these doses, as measured by the peak plasma 
concentration and area under the curve, was higher than for a 90 min infusion of 100 mg 
rt-PA. Due to the improved fibrin specificity of TNK-tPA, this increased systemic 
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exposure did not compromise clinical safety and resulted in less serious bleeding events 
compared to rt-PA [179]. 
 
Figure 4.1: Blood concentrations of TNK-tPA vs. rt-PA over time in the TIMI 10B trial. Mean plasma 
concentration vs. time  for the 3 doses  of TNK-tPA (30, 40 and 50 mg), given as bolus and for 1 dose of 
rt-PA (100 mg), given as bolus and 90 minute infusion  [179]. 
 Preparation of SonoVue MBs 
To study the effect of cavitation nuclei on sonothrombolysis efficacy, UCA were 
used. UCA are micron-sized MBs, with inert, high molecular weight gas core, surrounded 
by a lipid, surfactant, or biocompatible polymer shell.  SonoVue (Bracco, Milan, Italy) 
MBs contain a sulphur hexafluoride (SF6) gas core, which is a very stable molecule. The 
shell consists of a highly flexible phospholipid membrane, allowing the MBs to change 
the size and shape. The composition of the shell determines the stiffness of the bubbles 
and their resistance to rupture in the US field. As a result, MBs decreased solubility and 
low diffusion coefficient, prolong their lifespan within the circulation. The mean size of 
these MBs is 2.5 μm, and the resonance frequency ranges between 1 and 4 MHz [180]. 
SonoVue was obtained as kit with a vial containing a lyophilized powder (25 mg) and a 
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syringe prefilled with sterile saline solution (5 mL). The powder and the saline solution 
were mixed as per manufacturer’s instructions, a manual process that takes less than one 
min. The resultant suspension with a concentration of 1-5x108 MBs/mL, was injected in 
the reservoir of the circulating flow system on a constant rate, in order to replace the 
bubbles that were destroyed in process and sustain cavitation. 
 Experimental apparatus 
The experiments were carried out in an Acrylic tank (42 X 24 X 23 cm3) filled 
with degassed water to prevent reflections, that may affect the propagation of the beam. 
Since this research covered both focused and unfocused US experimental studies, 
different US systems were involved. 
For FUS studies, the US system used was consisted of two single element 
spherically shaped focused transducers, made from piezoelectric ceramic 
(Piezotechnologies, Etalon, Lebanon, IN, USA). The transducers were driven by a radio 
frequency (RF) generator/amplifier (750 W, JJ&A Instruments, Duvall, WA, USA). The 
one transducer used operates with 0.6 MHz centre frequency, while the other one operates 
with 1.18 MHz centre frequency. The focal length and the diameter of both transducers 
were 100 mm and 40 mm respectively. The acoustic output of the transducers was 
measured with an US power meter (UPM-DT100N, Ohmic Instruments Co. Easton MD 
21601).  
For unfocused US studies, the US system consisted of three flat rectangular 
ultrasonic transducers, operating at 3.7, 4.0 and 5.2 MHz respectively. The active size of 
each transducer was 2 X 10 mm2 and the transducer material was made out of Pz26-type 
piezoceramic (Ferroperm, Kvistgaard, Denmark) with epoxy backing. The electrical 
signal was produced by a function generator (Agilent technologies, 33220A 20 MHz 
Function/Arbitrary Waveform Generator, Englewood, CO, USA) and was amplified by a 
radio frequency amplifier (AR Research, 75A250, Souderton, PA, USA).  
The container comprising clot was fixed on a custom made plastic holder and 
immersed into the water tank. The rear surface of the container was lined with an 
absorbing rubber to minimize reflections and to prevent the generation of standing waves, 
since the enhancement of clot dissolution is much more pronounced in travelling than in 
standing acoustic waves [55]. 
The physiological situation of flow in a MCA occlusion, was reproduced by 
exposing the clots to a circulating pulsatile flow using a Masterflex peristaltic pump (Cole 
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Parmer, 7518-40, Vernon Hills, IL, USA). The flow system was consisted of a reservoir 
connected to a peristaltic pump and the container with the clot. The outlet tubing from the 
reservoir after passing the peristaltic pump, where the pulsatile flow was generated, was 
connected to the upper left side of the container. The inlet tubing was connected to the 
opposite right side, in order to sustain circulation. The reservoir was filled with degassed 
water (fluid for the flow system) along with TNK-tPA. 
The transducer was mounted on the arm of an automated robotic system (VXM, 
Velmex Inc, Bloomfield, NY, USA), immersed in the water tank and arranged opposite 
the blood clot. The robotic system has 3 user-controlled degrees of freedom, capable to 
guide the transducer in X, Y and Z direction with sub-millimetre accuracy. 
All custom made 3D plastic models used in this research such as containers, 
holders, needles, arm of the robotic system, etc. (figure 4.2), were manufactured using a 
Stratasys 3D printer (FDM400, Eden Prairie, Minnesota, USA).  The machine uses a 
common thermoplastic material known as Acrylonitrile Butadiene Styrene (ABS). This 
raw material satisfied the prerequisite of building MR compatible 3D models, since ABS 
is a non-magnetic material. 
 Beam positioning 
  For FUS studies, a custom made plastic needle with length equal to the focal 
length of the transducer (figure 4.2A), was attached at the transducer’s face (figure 4.2B).  
 
Figure 4.2: The attachment of the plastic needle (A) on the transducer’s face (B) 
Then, the needle was moved by the robotic system until its tip touched the target. Beam 
focus was always positioned at clot’s edge in order to increase the uptake, penetration and 
binding of the thrombolytic drug into the clot. When it was confirmed that the focus of 
the US beam was positioned precisely on target, the plastic needle was carefully removed.  
A B 
Arm of the robotic system 
Plastic needle 
FUS transducer 
Plastic holder 
  
75 
Two different flow models were designed to study the effect of FUS on 
thrombolytic efficacy. In the case where the blood clot was formed into a plastic tubing 
mimicking MCA occlusion occurred 4 cm deep into a brain tissue, precise beam 
positioning was achieved when the tip of the needle touched anteriorly the mid-height of 
the tubing at clot’s edge (figure 4.3). 
 
Figure 4.3: Beam positioning for FUS studies. 
In the case where the blood clot was formed into a container mimicking MCA 
occlusion, occurred superficially, precise beam positioning was achieved when the tip of 
the needle touched anteriorly the clot’s edge (figure 4.4). 
 
Figure 4.4: Beam positioning for FUS studies. 
Heater 
Peristaltic pump 
Reservoir 
Clot 
Tip of the needle 
Peristaltic pump 
Reservoir 
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Clot 
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For unfocused US studies, the flow clot model was designed to study a MCA 
occlusion treated invasively with a catheter-directed US device. Precise beam positioning 
was achieved when the transducer was placed as close as physically possible to the 
proximal portion of the clot, since the acoustic pressure decreases rapidly with distance 
due to the high frequencies used (figure 4.5). 
 
Figure 4.5: Beam positioning for unfocused US studies. 
 Experimental protocol 
The main aspect for establishing a treatment protocol was to ensure the negligible 
contribution of thermal effects to clot lysis, i.e. providing that thrombolysis occurred 
mainly through non-thermal mechanisms. 
Regarding thermal mechanisms for biological effects of US, Miller and Ziskin 
1989 [181], suggested that a temperature rise of 1-2 0C in an afebrile patient would not 
be likely to have a damaging effect. However, for exposures resulting in temperature rises 
of greater than 2 0C, the duration of exposure becomes an important consideration in 
risk/benefit assessment. Moreover, a comprehensive review on thermal bioeffects by the 
World Federation of Ultrasound in Medicine (WFUMD), concluded that “Based solely 
on a thermal criterion, an US exposure that produces a maximum temperature rise of 1.5 
0C above normal physiological levels (37 0C), may be used without reservation in clinical 
examinations” [182]. 
Arm attached to the robotic system 
US transducer holder 
Container with the clot 
Plastic holder 
Inlet for tubing 
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Based on the above mentioned thermal criterion, in all experimental studies, the 
temperature increase within the clot was maintained even lower, i.e. not to exceed 1˚C 
(called safe temperature). This means that during sonication, the temperature of the 
medium surrounding the clot was held constant with a localized temperature increase of 
1˚C, at the target. For the assessment of heat produced during sonication, a thermocouple 
(OMEGA Engineering, INC. Stamford, Connecticut, USA), was fixed at the position of 
target. The thermocouple was connected to a data acquisition-DAQ interface (National 
Instruments Corporation, Austin, Texas, USA), that fed real time temperature 
measurements to a computer. 
Pulsed US protocols to ensure that clot lysis occurred mainly through non-thermal 
mechanisms, were applied. Each sonication set, included a pulse “ON” period followed 
by a pulse “OFF” period and both the “ON” and “OFF” pulses were repeated in 
succession for the duration of the treatment. In each experiment, only one parameter was 
varied, while all others parameters were kept constant provided that no excessive heating 
(> 1 0C) was produced (figure 4.6). 
 
Figure 4.6: Time temperature profile at 37 0C baseline value, using 1.18 MHz FUS with 10 % DF, 60 W 
AP and 30 min sonication time.   
The optimal frequency for US applications varies by treatment and is always a 
trade-off between the depth of penetration and the sharpness of the focus. For 
transcutaneous sonothrombolysis, frequencies up to 2 MHz are employed as a best trade-
off between focus and penetration, while for intravascular sonothrombolysis, where 
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smaller penetration depths are required, frequencies greater than 2 MHz have been 
employed.  
The acoustic parameters that mainly control heating are the AP, which is the 
amount of power sent to the transducer´s surface and the DF, which is the fraction of time 
that the US system is transmitting. Although longer DFs achieve better thrombolysis 
efficacy, the use of shorter DFs (≤ 10 %) is very attractive, since thrombolysis efficacy 
can be enhanced by increasing AP levels and the desired reduction in heating can be 
achieved. Since the temperature at the target was continuously monitored, the value of 
AP was set to the appropriate level, where no excess heating was produced (ΔΤ ≤ 1 0C). 
All experiments were conducted in a circulating unidirectional flow system, 
simulating blood flow in MCA occlusion. The peristaltic pump was set to maintain the 
appropriate flow rate for each study and degassed water was used as a fluid for the closed-
loop flow system. The values for flow rate and TNK-tPA concentration were selected to 
be well below the maximum levels occurred in a physiological situation of MCA 
occlusion, following iv thrombolysis with thrombolytic drug.  
During treatments, the temperature in the water tank was kept constant at 37 0C, 
using a heating element (Thermo Scientific, SC001, Haake, Germany). For each 
experimental study, a group of 5 clots was used. The group of clots treated with neither 
US exposure nor TNK-tPA, was served as the control, or untreated group. 
 Determination of the experimental parameters that influence 
thrombolysis efficacy 
To maximize the effect of US on TNK-tPA mediated thrombolysis it was necessary 
to determine and evaluate all experimental parameters (both operating and physical), 
involved in this technique. Therefore, for the establishment of an optimised treatment 
protocol for therapeutic purposes, it was critically important to elucidate the role that each 
one of the following experimental parameters plays on thrombolysis efficacy. 
Effect of frequency 
The effect of frequency on thrombolysis efficacy was investigated in both focused 
and unfocused US studies. In all studies, two groups of clots were treated with US + TNK-
tPA. For focused US studies, mass loss data were collected from clots exposed at 0.6 
MHz compared with clots exposed at 1.18 MHz. For unfocused US studies, mass loss 
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data were collected from clots exposed at 3.7 MHz compared with clots exposed at 5.2 
MHz respectively. 
Effect of acoustic power 
To examine the effect of AP on clot lysis, three groups of clots were treated with 
FUS + TNK-tPA. The degree of thrombolysis was determined for clots treated at AP of 
20, 30 and 60 W respectively. 
Effect of pulse length and PRF 
To assess the effect of pulse length and associated PRF on clot lysis, two groups 
of clots were treated with FUS+TNK-tPA. Thrombolysis efficacy was measured as the 
relative reduction in the mass of the clots treated with 1000 Hz, and 100 Hz. 
Effect of DF 
To explore the effect of DF on thrombolysis efficacy, two groups of clots were 
treated with FUS+TNK-tPA. Data for clot lysis were collected from clots treated with a 
DF of 5 % compared to clots treated with a DF of 10 %. 
Effect of sonication time 
To evaluate the effect of sonication time on thrombolysis efficacy, three groups 
of clots were treated with FUS+TNK-tPA. Clot mass loss was assessed for exposure times 
of 15, 30 and 60 min respectively. 
Effect of each modality alone and with synergy 
To determine the enhancing effect of either focused on unfocused US waves on 
clot lysis, the decrease in clot weight of the group treated with US + TNK-tPA was 
compared with that of the group receiving the same TNK-tPA concentration but no US. 
Effect of temperature 
To study the effect of temperature on the lytic efficacy of TNK-tPA, three groups 
of clots were treated with TNK-tPA alone. Percentage mass loss was measured for clots 
treated at 37, 39 and 41 0C respectively. 
Effect of TNK-tPA 
To study the effect of TNK-tPA concentration on thrombolysis efficacy, two 
groups of clots were treated with TNK-tPA alone. Mass loss data were collected from 
clots treated at a concentration of 2.0 μg/mL compared to clots treated at a concentration 
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of 3.5 μg/mL. When the drug dose was established, the percentage decrease in clot weight 
of the group treated with TNK-tPA alone was compared with the control (untreated) 
group. 
Effect of flow rate 
To investigate the effect of flow rate on thrombolysis efficacy, two groups of 
clots were treated with FUS+TNK-tPA. Percentage mass loss was measured for clots 
exposed at a flow rate of 10 mL/min compared with clots exposed at a flow rate of 30 
mL/min. 
Effect of standing waves 
To estimate the effect of standing acoustic waves on thrombolysis efficacy, two 
groups of clots were treated with FUS+TNK-tPA. Data on clot mass loss were taken for 
clots treated with and without the use of absorber, which prevents the formation of 
standing waves. 
Effect of medium 
To examine the effect of the acoustic properties of the medium on thrombolysis 
efficacy, two groups of clots were treated with FUS+TNK-tPA. Data on clot mass loss 
were gathered for clots treated 4 cm deep into a brain tissue mimicking phantom, 
compared with clots treated into degassed water. 
Effect of bubbles 
The administration of UCA in the form of gaseous MBs, as a way to further 
enhance the thrombolytic activity of TNK-tPA, was studied for both focused and 
unfocused US waves. Data on mass loss were collected from two groups of clots. The one 
group was treated with US+TNK-tPA, while the other one was treated with US+TNK-
tPA and MBs. For FUS studies, a 0.5 mL bolus of MBs was injected in the reservoir of 
the flow system at the beginning of insonation. Since the half-life of the bubbles is 
between 3-6 minutes [108], [110], the procedure was repeated every 5 min, for the 
duration of a 30 min treatment (i.e. a total amount of 3 mL was used). For unfocused US 
studies, a 1.0 mL bolus of MBs was injected in the reservoir of the flow system at the 
beginning of insonation and the procedure was repeated every 6 min, for the duration of 
a 30 min treatment (i.e. a total amount of 5 mL was used). Moreover, the effect of MBs 
dose on the degree of clot lysis was investigated by comparing the percentage of 
  
81 
thrombolysis enhancement occurred at a dose of 3 mL with that occurred at a dose of 5 
mL. 
 Statistical analysis 
A paired difference test (Wilcoxon signed-rank test) was performed to determine if 
differences between pairs of experimental groups examined, follow a symmetric 
distribution around zero.  
For comparisons between pairs of groups, the following procedure was followed: 
1. The sample size, i.e., the number of pairs n = 5.  
2. For pairs i = 1-5 the measurements were denoted as X1,i and X2,i.  
3. The difference between pairs |X2,I –X1,i|, and sgn (X2,I –X1,i) was calculated, where sgn 
is the sign function.  
4. Pairs with |𝐗𝟐,𝐢 − 𝐗𝟏,𝐢,| = 𝟎 were excluded. The remaining pairs were ordered from 
smallest absolute difference to largest absolute difference and were ranked, starting with 
the smallest as 1. Ties receive a rank equal to the average of the ranks they span. Ri denotes 
the rank.  
5. The test statistic W was calculated as it is shown below: 
                             𝐖 = ∑ [𝐬𝐠𝐧(𝐱𝟐,𝐢 − 𝐱𝟏,𝐢)𝐑𝐢 ]
𝐧
𝐢=𝟏                                                 (4.4) 
Differences that yielded a test statistic |W| value > W0.05,n were considered to be 
significant. 
 Summary 
A summary table with the experimental parameters (operating and physical), investigated 
in this research in order to optimise through non-thermal mechanisms their thrombolytic 
efficacy for potential therapeutic purposes, is provided below: 
Table 6: List of experimental parameters that influence thrombolysis efficacy  
Operating Parameters Physical Parameters 
Frequency US energy alone 
US energy + TNK-tPA 
US energy + TNK-tPA + MBs 
Acoustic Power Temperature 
Pulse length TNK-tPA concentration  
Pulse Repetition Period  Flow rate  
Pulse Repetition Frequency  Standing waves  
Duty Factor  Attenuating medium 
Sonication time  MBs administration and dose  
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5. Focused ultrasound enhanced TNK-tPA mediated 
thrombolysis into a brain tissue mimicking phantom using 
an in vitro flow clot model 
5.1. Introduction 
The low and incomplete recanalization performance of thrombolytic therapy in 
patients with AIS has created the need to use US energy in synergy with thrombolytic 
drugs (sonothrombolysis), as a way to increase the degree of clot lysis. Recently, the use 
of FUS to enhance the activity of thrombolytic drugs has become an important area of 
investigation in sonothrombolysis, due to accurate clot targeting and low risk of side 
effects outside the beam focus.  
To evaluate the thrombolytic efficacy of FUS on thrombolysis induced by 
thrombolytic agent TNK-tPA, an in vitro flow clot model was designed reproducing the 
physiological situation of MCA thrombosis, occurred deep into brain tissue. In order to 
succeed this, fully retracted blood clot samples were embedded 4 cm deep into brain tissue 
mimicking phantoms. As a result, the FUS waves at beam focus were significantly 
attenuated, due to absorption and scattering. The objective was to establish an optimized 
treatment protocol for 1.18 MHz pulsed FUS exposures that maximizes the permeation 
of thrombolytic agent into the clot, leading to increase degree of thrombolysis, without 
excess heating.  
For this purpose, the role of various experimental parameters involved in this 
technique, was evaluated. These are: the TNK-tPA concentration, the FUS energy, the 
flow rate, the exposure time, the pulse length, the PRF, the DF, the formation of standing 
waves, the acoustic properties of the medium and the administration of MBs.  
5.2. In vitro experimental set up 
In this study, a set up as reliable as possible to the real situation of MCA 
thrombosis occurred 4 cm deep into a brain tissue was designed. Blood clots were formed 
into low density plastic tubing (4 mm inner diameter, 0.85 mm wall thickness), mimicking 
occluded cerebral arteries. Each tubing containing clot was positioned through a custom 
made ABS plastic holder (figure 5.1A) and immersed into a water tank filled with 
degassed water. A brain tissue mimicking phantom was constructed into a custom made 
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ABS plastic mould (figure 5.1B). The phantom was specially constructed to 
accommodate a clot tubing through it, reproducing a MCA occlusion occurred 4 cm deep 
into a brain tissue.  
 
 
 
 
 
5.2.1. Brain tissue mimicking phantom 
The ideal material for constructing a tissue mimicking phantom should have the 
same range of speed of sound as well as attenuation and scattering coefficient as soft 
tissues. Therefore, in our case a brain tissue mimicking phantom was constructed to 
simulate the biological properties of brain tissue [183]. Agar gel was selected as the base 
of the phantom, as it ensures mechanical characteristic similar to that of soft tissue. The 
agar powder used (Himedia Laboratories, Mumbai, India), produced a gel flexible enough 
to withstand high intensity US compression forces without cracking. To control the gel’s 
scattering coefficient, crystalline silica dioxide powder (Merck Millipore, Darmstadt, 
Germany), was added as scattering material to reproduce the acoustic properties of brain 
tissue. Furthermore, evaporated milk was also added to the mixture in order to raise its 
attenuation coefficient to the average value of the brain tissue, which is approximately 
0.6 dB/cmMHz [184]. The mixture was stirred and heated until agar melted (90 °C) and 
then poured in a custom made ABS plastic mould, specially designed to create a cavity 
(4 mm in diameter and 30 mm in height), at phantom’s bottom. When the mould was 
completely filled with the mixture, was stored overnight at 4 0C to gellify. After the 
precise positioning of the US beam on target, the agar-evaporated milk-silica gel 
phantom, which was designed to fit exactly into the plastic holder, was placed with great 
caution over the tubing (figure 5.2). It should be noted that the distance between the clot 
and the front surface of the phantom was 4 cm. 
5.2.2. Unidirectional circulating flow system 
To provide a more realistic clinical environment, the physiological situation of 
flow was reproduced by exposing blood clots to a unidirectional circulating pulsatile flow. 
A B 
Figure 5.1: A) Custom made plastic holder, B) Custom made plastic mould for phantom’s construction. 
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The outlet tubing from the reservoir of the flow system after passing the peristaltic pump 
was connected to a Y-shaped connector. The one end was connected back to the reservoir 
(inlet tubing), in order to sustain circulation and the other end was connected to the clot 
tubing, embedded into the brain tissue mimicking phantom. The distal end of the tubing 
was terminated with a 3-way connector to ensure that the clot was not moving during 
treatment.  
 
Figure 5.2: Placement of brain tissue mimicking phantom over the clot tubing. 
The overall experimental set-up for in vitro FUS exposures into a brain tissue mimicking 
phantom, using a flow clot model is shown in figure 5.3. 
 
Figure 5.3: Experimental set-up for FUS exposures into a brain tissue mimicking phantom, using an in 
vitro flow clot model. 
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3-way connector 
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Arm of the robotic system 
Brain tissue mimicking phantom 
FUS transducer 
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5.3. Optimum frequency 
Although low US frequencies (< 1 MHz), penetrate better with minimal heating, an 
experimental kHz delivery system in combination with rt-PA resulted in a significant 
increase of intracerebral haemorrhage in patients with AIS, due to the formation of 
standing waves at and away from the therapeutic target locations [89], [133]. The 
increased potential of low frequency transcranial thrombolysis to induce standing waves, 
can be associated with the occurrence of longer wavelengths and reduced absorption in 
the brain tissue [185].  
Motivated by these observations, a higher US frequency was examined as the best 
approach for eliminating the induction of standing waves in the skull without increasing 
the risk for producing adverse biological effects, such as thermal heating. Taking into 
consideration the above mentioned studies in association with the study by Spengos et al. 
2000 [58], where they suggested that transcranial application of 1 MHz pulse wave US, 
may accelerate reperfusion and recanalization rate of occluded intracerebral vessels, by 
enhancing rt-PA mediated thrombolysis, it seems that an US frequency in the range 
between 1-1.5 MHz is the best choice for transcranial sonothrombolysis, as it penetrates 
the temporal bone with less attenuation than higher frequencies and hence, reduced 
heating [186-187]. Based on the above findings, all experimental studies in this chapter 
were conducted using 1.18 MHz FUS frequency.  
5.4. Optimisation of treatment protocol 
The effect of each one of the following experimental parameters on thrombolysis 
efficacy (see equation 4.2 in chapter 4), was evaluated. Values of thrombolysis (T) as a 
function of the experimental parameters examined are presented as mean ± SD. To make 
sure that the contribution of thermal mechanisms to clot lysis was negligible, the value of 
AP was set to the maximum possible level that maintained a temperature elevation at 
beam focus of 1 ˚C. The 1.18 MHz FUS transducer was driven in a pulsed mode with a 
DF of 10 % and a PRF of 100 Hz. This resulted in a pulse “ON” period (1 ms) followed 
by a pulse “OFF” period (9 ms). The sonication time was fixed at 30 min and the 
peristaltic pump was set to the lowest flow rate achievable (10 mL/min). Temperature 
measurements at the focus were taken every 1 second.  
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5.5. Results 
Effect of TNK-tPA concentration 
To explore the effect of TNK-tPA concentration alone, mass loss data were collected 
from clots treated at a concentration of 2.0 μg/mL compared to clots treated at a 
concentration of 3.5 μg/mL. When the drug dose was established, the percentage decrease 
in clot weight of the group treated with TNK-tPA alone was compared with that of the 
control (untreated) group. Figure 5.4 shows the thrombolysis vs. TNK-tPA concentration 
for treatment time = 30 min and flow rate = 10 mL/min. 
 
Figure 5.4: The effect of TNK-tPA concentration on thrombolysis efficacy. Experimental parameters: 
treatment time = 30 min, flow rate = 10 mL/min, water bath temperature = 37 0C, no FUS and no MBs. 
Effect of each modality alone and in synergy 
Next, the effect of each modality alone (FUS, TNK-tPA) and in in synergy was 
evaluated. Figure 5.5 shows the effect of no FUS, no TNK-tPA (control), TNK-tPA alone, 
FUS alone and FUS+TNK-tPA for f = 1.18 MHz, DF = 10 %, AP = 20 W, Pulse length 
= 1 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 10 mL/min, TNK-tPA 
concentration = 3.5 μg/mL and no MBs. This result shows that even with no treatment 
there is a 30 % reduction in mass due to the placement of the clot in the experimental 
setup. Treatment of FUS alone or TNK-tPA alone has some effect, but clearly the 
combination of the two has enhanced effect. 
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Figure 5.5: The degree of thrombolysis in untreated clots, in clots treated with FUS alone, in clots treated 
with TNK-tPA alone and in clots treated with FUS+TNK-tPA. Experimental parameters: f = 1.18 MHz, 
DF = 10 %, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 10 
mL/min, water bath temperature = 37 0C and no MBs. 
Similarly, by subtracting thrombolysis achieved in the control group, the enhancing 
effect of FUS on TNK-tPA mediated thrombolysis was assessed. Figure 5.6 shows the 
thrombolysis vs. FUS for f = 1.18 MHz, DF = 10 %, AP = 20 W, pulse length = 1 ms, 
PRF = 100 Hz, treatment time = 30 min, flow rate = 10 mL/min, TNK-tPA concentration 
= 3.5 μg/mL and no MBs. The reduction on clot mass is almost double with TNK-tPA 
and FUS compared to TNK-tPA alone. Therefore, in all subsequent experiments the 
synergy of TNK-tPA and FUS was implemented. 
 
Figure 5.6: The enhancing effect of FUS on TNK-tPA mediated thrombolysis. Experimental parameters: f 
= 1.18 MHz, DF = 10 %, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, treatment time = 30 min, flow 
rate = 10 mL/min, TNK-tPA concentration = 3.5 μg/mL, water bath temperature = 37 0C, and no MBs. 
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Effect of flow rate 
 To investigate the effect of flow, 2 different rates were used (10 mL/min and 
30 mL/min). Figure 5.7 shows the thrombolysis vs. flow rate for f = 1.18 MHz, DF = 10 
%, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, treatment time = 30 min, TNK-tPA 
concentration = 3.5 μg/mL and no MBs. 
 
Figure 5.7: The beneficial role of flow rate on thrombolysis efficacy. Experimental parameters: f = 1.18 
MHz, DF = 10 %, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, treatment time = 30 min, TNK-tPA 
concentration = 3.5 μg/mL water bath temperature = 37 0C, and no MBs. 
Effect of sonication time 
The effect of sonication time was evaluated at 15, 30 and 60 min respectively. 
Figure 5.8 shows the thrombolysis vs. time for f = 1.18 MHz, DF = 10 %, AP = 20 W, 
pulse length = 1 ms, PRF = 100 Hz, flow rate = 10 mL/min, TNK-tPA concentration = 
3.5 μg/mL and no MBs. 
This result shows that saturation was achieved in 30 min, therefore in all subsequent 
experiments the 30 min duration was used. 
 
Figure 5.8: The effect of time on thrombolysis efficacy. Experimental parameters: f = 1.18 MHz, DF = 10 
%, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, flow rate = 10 mL/min, TNK-tPA concentration = 3.5 
μg/mL, water bath temperature = 37 0C and no MBs. 
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Effect of pulse length-PRF 
The effect of pulse length was estimated, using 2 different pulse durations (1 ms and 
100 ms). Figure 5.9 shows the thrombolysis vs. pulse length for f = 1.18 MHz, DF = 10 
%, PRF = 100 and 1 Hz, AP = 20 W, treatment time = 30 min, Flow rate = 10 mL/min, 
TNK-tPA concentration = 3.5 μg/mL and no MBs. 
 
Figure 5.9: The effect of pulse length on FUS enhanced TNK-tPA induced thrombolysis. Experimental 
parameters: f = 1.18 MHz, DF = 10 %, PRF = 100 and 1 Hz, AP = 20 W, treatment time = 30 min, flow 
rate = 10 mL/min,   TNK-tPA concentration = 3.5 μg/mL, water bath temperature = 37 0C and no MBs. 
Effect of DF 
The effect of DF was assessed at values of 5 % and 10 % with AP 40 W and 20 
W respectively, thus establishing the same temporal average intensity. Figure 5.10 shows 
the thrombolysis vs. DF for f = 1.18 MHz, pulse length = 0.5 ms and 1 ms, PRF = 100 
Hz, treatment time = 30 min, flow rate = 10 mL/min, TNK-tPA concentration = 3.5 μg/mL 
and no MBs. Obviously, DFs < 10 % did not play an important role on thrombolysis 
efficacy. 
 
Figure 5.10: Relative thrombolysis enhancement as a function of DF. Experimental parameters: f = 1.18 
MHz, AP = 20 W, pulse length = 0.5 and 1 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 10 
mL/min, TNK-tPA concentration = 3.5 μg/mL, water bath temperature = 37 0C and no MBs. 
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Effect of standing waves 
The effect of standing as well as travelling acoustic waves was estimated by using an 
absorbing medium. Figure 5.11 shows the thrombolysis vs. presence or absence of 
absorbing material for f = 1.18 MHz, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, 
treatment time = 30 min, flow rate = 10 mL/min, TNK-tPA concentration = 3.5 μg/mL 
and no MBs. 
 
Figure 5.11: The impact of standing acoustic waves on thrombolysis efficacy. Experimental parameters: f 
= 1.18 MHz, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 10 
mL/min, TNK-tPA concentration = 3.5 μg/mL, water bath temperature = 37 0C and no MBs. 
Effect of medium 
The effect of the medium was studied using water and agar. Figure 5.12 shows the 
thrombolysis vs. medium for f = 1.18 MHz, AP = 20 W, pulse length = 1 ms, PRF = 100 
Hz, treatment time = 30 min, flow rate = 10 mL/min, TNK-tPA concentration = 3.5 μg/mL 
and no MBs. 
 
Figure 5.12: The influence of the medium on thrombolysis efficacy. Experimental parameters: f = 1.18 
MHz, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 10 mL/min, 
TNK-tPA concentration = 3.5 μg/mL water bath temperature = 37 0C, and no MBs. 
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Effect of bubbles 
The effect of cavitation nuclei was investigated by injecting 2.5 mL of MBs (0.5 mL/5 
min). Figure 5.13 shows the thrombolysis vs. MBs for f = 1.18 MHz, AP = 20 W, pulse 
length = 1 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 10 mL/min, TNK-
tPA concentration = 3.5 μg/mL and MBs rate = 0.5 mL every 5 min. 
 
Figure 5.13: Thrombolysis enhancement due to MBs administration. Experimental parameters: f = 1.18 
MHz, AP = 20 W, pulse length = 1 ms, PRF = 100 Hz, Treatment time = 30 min, flow rate = 10 mL/min, 
TNK-tPA concentration = 3.5 μg/mL, water bath temperature = 37 0C and MBs rate = 0.5 mL every 5 min. 
5.6. Statistical analysis 
Statistical analysis was performed using the Wilcoxon signed-rank test. This paired 
difference test was used to test for significant differences on thrombolysis efficacy 
between the following pair groups: 
1. TNK-tPA (2 μg/mL) group with TNK-tPA (3.5 μg/mL) group 
2. Control group with TNK-tPA alone group 
3. TNK-tPA alone group with FUS (1.18 MHz) + TNK-tPA group 
4. Flow rate (10 mL/min) group with Floe rate (30 mL/min) group  
5. Sonication time (15 min) group with Sonication time (30 min) group 
6. Pulse length (100 ms) group with Pulse length (1 ms) group 
7. Duty Factor (10 %) group with Duty Factor (5 %) group 
8. Standing waves (no absorber) group with travelling waves (absorber) group 
9. Medium (water) group with Medium (agar) group 
10. FUS (1.18 MHz) + TNK-tPA group with FUS + TNK-tPA + MBs group 
Applying the Wilcoxon signed-rank test for the difference (of the mean) between all 
pairs of experimental groups examined in this chapter, it turns out that |W| >> W0.05,5, 
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leading to a strong rejection of the null hypothesis. Hence, it can safely be said that in all 
cases, the second sample (group) has a higher population mean. 
5.7. Discussion 
Thrombolysis efficacy is dependent on TNK-tPA concentration and increases with 
increasing thrombolytic concentration as shown in figure 5.4. Treatment with TNK-tPA 
alone produced more thrombolysis than that achieved either in the control or in the FUS 
alone (figure 5.5). Clots treated with FUS plus TNK-tPA exhibited a 25 % (56.2/45), 
greater degree of thrombolysis compared with clots treated with TNK-tPA alone (figure 
5.5). The degree of thrombolysis achieved in the control was subtracted from that 
achieved in the other methods. Clots treated with FUS plus TNK-tPA exhibited enhanced 
thrombolysis over clots treated with TNK-tPA alone, as much as 80 % (25.2/14), as it is 
presented in figure 5.6. Study results are in good agreement with those from another in 
vitro study by Frenkel et al. [75]. In 2006, Frenkel and colleagues demonstrated that clots 
treated for 30 min with 1 MHz FUS + rt-PA (10 μg/mL), utilizing 100 ms pulses, 
exhibited 19 % greater degree of thrombolysis compared to clots treated with TNK-tPA 
alone. Thrombolysis enhancement was increased to 50 % when the degree of 
thrombolysis achieved in the control group was subtracted. Although the level of the AP 
used in their study was significantly higher than ours, we demonstrated a 33 % (25.2/19) 
greater degree of thrombolysis probably due to the following effects: 
1. The presence of perfusion gradient through occlusive clots due to flow. The penetration 
of the thrombolytic agent into clots by perfusion is much more effective than by diffusion 
[188]. 
2. The type of the thrombolytic agent. TNK-tPA has a longer half-life and greater binding 
affinity for fibrin than rt-PA [21]. 
3. The acoustic properties of the medium. We demonstrated that the enhancement of clot 
dissolution is much more pronounced in a brain tissue mimicking phantom than in water, 
possibly due to preservation of the acoustic field. Study results showed that thrombolysis 
efficiency is 45 % (25.2/17.4) more effective, when is conducted in the agar medium, 
compared to the water (figure 5.12). 
The effect of flow on the speed of fibrinolysis is always considered beneficial, since 
it is directly responsible for increased transport and penetration of PAs into blood clots, 
leading to enhanced thrombolysis. In the case of full occlusion, a situation occurred in 
our study, lysis proceeded from the inside, due to the non-uniform permeation of PAs into 
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the blood clot, through the least permeation-resistant. In a highly ischemic MCA, flow 
rates can vary between 0 and 15 cm/s [189]. In contrary, flow rates in an open MCA 
(without occlusion), can be as high as 50 cm/s [190]. In our experimental study, flow rate 
was set 6-times lower (8.3 cm/s). A 3 fold increase on the flow rate (25 cm/sec) resulted 
in 17 % (29/25.2) enhancement on thrombolysis efficacy, indicating that flow rate is 
directly proportional to pressure gradient (figure 5.7). In addition, it should be taken into 
account that in our in vitro case the clot was located at a dead end and thus flow was 
minimal. Normally, in an in vivo case, there is also flow from the veins resulting in an 
increased concentration of the thrombolytic agent that is in direct contact with the clot. 
So, our results are underestimated with this in vitro model. 
Regarding the effect of time on clot lysis, study findings showed a steep increase in 
thrombolysis efficiency during the first 15 min of FUS exposure, where 90 % of clot mass 
loss was observed. After 30 min of treatment, the peak thrombolytic activity of TNK-tPA 
was measured, followed by a plateau for longer exposure times, where no further 
thrombolysis occurred (figure 5.8). The phenomenon that no thrombolytic activity took 
place between 30-60 min of treatment, can be explained from the time dependence curve 
of TNK-tPA concentration in blood, as presented in TIMI 10B trial [179], which was 
designed to compare prospectively the efficacy and safety of rt-PA and TNK-tPA. The 
blood concentration of TNK-tPA over time in the TIMI 10B trial, shows that after 30 min 
of treatment the initial concentration of the agent reduces below 50 % (17-24 min half-
life) and drops down to 25 % at 60 min. Taking into consideration that FUS alone did not 
enhance thrombolysis compared to control clots, it is reasonable to assume that that the 
thrombolytic activity of TNK-tPA between 30-60 min of treatment was probably very 
low to cause further fibrinolysis. 
Pulse length and associated PRF are directly related with the degree of clot 
displacement and thus, the depth of penetration of the thrombolytic agent into the clot. 
Study findings have shown that the transmission of 1 ms pulse with 100 Hz PRF, 
promoted deeper TNK-tPA penetration compared to the transmission of 100 ms pulse 
with 1 Hz PRF, resulting in a 26 % (25.2/19.4) thrombolysis enhancement (figure 5.9). 
Consequently, it is more effective to transmit shorter pulses more frequently, which keep 
the clot in constant motion, than to transmit longer pulses less frequently, which saturate 
clot’s displacement for an extended period of time. 
Since one of the main aspects of our treatment protocol was to avoid excessive 
heating, short DFs values were applied (≤ 10 %). The outcome of this experiment, 
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demonstrated a 7 % (27.0/25.2) enhancement in thrombolysis efficiency using a DF of 5 
% (AP = 40 W and pulse length = 0.5 ms), compared to that of 10 % (AP = 20 W and 
pulse length = 1 ms), as it is presented in figure 5.10. Thrombolysis enhancement using 
5 % DF, might be due to the increased level of ARF (AP was doubled), since it is well 
established that there is linear increasing dependence between AP levels and thrombolysis 
efficacy [75]. On the other hand, since the difference in thrombolysis enhancement 
between DFs of 5 and 10 % is within the statistical error, further investigation is required. 
Concerning the effects of standing and travelling US waves on thrombolysis 
enhancement, experimental results have shown a significant difference in clot mass loss 
in relation with the wave type applied. Study findings demonstrated that the impact of 
travelling acoustic waves on enzymatic fibrinolysis is much more pronounced than in 
standing waves, resulting in a 163 % (25.2/9.6) enhancement in thrombolysis efficacy 
(figure 5.11). 
The largest thrombolysis enhancement was estimated for clots treated with FUS 
plus TNK-tPA, in the presence of MBs. A clear synergistic effect was observed on 
enzymatic fibrinolysis induced by TNK-tPA when FUS waves interacted with injected 
MBs. Study outcome demonstrated that the injection of MBs (SonoVue) on a constant 
rate (to replace the destroyed bubbles), enhanced thrombolysis efficacy by 53 % 
compared to thrombolysis induced using only FUS and TNK-tPA (figure 5.13). In 2007, 
Prokop et al. reported that the enhancement of clot lysis in the presence of a thrombolytic 
drug is related to the cavitation process caused by the combination of US and MBs [66]. 
It is assumed that the administration of MBs (acting as cavitation nuclei) on a constant 
rate to sustain cavitation, significantly reduced acoustic cavitation threshold, giving rise 
to cavitation activity. In 1991, Apfel and Holland [191], quantified the threshold for 
inertial cavitation to occur (MI > 0.7), assuming that a full range of bubble sizes were 
present to provide nucleation centres and linear propagation occurs. It was estimated that 
during this experimental study, the physical conditions to support the onset of inertial 
cavitation probably did not existed and hence it is presumed that MBs enhanced 
sonothrombolysis was based mainly on stable cavitation activity. 
In the light of our findings, although cavitation activity was not measured, it is 
reasonable to hypothesize, that the mechanism by which the administration of MBs 
improved FUS enhanced TNK-tPA thrombolysis is related with cavitation based 
phenomena and most likely with stable cavitation. 
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5.8. Conclusions 
In the present study, an in vitro flow clot model was developed to evaluate the 
influence of experimental parameters involved on thrombolysis efficiency. We have 
demonstrated that the application of 1.18 MHz FUS waves, accelerated enzymatic 
fibrinolysis of porcine blood clots induced by the thrombolytic agent TNK-tPA. In 
addition, the injection of MBs, was also demonstrated as a way to further enhance the 
effect of FUS on TNK-tPA mediated thrombolysis. In all parametric studies, the 
enhancement of enzymatic fibrinolysis was occurred through non-thermal mechanisms, 
since the temperature at beam focus never exceeded 1 0C. Although the lytic effect of 
FUS was clearly demonstrated, the mechanisms behind clots dissolution were not 
elucidated. It is speculated that ARF and cavitation activity with accompanying 
microstreaming, are probably the most important mechanisms of FUS that dominantly 
appeared in our study contributing to thrombolysis enhancement. 
Study findings, which are all associated with enhanced thrombolysis, helped us to 
optimize the treatment protocol for 1.18 MHz pulsed FUS waves that maximizes the 
thrombolytic efficiency of TNK-tPA. However, since the potential objective of 
thrombolytic treatment is the fast and complete clot dissolution, it is possible that even 
with this optimization, the proposed treatment might not unblock on time large occluded 
volumes. Therefore, the following needs should be done in order to improve thrombolysis 
efficacy: 
1. Study results even with the use of low flow rates and TNK-tPA concentrations, has 
shown a significant increase in thrombolysis efficacy. Thus, it is likely that our findings 
would have been even more significant, under higher levels of flow rates and TNK-tPA 
concentrations. 
2. Beam focus was stationary during the treatment period. We hypothesize, that if the 
beam focus was moving with the robotic system across the long axis of the clot following 
clot’s edge (due to clot lysis, the position of clot’s edge will change with time), 
presumably the degree of thrombolysis rate would have been even higher. 
3. The use of a transducer that produces a larger beam area on clot’s surface, in order to 
increase the uptake, penetration and binding of the thrombolytic agent into the clot. 
Therefore, further optimization parametric studies are needed, before the proposed 
treatment protocol translated in vivo. 
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5.9. Summary 
A summary table with the recommended therapeutic protocol for the treatment of a 
MCA occlusion occurred 4 cm deep into a brain tissue is provided below: 
Table 7: Recommended therapeutic protocol for the treatment of a deep-seated 
MCA occlusion 
Experimental Parameters Values 
Mode MR compatible FUS transducer 
Frequency 1.18 MHz 
Acoustic Power 20 W 
Duty Factor 10 % 
Pulse length 1 ms 
Pulse Repetition Period 10 ms 
Pulse Repetition Frequency 100 Hz 
Treatment time 30 min 
Temperature 37 0C 
Flow rate 10 mL/min 
TNK-tPA concentration 3.5 μg/mL 
MBs dose 3 mL (0.5 mL/5 min) 
Treatment’s outcome 370 mg of mass clot removed 
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 The enhancing effect of focused ultrasound on TNK- tPA 
induced thrombolysis of a superficial target using an in vitro 
circulating flow model 
6.1 Introduction 
Since the most common cause of stroke is due to occlusion of MCA or one of its 
branches, an in vitro flow clot model was developed to reproduce the physiological 
situation of MCA branch occlusion, occurred superficially. For this purpose, fully 
retracted porcine blood clots were exposed to a circulating pulsatile flow and were treated 
with pulsed FUS exposures as an adjunct to thrombolytic TNK-tPA and in the presence 
or absence of MBs. FUS waves were delivered to the target through a cellophane window 
to minimize absorption. 
In this study, the influence of various parameters such as temperature, frequency, 
AP, FUS energy and MBs administration on thrombolysis efficacy, was evaluated. The 
objective was to obtain the optimum value for each one of the parameter examined, in 
order to maximize the uptake, the penetration and the binding of the drug into the clot, 
leading to increase enzymatic thrombolysis. Thrombolysis efficacy was measured in mg 
of blood clot removed, except from that concerning the effect of temperature, where it 
was measured as a percentage of clot lysis. 
The optimum operating parameters obtained in the previous chapter such as DF, 
pulse length, PRP, PRF and treatment time [76], were employed in this study in order to 
establish a treatment protocol that through non-thermal mechanisms, maximizes the 
amount of mass clot removed from a superficial target. 
6.2 In vitro experimental set up 
Porcine blood clots were formed into custom made ABS plastic containers. The 
lower part of each container (where the blood was naturally coagulated), included a 20 x 
30 mm2 window, closed with a thin cellophane membrane. The container comprising clot 
was fixed on a custom made ABS plastic holder and immersed into the water tank filled 
with degassed water. The physiological situation of flow in a MCA branch occlusion, was 
reproduced by exposing the clots to a unidirectional circulating pulsatile flow. The outlet 
tubing from the reservoir after passing the peristaltic pump was connected to the upper 
left side of the container. The inlet tubing was connected to the opposite right side, in 
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order to sustain circulation. The FUS transducer was mounted on the arm of the automated 
robotic system, immersed in the water tank and arranged opposite to the blood clot at such 
a distance in order to focus the US beam precisely on the target. The overall experimental 
set-up to evaluate the enhancing effect of FUS on TNK-tPA mediated thrombolysis, using 
an in vitro flow clot model is presented in figure 6.1 below. 
 
Figure 6.1: Experimental set up for direct FUS exposures, using an in vitro flow clot model. 
6.3 Optimisation of treatment protocol 
Once again, the main aspect for establishing the experimental protocol, was to 
maintain a localized temperature increase at beam focus that does not exceed 1˚C and 
keep the surrounding temperature constant. Values of thrombolysis (T) as a function of 
the experimental parameters examined such as, temperature, frequency, AP, FUS energy 
and MBs administration, are presented as mean ± SD. 
Since the values for DF, PRF, PRP and exposure time, were kept the same as those 
obtained in the previous experimental study [76], the FUS transducer was driven in a 
pulsed mode with a DF of 10 % and a PRF of 100 Hz. As a result, each sonication set 
included a pulse “ON” period (1 ms) followed by a pulse “OFF” period (9 ms) and both 
the “ON” and “OFF” pulses were repeated in succession for the duration of a 30 min 
treatment (i.e., 3000 pulses). 
Peristaltic pump 
Plastic holder 
FUS transducer 
Heater 
Arm of the robotic system 
Reservoir 
Inlet tubing 
Outlet tubing 
Container with the clot 
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In order to maximise thrombolysis efficacy, the levels of flow rate and TNK-tPA 
concentration were increased, compared with those used previously. As a result, the 
peristaltic pump was set to maintain a flow rate of 40 cm/s (5 fold increase) and the 
concentration TNK-tPA used was 7 μg/mL (2 fold increase). It is important to note that 
the values for flow rate and drug concentration were selected to be well below the 
maximum levels occurred in a physiological situation of MCA occlusion, following iv 
thrombolytic therapy. In such a case, the flow rate in an open MCA can be as high as 50 
cm/s [190] and the average maximum TNK-tPA concentration in blood following iv bolus 
administration of 50 mg can be as high as 11.6 μg/mL [192]. 
6.4 Results  
Effect of temperature 
Firstly, data on the temperature dependence of TNK-tPA lytic efficacy would be 
useful in establishing an optimal treatment protocol. To study the effect of temperature 
on the lytic efficacy of TNK-tPA, 3 groups of clots were treated with TNK-tPA alone. 
Percentage mass loss was measured for clots treated at 37, 39 and 41 0C respectively. 
Figure 6.2 shows the thrombolysis vs. temperature for treatment time = 120 min, TNK-
tPA concentration = 10.0 μg/mL and no flow rate. Study results demonstrated that the 
peak fibrinolytic activity of TNK-tPA was achieved at 37 0C. 
 
Figure 6.2: The effect of temperature on the lytic efficacy of TNK-tPA. Experimental parameters: no FUS, 
no MBs, no flow rate, treatment time = 120 min and TNK-tPA concentration = 10 μg/mL. 
Effect of frequency 
Generally, investigators use two commonly frequency ranges to enhance 
thrombolysis: 
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1. US frequencies in the kilohertz range, which are classified as low and have the 
advantage of better tissue penetration with reduced heating due to lower absorption rate,  
2. US frequencies in the megahertz range, which are classified as high and have the 
advantage of sharp focus.  
In this work, thrombolysis efficacy was evaluated using FUS pulses at 0.6 and 
1.18 MHz respectively. To investigate the effect of frequency on thrombolysis efficacy, 
two groups of clots were treated with FUS + TNK-tPA. Mass loss data were collected 
from clots exposed at 0.6 MHz compared with clots exposed at 1.18 MHz. Figure 6.3 
shows the thrombolysis vs. frequency for DF = 10 %, AP = 60 W, pulse duration = 1 ms, 
PRP = 10 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 50 mL/min, TNK-tPA 
concentration = 7.0 μg/mL, temperature of the water bath = 37 0C and no MBs. Since 
study results showed that the frequency in the kilohertz range produced less thrombolysis 
compared to that in the megahertz range, all subsequent experiments were conducted 
using a 1.18 MHz transducer. 
 
Figure 6.3: The effect of frequency on thrombolysis efficacy. Experimental parameters: DF = 10 %, AP = 
60 W, pulse duration = 1 ms, PRP = 10 ms and PRF = 100 Hz, treatment time = 30 min, flow rate = 50 
mL/min, TNK-tPA concentration = 7.0 μg/mL, water bath temperature = 37 0C and no MBs. 
Effect of acoustic power 
The degree of thrombolysis was examined over a range of APs up to the level where 
the temperature at beam focus did not exceed 1 0C. To examine the effect of AP on clot 
lysis, three groups of clots were treated with FUS + TNK-tPA. The degree of 
thrombolysis was determined for clots treated at AP of 20, 30 and 60 W respectively. 
Figure 6.4 shows the thrombolysis vs. AP for f = 1.18 MHz, pulse duration = 1.0 ms, PRP 
= 10 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 50 mL/min, TNK-tPA 
concentration = 7.0 μg/mL, temperature of the water bath = 37 0C and no MBs. 
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Figure 6.4: The effect of AP on clot lysis. Experimental parameters: f = 1.18 MHz, DF = 10 %, pulse 
duration = 1 ms, PRP = 10 ms and PRF = 100 Hz. treatment time = 30 min, flow rate = 50 mL/min, TNK-
tPA concentration = 7.0 μg/mL, water bath temperature = 37 0C and no MBs. 
Effect of FUS energy 
To determine the enhancing effect of FUS on clot lysis, the decrease in clot weight of 
the group treated with FUS + TNK-tPA was compared with that of the group receiving 
the same TNK-tPA concentration but no FUS. Moreover, the effect of each modality 
alone (FUS, TNK-tPA) and in in synergy was determined. Figure 6.5 shows the effect of 
no FUS, no TNK-tPA (control), FUS alone, TNK-tPA alone and FUS + TNK-tPA for f 
= 1.18 MHz, DF = 10 %, AP = 60 W, pulse duration = 1 ms, PRF = 100 Hz, treatment 
time = 30 min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL, temperature 
of the water bath = 37 0C and no MBs. Even with no FUS, no TNK-tPA (control), the 
placement of the clots in the circulating flow system, resulted in 1200 mg of mass clot 
removed.  
 
Figure 6.5: The degree of thrombolysis in untreated clots, in clots treated with FUS alone, in clots treated 
with TNK-tPA alone and in clots treated with FUS + TNK-tPA. Experimental parameters: f = 1.18 MHz, 
DF = 10 %, AP = 60 W, pulse duration = 1 ms, PRP = 10 ms and PRF = 100 Hz, treatment time = 30 min, 
flow rate = 50 mL/min, water bath temperature = 37 0C and no MBs. 
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Similarly, by subtracting thrombolysis achieved in the control group, the enhancing 
effect of FUS on TNK-tPA induced thrombolysis was assessed. Figure 6.6 shows the 
thrombolysis vs. FUS for f = 1.18 MHz, DF = 10 %, AP = 60 W, pulse duration = 1 ms, 
PRP = 10 ms, PRF = 100 Hz, treatment time = 30 min, flow rate = 50 mL/min, TNK-tPA 
concentration = 7.0 μg/mL, temperature of the water bath = 37 0C and no MBs. 
 
Figure 6.6: The enhancing effect of FUS on TNK-tPA mediated thrombolysis. Experimental parameters: f 
= 1.18 MHz, DF = 10 %, AP = 60 W, pulse duration = 1 ms, PRP = 10 ms and PRF = 100 Hz, treatment 
time = 30 min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL, water bath temperature = 
37 0C and no MBs. 
Effect of bubbles 
The effect of cavitation nuclei on thrombolysis efficacy was explored by injecting 
0.5 mL of MBs every 5 min. Figure 6.7 shows the thrombolysis vs. MBs for f = 1.18 
MHz, AP = 60 W, pulse duration = 1 ms, PRF = 100 Hz, treatment time = 30 min, flow 
rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL, temperature of the water bath = 
37 0C and MBs rate = 0.5 mL every 5 min. 
 
Figure 6.7: The effect of MBs administration on thrombolysis efficacy. Experimental parameters: f = 1.18 
MHz, DF = 10 %, AP = 60 W, pulse duration = 1 ms, PRP = 10 ms and PRF = 100 Hz, treatment time = 
30 min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL, Water bath temperature = 37 0C and 
MBs rate = 0.5 mL/5 min. 
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6.5 Statistical analysis 
Statistical analysis was performed using the Wilcoxon signed-rank test. This paired 
difference test was used to test for significant differences on thrombolysis efficacy 
between the following pair groups: 
1. Temperature (41 0C) group with Temperature (39 0C) group 
2. Temperature (39 0C) group with Temperature (37 0C) group 
3. Frequency 0.6 MHz group with Frequency 1.18 MHz group 
4. Acoustic Power (20 W) group with Acoustic Power (30 W) group 
5. Acoustic Power (30 W) group with Acoustic Power (60 W) group 
6. Control group with TNK-tPA alone group 
7. TNK-tPA alone group with FUS (1.18 MHz) + TNK-tPA group  
8. FUS (1.18 MHz) + TNK-tPA group with FUS (1.18 MHz) + TNK-tPA + MBs group 
Applying the Wilcoxon signed-rank test for the difference (of the mean) between 
all pairs of experimental groups examined in this chapter, it turns out that |W| >> W0.05,5, 
leading to a strong rejection of the null hypothesis. Hence, it can safely be said that in all 
cases, the second sample (group) has a higher population mean. 
6.6 Discussion 
An in vitro flow clot model was used to investigate the effect of temperature on 
the thrombolytic efficacy of TNK-tPA. In this model, blood clots were exposed to a 
certain concentration of TNK-tPA, at fixed temperatures (37, 39 and 41 0C). 
Temperatures below the body baseline temperature of 37 0C were not investigated 
because: 
1. Some other in vitro studies, showed that the thrombolytic efficacy of rt-PA is reduced 
at lower temperatures (T ≤ 35 °C), which anticipated for clinical hypothermic therapy 
[193-194]. 
2. Hypothermic studies showed an increased risk of hemorrhage [193]. 
Study results showed that temperature has a significant impact on thrombolysis in 
clots exposed to TNK-tPA. The study also demonstrated that the peak fibrinolytic activity 
of TNK-tPA occurred at 37 0C and decreases approximately 4 %/0C increase in 
temperature (figure 6.2). These findings are in good agreement with those from other in 
vitro studies [194], which have shown that the fibrinolytic activity of rt-PA, decreases 5 
%/0C increase in temperature. 
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The optimal frequency for US applications is a trade-off between the sharpness of the 
focus and the depth of penetration. Although low US frequencies are more penetrating 
(due to less attenuation), does not allow energy focusing so sharply as high frequencies 
does. Due to their narrower focal spots, higher frequencies generate higher pressures and 
intensities, leading to higher ARF output [195]. 
In the case of fluids, ARF creates acoustic streaming [196], while in tissues it 
causes motion [197]. The ARF generated in tissue as a result of FUS exposures, has been 
reported to cause repetitive micron sized tissue displacements, creating structural changes 
that enable greater amounts of TNK-tPA to penetrate the clots and expose additional 
binding sites, leading to increase thrombolysis efficacy. In our study, clots treated with 
the operating frequency of 1.18 MHz exhibited 11.4 % (1950/1750), increased degree of 
thrombolysis compared to clots treated with the operating frequency of 0.6 MHz (figure 
6.3). Therefore, according to literature, the differences in measured clot lysis may be 
attributed to the 175 % difference between the two operating frequencies used (1.18 vs. 
0.6 MHz), since it is reported that the higher the operating frequency the higher the 
associate ARF [75], [198]. 
Regarding the effect of acoustic power on thrombolysis efficacy, a linear 
relationship was observed, in the range between 20-60 W (figure 6.4). Thrombolysis 
efficacy at AP levels above 60 W was not attempted since the temperature at beam focus 
would exceeded our prerequisite of 1 0C. The application of 20 W AP resulted in 1670 
mg of mass clot removed. When AP was increased from 20 to 40 W, a significant 
increased rate in thrombolysis efficacy was achieved, leading to 1820 mg of mass clot 
removed. A second increase in AP from 40 to 60 W caused a further significant increase 
in thrombolysis efficacy with 1950 mg of mass clot removed. Our observation is 
supported by another in vitro study showing that a linear increase of AP is directly related 
with enhanced thrombolysis, due to a proportional increase in the ARF [75]. In 2006, 
Frenkel et al. using 1 MHz FUS pulses, demonstrated a linear increasing dependence 
between transmitted AP and thrombolysis efficacy, in the range of 20-80 W [75]. 
Similarly, Hancock et al. [49] and Wright et al. [199], using FUS pulses at 1.0 and 1.5 
MHz respectively, also observed a linear correlation between transmit AP and the 
magnitude of clot displacement, as predicted for the generation of radiation forces [200]. 
Using a theoretical model described by Zanelli et al. [201], the intensity gain of 
our 1.18 MHz FUS transducer at beam focus was estimated and then, by applying 
equation 2.10, a peak clot displacement (ξmax), of 256 nm was calculated at a transmit AP 
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of 60 W (see appendix 3). In another in vitro study published by Jones et al. 2010 [198], 
a peak clot displacement of 243 μm was measured with a 1 MHz, around 5 % decrease 
from the value calculated in this study (with 1.18 MHz), at equivalent AP. Similarly, 
Wright et al. [199], measured a peak clot displacement of 263 μm with 1.5 MHz at 60 W 
AP. Consequently, the peak clot displacement calculated in this study is in a good 
agreement with those measured experimentally at equivalent AP and in the frequency 
range between 1-1.5 MHz, showing that the generation of clot displacements through 
ARF, is responsible for increasing thrombolytic drug’s efficacy and hence is associated 
with enhanced thrombolysis.  
In view of the findings in the above mentioned studies, in association with the 
results of the present study, it is speculated that ARF is the mechanism of action that 
dominantly appears in the propagation of pulsed FUS waves through a blood clot and is 
accompanying by enhanced thrombolysis.  
Treatment with TNK-tPA alone produced more thrombolysis than that achieved 
either in the control or in the FUS alone (figure 6.5). The effect of FUS alone on 
thrombolysis efficacy is practically negligible (figure 6.5). Clots treated with FUS plus 
TNK-tPA exhibited almost 26 % (1950/1550), greater degree of thrombolysis compared 
with clots treated with TNK-tPA alone (figure 6.5). When the degree of thrombolysis 
achieved in the control was subtracted from that achieved in the other methods, clots 
treated with FUS plus TNK-tPA exhibited enhanced thrombolysis over clots treated with 
TNK-tPA alone, as much as 114 % (750/350), as it is presented in figure 6.6. 
Frenkel and colleagues[75], demonstrated in their study, that clots treated for 30 
min with 1 MHz FUS + rt-PA (10 μg/mL), exhibited 19 % greater degree of thrombolysis 
compared to clots treated with TNK-tPA alone. Thrombolysis enhancement was 
increased to 50 % when the degree of thrombolysis achieved in the control group was 
subtracted. Although the levels of acoustic parameters applied in both studies were the 
same (DF = 10 %, AP = 60 W), a significant greater degree of thrombolysis was observed 
in our study, which might be probably due to the following effects: 
1. The presence of perfusion gradient through occlusive clots due to flow. The penetration 
of the thrombolytic agent into clots by perfusion is much more effective than by diffusion 
[188]. 
2. The type of the thrombolytic agent. TNK-tPA has a longer half-life and greater binding 
affinity for fibrin than rt-PA [21]. 
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3. The 18 % difference between the two operating frequencies used (1.18 vs. 1.0 MHz), 
since it is reported that the higher the operating frequency, the higher the ARF [75], [198]. 
The largest thrombolysis enhancement was assessed when clots were treated with 
FUS plus TNK-tPA in the presence of MBs. Study outcome demonstrated that the 
interaction of FUS waves with MBs, provided more efficient use of thrombolytic 
enzymes. The synergistic effect of FUS in combination with MBs on the enzymatic 
fibrinolysis induced by TNK-tPA, enhanced thrombolysis efficacy by 40 % (1050/750), 
compared to thrombolysis induced using only FUS + TNK-tPA (figure 6.7). This 
phenomenon can be explained by the ability of MBs to act as cavitation nuclei. As a result, 
the acoustic cavitation threshold is reduced, giving rise to cavitation activity. It is well 
established, that cavitation activity induces changes in the fibrin matrix, accelerates the 
transport and penetration of fibrinolytic agents into the clot and hence, increases the 
degree of clot dissolution [202]. In addition, it is important to bear in mind that the 
cavitation properties of MBs depend on their size, which influences their resonant 
frequency.  
According to equation 2.18 in chapter 2, the theoretical resonance radius of MBs 
in 1.18 MHz US field, is approximately 2.5 μm. Based on this approximation and taking 
into consideration that MBs mean size is between 2-8 μm [108-110], it is not  
unreasonable to assume that the bubbles in this study were driven near their resonance 
frequency, which is correlated with enhanced thrombolysis [147].  
Although cavitation activity was not detected in our experiments, the negligible 
contribution of thermal mechanisms on clot lysis, has lead us to make the hypothesis that 
MBs enhanced sonothrombolysis is directly related with cavitation based phenomena 
(non-thermal mechanisms). Since in this study, the theoretical threshold for the onset of 
inertial cavitation (MI > 0.7), probably never exceeded, we can postulate, that MBs 
enhanced sonothrombolysis is related most likely with stable cavitation. 
6.7 Conclusions 
In conclusion, this experimental work clearly demonstrated that thrombolysis 
efficacy can be significantly enhanced in vitro when pulsed FUS exposures are combined 
with the thrombolytic agent TNK-TPA. 
Furthermore, the administration of MBs on a constant rate to sustain cavitation 
activity, was established as a way to further accelerate FUS enhanced TNK-tPA mediated 
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thrombolysis. For that reason, MBs mediated sonothrombolysis may offer a new 
approach to improve outcomes in patients with AIS. 
Also, study results showed that the fibrinolytic activity of TNK-tPA varies with 
temperature and it is reasonable to say that temperature significantly affects thrombolysis 
in terms of both thrombolysis efficacy and haemorrhage risk.  
Taking into consideration that for intracranial occlusion, low-frequency US has 
the potential to cause intracerebral haemorrhage in association with the results of the 
present study, it is confirmed that for transcranial sonication, a frequency of 1.18 MHz, 
is employed as a best trade-off between focus and penetration. We can assume that 
transcranial application with 1.18 MHz pulsed FUS waves is a good choice for treating 
stroke patients, since: 
1. It penetrates the temporal bone with less attenuation than higher frequencies, i.e. 
reduces the possibility to overheat the skull [187],  
2. It is not associated with any excessive risk of intracerebral haemorrhage due to 
formation of standing waves in the cerebral cavity [203], and  
3. It improves recanalization rates and clinical outcomes [58]. 
Moreover, emphasis should be given to the biological effects produced when FUS 
energy interacts with tissue, since bioeffects are the basis for new FUS therapies. The low 
DF used in our experiments, lead to low energy deposition rates in tissue and hence 
minimal thermal rise at beam focus (≤ 1 0C), making sure that no bioeffects were 
generated from thermal mechanisms. 
As a final point, this study has shown promising results concerning the enhancing 
effect of FUS pulses in synergy with MBs, on TNK-tPA induced thrombolysis, since with 
30 min of treatment, 1050 mg of clot was removed with no excess heating. Taking into 
consideration that stroke is time dependent, this thrombolytic rate should be sufficient for 
timely recanalization of the occluded cerebral artery. Based on the encouraging results of 
the study, the proposed therapeutic protocol can be applied in vivo for the treatment of a 
superficial target such as the fast and complete recanalization of an occluded carotid 
artery of a rabbit. 
6.8 Summary 
A summary table with the recommended therapeutic protocol for the treatment of 
a MCA occlusion occurred superficially is provided below: 
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Table 8: Recommended therapeutic protocol for the treatment of a superficial 
MCA occlusion 
Experimental Parameters Values 
Mode MR compatible FUS transducer 
Frequency 1.18 MHz 
Acoustic Power 60 W 
Duty Factor 10 % 
Pulse length  1 ms 
Pulse Repetition Period 10 ms 
Pulse Repetition Frequency 100 Hz 
Treatment time 30 min 
Temperature 37 0C 
Flow rate  50 mL/min 
TNK-tPA concentration 7 μg/mL 
MBs dose 3 mL (0.5 mL/5 min) 
Treatment’s outcome 1050 of mass clot removed 
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 Microbubble-based sonothrombolysis using a planar 
rectangular ultrasonic transducer 
 Introduction 
The objective of this experimental study, was to evaluate the ability of small 
planar rectangular (2x10 mm2) ultrasonic transducers, to enhance thrombolysis induced 
by the thrombolytic agent TNK-tPA. The intended clinical application of this study is the 
minimally invasive treatment of stroke patients, using intravascular ultrasonic transducers 
in combination with thrombolytic drugs and MBs. In future clinical trials, the transducer 
will be incorporated in a catheter for intravascular insertion (1-3 mm wide) and thus, the 
element of the transducer must be as compact as possible. 
Using an in vitro circulating flow clot model, the physiological situation of flow 
in a superficial MCA branch occlusion, was reproduced. To provide a more realistic 
clinical environment of an intravascular treatment of stroke, the transducer was positioned 
as close as physically possible to clot’s proximal surface, simulating an invasive approach 
of sonothrombolysis. For this purpose, fully retracted porcine blood clots were exposed 
to unidirectional circulating pulsatile flow and were treated with high frequency planar 
pulsed US waves, along with thrombolytic TNK-tPA, in the presence or absence of MBs. 
Degassed water was used as the fluid for the closed-loop flow system. 
 Two ultrasonic flat rectangular transducers were used, operating at 3.7 and 5.2 
MHz respectively. A pulsed US protocol that maintained temperature elevation at the 
target of 1 0C was applied, providing that thrombolytic enhancement occurred mainly 
through non-thermal mechanisms. The impact of different experimental parameters such 
as US energy, frequency and MBs administration on thrombolysis efficacy, was 
evaluated. Thrombolysis efficacy was measured in mg of blood clot removed.  
 In vitro experimental set up 
Porcine blood clots were formed into custom made ABS plastic containers. The 
lower part of each container (where the blood was naturally coagulated), included a 20 x 
30 mm2 window, closed with a thin cellophane membrane. The container comprising clot 
was fixed on a custom made ABS plastic holder and immersed into the water tank filled 
with degassed water. The planar rectangular US transducer was mounted on the arm of 
the automated robotic system, immersed in the water tank and positioned as close as 
physically possible to the proximal portion of the blood clot The overall experimental set-
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up to evaluate the effect of high frequency US waves on TNK-tPA mediated thrombolysis 
with the use of in vitro flow clot model, is presented in figure 7.1 below. 
 
Figure 7.1: The experimental set up for in vitro sonothrombolysis, using a planar rectangular transducer. 
  Optimisation of treatment protocol 
In all experiments, the values of thrombolysis are presented as mean ± SD. The 
main aspect for establishing the experimental protocol, was to maintain a temperature 
increase at the target that does not exceed 1 0C. The planar US transducers were driven in 
a pulsed mode with a DF of 10 % and a PRF of 1 Hz. As a result, each sonication set 
included a pulse “ON” period (100 ms) followed by a pulse “OFF” period (900 ms) and 
both the “ON” and “OFF” pulses were repeated in succession for the duration of a 30 min 
treatment. Since the temperature at the target was continuously monitored, AP was set to 
the appropriate level, where no excess heating was produced (≤ 1 0C). 
Flow rate and TNK-tPA concentration were set at the same levels as those used 
in the previous experimental study. The flow rate was selected to be 20 % lower than the 
maximum value occur in an open MCA [190], while the drug concentration was selected 
to be 40 % lower of the average maximum concentration in blood, following iv 
thrombolysis with 50 mg of TNK-tPA [192]. Hence, the peristaltic pump was set to 
Peristaltic pump 
Reservoir 
Heater 
Arm of the robotic system 
Container with the clot 
US transducer 
Inlet tubing 
Outlet tubing 
Plastic holder 
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maintain a flow rate of 40 cm/s and the concentration of the thrombolytic drug in the flow 
system was 7 μg/mL. 
 Results 
Effect of US energy 
To determine the enhancing effect of US energy on clot lysis, the effect of TNK-
tPA in synergy with US waves at frequencies 3.7 and 5.2 MHz respectively, was 
compared to that of TNK-tPA alone. Figure 7.2 shows the effect of no US and no TNK-
tPA (control), TNK-tPA alone and US + TNK-tPA for f = 5.2 MHz and 3.7 MHz, DF = 
10 %, AP = 20 W, pulse duration = 100 ms, PRP= 1000 ms, treatment time = 30 min, 
flow rate = 50 mL/min, TNK-tPA concentration =7.0 μg/mL, temperature of the water 
bath = 37 0C and no MBs. Even with no US, no TNK-tPA (control), the placement of the 
clots in the circulating flow system, resulted in 1000 mg of mass clot removed. 
 
Figure 7.2: The degree of thrombolysis in untreated clots, in clots treated with TNK-tPA alone, in clots 
treated with 5.2 MHz US + TNK-tPA and in clots treated with 3.7 MHz US + TNK-tPA. Experimental 
parameters: DF = 10 %, AP = 20 W, pulse duration = 100 ms, PRP = 1000 ms, PRF = 1 Hz, treatment 
time = 30 min, flow rate = 50 mL/min, water bath temperature = 37 0C and no MBs. 
By subtracting thrombolysis achieved in the control group, the enhancing effect 
of US on TNK-tPA induced thrombolysis was assessed. Figure 7.3 shows the 
thrombolysis with TNK-tPA alone and with US + TNK-tPA (f = 3.7 and 5.2 MHz), for 
DF = 10 %, AP = 20 W, pulse duration = 100 ms, PRP= 1000 ms, treatment time = 30 
min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL, temperature of the 
water bath = 37 0C and no MBs. 
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Figure 7.3: The enhancing effect of US waves on TNK-tPA mediated thrombolysis. Experimental 
parameters: f = 3.7 and 5.2 MHz, DF = 10 %, AP = 20 W, Pulse duration = 100 ms, PRP =1000 ms, PRF 
= 1 Hz, treatment time = 30 min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL. 
Effect of bubbles 
The effect of cavitation nuclei on thrombolysis efficacy was explored by injecting 
1 mL of MBs every 6 min. Figure 7.4 shows the thrombolysis vs. MBs for f = 5.2 MHz, 
DF = 10 %, AP = 20 W, pulse duration = 100 ms, PRP= 1000 ms, treatment time = 30 
min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL, temperature of the 
water bath = 37 0C and MBs rate = 1 mL every 6 min and figure 7.5 shows the 
corresponding results with f = 3.7 MHz. 
 
Figure 7.4: The effect of MBs administration on thrombolysis efficacy. Experimental parameters: f = 5.2 
MHz, DF = 10 %, AP = 20 W, pulse duration = 100 ms, PRP = 1000 ms, PRF = 1 Hz, treatment time = 
30 min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL. 
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Figure 7.5: The effect of MBs administration on thrombolysis efficacy. Experimental parameters: f = 3.7 
MHz, DF = 10 %, AP = 20 W, pulse duration = 100 ms, PRP = 1000 ms, PRF = 1 Hz, treatment time = 
30 min, flow rate = 50 mL/min, TNK-tPA concentration = 7.0 μg/mL. 
 Statistical analysis 
Statistical analysis was performed using the Wilcoxon signed-rank test. This paired 
difference test was used to test for significant differences on thrombolysis efficacy 
between the following pair groups: 
1. Control group with TNK-tPA alone group 
2. TNK-tPA alone group with US (5.2 MHz) + TNK-tPA group  
3. TNK-tPA alone group with US (3.7 MHz) + TNK-tPA group 
3. US (5.2 MHz) + TNK-tPA group with US (5.2 MHz) + TNK-tPA + MBs group 
4. US (3.7 MHz) + TNK-tPA group with US (3.7 MHz) + TNK-tPA + MBs group 
Applying the Wilcoxon signed-rank test for the difference (of the mean) between all 
pairs of experimental groups examined in this chapter, it turns out that |W| >> W0.05, 5, 
leading to a strong rejection of the null hypothesis. Hence, it can safely be said that in 
all cases, the second sample (group) has a higher population mean. 
 Discussion 
The goal of the study was to assess whether small rectangular ultrasonic 
transducers in combination with thrombolytic TNK-tPA and in the presence or absence 
of MBs, can remove effectively blood clots. Fully retracted porcine blood clots were 
exposed to a unidirectional flow rate and to a certain concentration of TNK-tPA, at fixed 
temperature (37 °C). Small planar rectangular ultrasonic transducers operating at high 
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frequencies, were positioned as close as physically possible to the clot for optimal 
thrombolytic treatment. 
To isolate the influence of frequency on thrombolysis efficacy, the experiments 
were performed with identical sonication parameters at frequencies 3.7 and 5.2 MHz 
respectively. Clots treated with 5.2 MHz US waves plus TNK-tPA exhibited 15 % 
(1380/1200), greater degree of thrombolysis compared to clots treated with TNK-tPA 
alone (figure 7.2). Clots treated with 3.7 MHz US waves plus TNK-tPA exhibited 20 % 
(1440/1200), greater degree of thrombolysis compared to clots treated with TNK-tPA 
alone (figure 7.2). In order to have a quantitative measurement of thrombolysis efficacy, 
the degree of thrombolysis achieved in the control was subtracted from that achieved in 
the TNK-tPA alone and in the US + TNK-tPA (figure 7.3). Clots treated with 5.2 MHz 
US plus TNK-tPA exhibited enhanced thrombolysis over clots treated with TNK-tPA 
alone, as much as 90 % (380/200), while thrombolysis enhancement reached 120 % 
(440/200), in clots treated with 3.7 MHz US plus TNK-tPA over clots treated with TNK-
tPA alone. 
Study results exhibited that thrombolysis efficacy decreases with higher US 
frequencies (figure 7.3). This is in accordance with previous work of Suchkova et al. 1998 
[130] and Schäfer et al. 2005 [54], who showed that the thrombolytic efficacy of US is 
inversely depended on frequency. Similarly, another in vitro study by Blinc et al. [129], 
demonstrated that the acceleration of fibrinolysis by US was maximum at frequencies 
between 1 and 2.2 MHz, but decreased at 3.4 MHz, also indicating that frequency exerts 
a significant impact on thrombolysis efficacy. 
It is well documented that the interaction of acoustic US waves with target tissue 
can produce either thermal or non-thermal effects, which contribute to thrombolysis 
enhancement. The non-thermal effects can generally be categorized into primary 
mechanical effects such as radiation force, or secondary mechanical effects such as 
acoustic cavitation. 
In our experiments, the temperature increase within the clot never exceeded 1°C. 
As observed in the studies by Blinc et al. 1993 [129], Francis et al. 1992 [176] and Olsson 
et al. 1994 [127], such a minor degree of heating is insufficient to influence thrombolytic 
efficacy, establishing that thrombolysis enhancement occurred through non-thermal 
mechanisms.  
Taking into consideration that in our study the contribution of thermal effects in 
clot lysis was negligible, it is reasonable to assume that the enhancement of enzymatic 
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fibrinolysis due to the application of high US frequencies, occurred primarily due to non-
thermal mechanisms (e.g. radiation force). Radiation force is generated through a transfer 
of momentum from an acoustic US wave to the propagation medium and can initiate 
motion in fluids (acoustic streaming) [196] and displacement in tissues [197]. Hence, it 
is speculated that clot’s displacements due to ARF, mediated changes in the fibrin 
structure that may increase the permeation and penetration of the thrombolytic drug into 
the clot leading to enhance thrombolysis.  
When clots were treated with US plus TNK-tPA in the presence of MBs, further 
thrombolysis enhancement was observed. Study outcome demonstrated that the 
interaction of US waves with systemic administration of MBs, strongly accelerated the 
enzymatic fibrinolysis induced by TNK-tPA. The combination of 5.2 MHz US waves 
with MBs enhanced TNK-tPA mediated thrombolysis by almost 58 % (600/380) 
compared to thrombolysis induced using only 5.2 MHz US + TNK-tPA (figure 7.4). In 
addition, the combination of 3.7 MHz US waves with MBs enhanced TNK-tPA mediated 
thrombolysis by more than 59 % (700/440), compared to thrombolysis induced using only 
3.7 MHz US + TNK-tPA (figure 7.5).  
The degree of thrombolysis enhancement due to MBs administration (almost 60 
%), was significantly higher compared to that obtained in a previous in vitro study 
conducted by the same group [77], where MBs enhanced sonothrombolysis by 40 %. 
Considering that in the present work, the administered dose of MBs was almost double 
(5 mL) compared to that administered previously (3 mL), it is reasonable to assume that 
thrombolysis efficacy increases with higher doses of MBs, contributing to thrombolysis 
enhancement. 
The phenomenon of sonothrombolysis enhancement due to MBs administration, 
can be explained by the ability of bubbles to act as cavitation nuclei, reduce the acoustic 
cavitation threshold and give rise to cavitation activity. Cavitation activity can be 
classified as stable or inertial. Stable cavitation is associated by sustained small amplitude 
oscillations of the bubbles about their equilibrium, generating flow around them termed 
microstreaming. Inertial cavitation is associated by bubbles collapse, capable of 
producing shock waves free radicals, fluid jetting and erosion of materials. The pressure 
amplitude required to initiate stable oscillations is always lower than that required for 
inertial cavitation [204]. Although, cavitation activity was not detected in our 
experiments, we can suspect that MBs enhanced sonothrombolysis is based on cavitation 
related phenomena.  
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 Since the MI at both frequencies used in this study was estimated to be well below 
the theoretical threshold for the onset of inertial cavitation (MI > 0.7), it is suspected that 
the enhancement in thrombolysis efficacy was due to stable cavitation. The 
microstreaming produced by stable cavitation, can promotes both the transport [69] and 
penetration [143] of the thrombolytic drug into the clot, leading to faster clot dissolution. 
Furthermore, the presence of MBs, could modify both the attenuation and sound speed of 
the clot [205] and thus increasing the acoustic radiation force. This phenomenon may also 
contribute to thrombolysis enhancement. 
 Conclusions 
This study, presents two flat rectangular ultrasonic transducers, operating at 
frequencies 3.7 and 5.2 MHz respectively, which can be incorporated in a catheter and 
used in the future for invasive applications of therapeutic US, such as intravascular 
sonothrombolysis. 
Study results demonstrated that intravascular sonothrombolysis using a high 
frequency (in the megahertz range) small planar ultrasonic transducer, seems to be a 
promising method for effective clot lysis and potentially, may offer a new approach for 
the treatment of stroke patients.  
The maximum thrombolytic enhancement occurred when 3.7 MHz pulsed US 
waves combined with the thrombolytic agent TNK-tPA in the presence of MBs. Using 
this method, 700 mg of clot mass was removed with 30 min of treatment, which may be 
sufficient for timely recanalization of occluded cerebral arteries. 
Study findings showed that thrombolysis efficacy decreases with higher 
frequencies and hence lower US frequencies should be employed to improve outcomes. 
Since the optimal frequency for endovascular treatment is a trade-off between depth of 
penetration and thrombolysis efficacy, US frequencies in the range between 2-2.5 MHz 
[129], might be a good choice for intravascular sonothrombolysis and should be further 
investigated. 
On the other hand, a major issue is resulting from the possibility of this type of 
transducer to be utilized in combination with diagnostic imaging. In that case, the 
frequency has to be increased (probably between 20-40 MHz) [206]. Therefore, a 
compromised frequency needs to be derived that serves both the therapeutic and 
diagnostic purposes.  
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The acceleration of enzymatic fibrinolysis by US waves has been shown to occur 
mainly through non-thermal mechanisms. Consequently, it is speculated, that ARF and 
acoustic cavitation are the mechanical effects that dominantly appear in the propagation 
of high frequency pulsed US waves through a blood clot and contribute to thrombolysis 
enhancement. 
In conclusion, although intravascular sonothrombolysis seems to be an effective 
treatment method for stroke, further in vitro and in vivo studies are needed to determine 
the optimal frequency and to confirm the safety and the efficacy of this technique, before 
translated into clinical trials. 
 Summary 
A summary table with the recommended therapeutic protocol for the treatment of a 
MCA occlusion with a small flat rectangular ultrasonic transducer is provided below: 
Table 9: Recommended therapeutic protocol for intravascular treatment of 
MCA occlusion 
Experimental Parameters Values 
Mode Small planar rectangular ultrasonic transducer 
Frequency 3.7 MHz 
Acoustic Power 20 W 
Duty Factor 10 % 
Pulse length  1 ms 
Pulse Repetition Period 10 ms 
Pulse Repetition Frequency 100 Hz 
Treatment time 30 min 
Temperature 37 0C 
Flow rate  50 mL/min 
TNK-tPA concentration 7 μg/mL 
MBs dose 3 mL (0.5 mL/5 min) 
Treatment’s outcome 700 mg of mass clot removed 
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 Evaluation of a small flat rectangular therapeutic ultrasonic 
transducer intended for intravascular treatment of 
atherosclerosis 
 Introduction 
Atherosclerosis is a condition in which fatty material collects along the walls of 
arteries. This fatty material thickens and may eventually block the arteries [207]. 
Atherosclerosis treatment may require special surgical procedures such as balloon 
angioplasty and stenting [208], cutting balloon [209], atherectomy [210-211] and surgical 
bypass [212], to open an artery and improve blood flow. 
Another technological modality with therapeutic capabilities in treating 
atherosclerosis, is the application of US. This technology can be used in the future for 
clinical trials primarily to treat plaques in the vascular system. Unstable plaques in a blood 
vessel are a major source of risk to cause an embolic stroke, since the plaque can breaks 
off and a part of it through the bloodstream can reach the brain, becomes lodged to a brain 
vessel and blocks the blood flow. The US device can be attached to a catheter of 
appropriate size and guided intravenously to the vessel for ultrasonic treatment. Care will 
be taken to avoid the escape of debris which may cause further vessel blockage. 
In this experimental study, a small flat rectangular (2 X 10 mm²), MRI compatible 
ultrasonic transducer, operating at a frequency of 4 MHz was used. The aim of the study 
was to evaluate the thermal capabilities of such a transducer. Transducer’s efficacy was 
tested in two different gel phantoms fabricated to mimic tissue. A polyacrylamide 
hydrogel phantom was used to visualize the size and shape of the thermal lesion and an 
agarose based gel phantom was used to measure temperature elevation.  
The thermal effects of US energy were monitored under MRI guidance, since it is 
considered as the optimal imaging modality due to its unsurpassed soft tissue contrast and 
its temperature sensitivity [83], [213], [214]. Therefore, thermal lesions were visualised 
with MR imaging and temperature changes were demonstrated with MR thermometry. 
The intended application of this type of transducer is the intravascular treatment of 
atherosclerosis. 
  
119 
 Experimental set up to measure temperature elevation with a 
thermocouple 
The active size of the transducer under evaluation is 2 X 10 mm². It operates at 4 
MHz and it is made of Pz26-type PZT piezoceramic material with epoxy backing. The 
transducer was fixed on a custom made ABS plastic holder, which includes a cavity to 
accommodate the 1 mm thick coaxial cable (figure 8.1). 
 
Figure 8.1: A) CAD drawing of transducer. B) Photo of the2x10 mm2 prototype transducer. 
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The plastic holder was attached on the arm of the robotic system and immersed in 
an acrylic tank containing degassed water. The robotic system positioned the transducer 
on the surface of the tissue mimicking gel phantom. Tissue mimicking phantoms simulate 
the biological properties of tissue in order to provide a more realistic clinical environment. 
The phantom is made of agar powder, silica dioxide (SiO2) and evaporated milk (agar: 
2% w/v, silica: 1.2 % w/v, evaporated milk: 25% v/v). The details of the recipe and the 
steps for the preparation of the phantom are described in Menikou et al. [183]. To measure 
temperature elevation, a thermocouple was placed between the transducer’s face and the 
gel phantom. The thermocouple was connected to a data acquisition (DAQ) station that 
sampled temperature measurements for every 1 s. The size of the thermocouple was 
chosen to be 50 μm, so that the interaction with the US beam was minimized. At the 
bottom of the phantom, an acoustic absorber was placed to reduce the reflections of the 
US waves. The experimental set up for the placement of the transducer on the 
agar/silica/evaporated milk gel phantom is shown in figure 8.2. 
 
Figure 8.2: Placement of the transducer on the agar/silica/evaporated milk phantom. 
Figure 8.3 shows the temperature elevation in the agar/silica/evaporated milk 
phantom, from a baseline value of 28 °C to temperatures as high as 93 0C within 60 s. 
Temperature changes were measured with a thermocouple, placed between the 
transducer’s face and the gel phantom. The AP used was 6 W. 
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Figure 8.3: Temperature elevation in the agar/silica/evaporated milk phantom using the thermocouple 
placed in the face of the transducer. The acoustic power used was 6 W for 60 s. 
 MR thermometry  
The safety and efficacy of thermal therapy requires accurate temperature 
monitoring throughout the treatment, which is feasible with MR based thermometry 
method. This method is based on temperature sensitive MR parameters such as the proton 
density, the diffusion coefficient (D), the spin-lattice relaxation time (T1), the spin-spin 
relaxation time (T2), the magnetization transfer and the proton resonance frequency shift 
(PRFS). Among these different temperature dependent parameters, the excellent linearity 
of signal with temperature over a large temperature range and the low susceptibility to 
tissue type, has made the PRFS method the preferred choice for MR thermometry. 
Therefore, in this experimental study the temperature elevation during US 
exposures was estimated using the PRFS method [107]. This method relates the 
associated phase shift derived from the frequency shift of the MR signal due to the local 
temperature elevation (see equation 2.15 in chapter 2).  
In a 1.5 T MR system (Signa, General Electric, Fairfield, CT, USA), the pulse 
sequence used to extract the thermometry maps was the T1-weighted spoiled gradient 
recalled echo (SPGR), with the following parameters: Repetition time (TR) = 40 ms, Echo 
time (TE) = 20 ms, slice thickness=2.1 mm Field of view (FOV) = 21 cm, matrix = 
128x128, flip angle = 200, Number of excitations (NEX) = 1. Phase maps were 
reconstructed by calculating the phase on a pixel-by-pixel basis after combining pixel 
data from real and imaginary channels. Although the scanner is capable of producing 
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directly phase image reconstructions, the applied intra-scan gradient nonlinearity 
corrections induced phase interpolation problems. Transient phase shifts developed 
during the acquisition of non-treated (mask) and treated images were compensated by 
subtracting internal references in regions away from the treated site. Temperature 
elevation was returned by the software as the maximum value in a prescribed region of 
interest (ROI) that was manually positioned. Temperature-colour coded maps were 
produced by adjusting the colour map (blue to red) for a range of minimum to maximum 
ROI temperature. 
The MR temperature map for the planar transducer is shown in figure 8.4. MR 
thermometry was performed using the 2D SPGR sequence. The temperature indicated in 
this graph is temperature increase. US was activated during the first 4 images. The AP 
used during temperature acquisition was 6 W for 60 s. The phantom used was 
agar/silica/evaporated milk (agar: 2% w/v, silica: 1.2 % w/v, evaporated milk: 25% v/v).  
 
Figure 8.4: MR temperature map for the planar transducer using the 2D SPGR sequence. The acoustic 
power used was 6 W for 60 sec. The phantom used was agar/silica/evaporated milk. Thermal maps 1-9 
represent temperature evolution with time at a temporal resolution of 12 s per frame and US was activated 
during the first 4 images. 
 In vitro experimental set up to visualize the transducer’s lesion 
To visualize the lesions created by this type of transducer, the experiments were 
carried out in a commercial polyacrylamide gel phantom (ONDA Corporation, 
Sunnyvale, CA, USA). This type of phantom is a crystal clear synthetic gel that produce 
1 cm 
1 cm 1 cm 1 cm 
1 cm 1 cm 
1 cm 1 cm 1 cm 
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lesions of the same position, size and shape as those produced in real tissue due to the 
application of US power. The lesions appear as white, three-dimensional solid profiles 
inside the clear gel and can detect many defects in US systems such as beam shape 
variations and alignment problems.  
 MR Imaging  
A safe and effective use of thermal therapy requires that the thermal dose to the 
targeted tissue be spatially localized and monitored in real time. In this work, the thermal 
effects of US energy were monitored under MRI guidance. The therapeutic protocol was 
tested using a GPFLEX coil (USA instruments, Cleveland, OH, USA). In order to 
evaluate the thermal capabilities of the transducer, the signal in the polyacrylamide gel 
phantom was acquired. High-resolution MR imaging was performed in order to evaluate 
the lesions of the transducer using a Fast Recovery Fast Spin Echo (FRFSE) T2-weighted 
fast spin echo sequence with the following parameters: TR = 2200 ms, TE= 61.2 ms, slice 
thickness=1.5 mm, matrix=192 x 192, FOV=17 cm, NEX=1 and echo train length (ETL) 
= 16. 
The thermal lesion in the ONDA phantom is shown in figure 8.5. The size and 
shape of the lesion matches the geometry of the transducer element. An AP of 6 W was 
used for a duration of 60 s. 
 
Figure 8.5: Thermal lesion in the ONDA phantom, using 4 MHz frequency, 6 W acoustic power and 60 s 
exposure time. 
Figure 8.6 A shows lesions (deep into the gel) developed in the ONDA gel using 
10 W AP for 5 s, using the 2 X 10 mm2 transducer operating at 4 MHz. The maximum 
temperature as measured by the thermocouple was 92 0C. The lesion depth ranged from 
1 to 2 mm (average 1.8 mm). Figure 8.6 B shows the corresponding lesions in a plane 
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parallel to the transducer face. The average length of these lesions was 10.5 mm, and the 
average width was 2.2 mm. Therefore, the lesion size slightly extends beyond the 2 X 10 
mm2 area due to the conduction effect. Figure 8.6 C shows the MRI image of the lesions 
shown in fig. 8.6 B using T2 weighted FRFSE. Note that because the lesion depth is small 
(1-2 mm) and because of the slice thickness and orientation, some lesions were not clearly 
shown in the MR images. 
 
Figure 8.6: A) The use of 2 X 10 mm2 transducer (operating at 4 MHz), developed deep lesions into the 
ONDA gel, by applying 10 W acoustic power for 5 s. B) the corresponding lesions in a plane parallel to 
the transducer face. C) MRI image of the lesions shown in figure 6B using T1 weighted SPGR. 
  
125 
 Discussion 
The continuous transmission of acoustic energy raises temperature at the targeted 
tissue in the body [215]. The magnitude and duration of this temperature elevation is 
quantified as the “thermal dose” delivered to the targeted tissue.  Different levels of 
thermal dose are associated with different biological outcome such as:  
1. Low temperature hyperthermia, where temperatures are in the range of 43–45 °C, 
2. High temperature thermal ablation, where temperatures are in the range of 50–80 °C 
(or higher).  
In hyperthermia, US energy is used to create a low level thermal rise over several 
minutes or hours that kills cancer cells directly [216]. Conversely, in thermal ablation, a 
situation that was tested in our study, US energy is applied for a short period of time 
(seconds), to create a high temperature rise that coagulates the tissue and induce necrosis 
through protein denaturation [217]. 
The ability of MR imaging to define the tissue to be treated, to measure induced 
temperature changes [218–220], to ensure proper targeting [221] and to image the tissue 
after thermal treatment [222–224], makes MRI a superior modality for guiding and 
monitoring thermal therapies.  
In this study, the thermal capabilities of a small flat rectangular ultrasonic 
transducer were evaluated. This type of transducer can be used in the future for 
intravascular applications, such as the treatment of atherosclerotic plaques with thermal 
ablation. The transducer was evaluated in two different gel phantoms. A commercial 
polyacrylamide gel phantom was used to visualize the size and shape of the thermal 
lesion. A custom made agar/silica/evaporated milk gel phantom was utilized to measure 
temperature elevation above a baseline value, either with a thermocouple or with MR 
thermometry.  
One of the main targets in this study was to create thermal lesions of sufficient 
depth (1-2 mm). This lesion size is sufficient enough to potentially shrink a vascular 
plaque and improve blood flow, without causing harmful thermal damage to the surface 
tissue layer of the artery that is in close proximity to the plaque.  
Due to the phenomenon of conduction, the size of necrosis in a plane parallel to 
the transducer’s face was always slightly higher than the area of the transducer (2 X 10 
mm2). At a deeper level, the size of the lesion was smaller. This is attributed to the fact 
that deeper in the tissue the intensity of US beam drops due to attenuation and so does the 
temperature. If deeper lesions are required, then either the power of the transducer or the 
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exposure time has to be increased. In any case, care should be taken not to exceed 
temperatures above 100 0C, which is the threshold for tissue boiling regardless of the 
exposure time. The thermal ablation time for this application is not a major issue since in 
future clinical trials, the time needed to place a catheter in a vessel (10-30 min) is much 
longer.  
With an AP of 6 W, temperatures as high as 93 0C were reached within 60 s. When 
the AP was increased to 10 W, thermal lesions were created in just 5 s (figure 8.6 A), 
indicating that AP is the main operating acoustic parameter for controlling thermal 
heating. 
A transducer operating at the frequency of 4 MHz was chosen, although a 
transducer operating at higher frequencies could be more beneficial due to lower depth of 
penetration. However, taking into consideration that in future clinical trials, the transducer 
(attached to a catheter), that will be inserted through a vessel is consumable, going to 
higher frequencies means a more expensive and more fragile transducer. 
 Conclusions 
In this chapter the capability of a small flat rectangular ultrasonic transducer to 
create thermal lesions of the appropriate shape and size within seconds, was 
demonstrated. The transducer can be attached to a catheter of appropriate size and guided 
intravenously to the vessel for ultrasonic treatment. In the future, this technology can be 
used for clinical trials primarily to treat atherosclerotic plaques in the vascular system. 
Care will be taken to avoid the escape of debris which will cause further vessel blockage. 
A suction mechanism incorporated to US system would be a good idea for debris 
collection. Such a mechanism was used in atherectomy studies to collect the removed 
particles [225-226].  
Taking into account that the transducer used seems to be able to remove a 
sufficient amount of plaque within seconds without harming adjacent normal tissue 
(artery), in association with the fact that it is not expensive, we can assume that 4 MHz 
US frequency, potentially might be a good choice for the treatment of atherosclerosis. 
Of course, the lesion penetration in plaque tissue might not be the same as it was 
shown in this gel phantom, because the ultrasonic absorption of plaque is unknown and 
might be quite different from the value of absorption in gel phantoms. Another, property 
that is not known is the thermal dose threshold of necrosis for plaque. Although this 
property was reported for many tissues [227], for plaque it is not known at the moment, 
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possibly because researchers in the past did not believe that US would have a role in 
plaque interventions. 
 Summary 
A summary table with the recommended treatment protocol for visualizing the size 
and shape of the thermal lesion using MR imaging and for measuring temperature 
elevation using MR thermometry, is provided below: 
Table 10: Recommended therapeutic protocol for creating thermal lesions with 
sufficient depth within seconds 
Experimental Parameters Values 
Mode Small planar rectangular ultrasonic transducer 
Frequency 4 MHz 
Acoustic Power 6 W 
Exposure time 60 s 
MR imaging 
T2 weighted Fast Recovery Fast Spin Echo (T2wFRFSE) 
TE= 61.2 ms 
 TR = 2200 ms 
 slice thickness =1.5 mm 
 matrix=192 x 192 
 FOV=17 cm 
 flip angle = 200 
 NEX=1 
 ETL = 16 
MR thermometry 
T1 weighted Spoiled Gradient Echo (T1wSPGR) 
TE= 20 ms 
 TR = 40 ms 
 slice thickness = 2.1 mm 
 matrix=128 x 128 
 FOV=21 cm 
 flip angle = 200 
 NEX=1 
 ETL = 16 
Treatment’s outcome 700 mg of mass clot removed 
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 MRI-guided sonothrombolysis in vivo using a rabbit carotid 
artery model 
 Introduction 
In the last few years, an innovative new technology is emerging, which offers FUS 
treatments under MR guidance and monitoring, commonly used by the term MRgFUS. 
Lately, the possibility of using MRgFUS for treating stroke has become an important area 
of investigation, since stroke is the primary focus of sonothrombolysis research due to the 
high mortality rate associated with it. This relatively new approach to sonothrombolysis, 
permits a highly concentrated US energy from an external source, to be deposited into 
millimetre sized focal volumes within the brain, without harming adjacent healthy tissue. 
In this experimental study, the enhancing effect of FUS on TNK-tPA induced 
thrombolysis in the presence of MBs, was evaluated in vivo using an animal model. In 
vivo animal models allow the full biological response of a living organism to US, 
thrombolytics and MBs to be assessed, including the efficacy of the treatment, the ability 
to guide and monitor treatment progress, physiologic alterations and the potential to 
evaluate healthy tissue damage. 
For our in vivo study, a New Zealand adult rabbit was used weighting 
approximately 4 kg. An artificial method was applied to form a blood clot in the right 
carotid artery of the rabbit, which completely blocked the blood flow. Therapeutic US 
waves were delivered to the target with a MR compatible spherically focused transducer, 
4 cm in diameter, focusing at 10 cm and operating at 1.18 MHz. A pulsed US protocol 
that maintains a temperature elevation of 1 0C in the clot (called safe temperature) was 
applied, in order to avoid any adverse health effects, such as thermal heating. The animal 
experiment protocol was approved by the national body in Cyprus responsible for animal 
studies (Ministry of Agriculture, Animal Services). 
The blood clot was exposed to a highly FUS beam and was treated with TNK-tPA 
in association with MBs. The proposed treatment protocol was monitored using MR 
angiography. The goal of this animal study, was to achieve fast and complete flow 
restoration in the carotid artery of the rabbit, with no excess heating. This would be 
advantageous, since the speed of clot lysis for fast and complete artery recanalization is 
the key of therapeutic success in the treatment of stroke patients. Additionally, it would 
be beneficial, if successful clot lysis achieved with the use of low doses of thrombolytic 
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drug and MBs, as this would minimize the risk of undesirable bleeding complications to 
occur, during or after thrombolytic treatment. 
 Rabbit carotid artery model 
Small animal models, such as rats or rabbits are used in sonothrombolysis due to their 
low cost, ease of handling, and data accumulation from previous studies. The carotid 
artery of a rabbit is the preferred in vivo sonothrombolysis model because it fulfils the 
following requirements: 
1. A rabbit carotid artery has arterial dimensions that are comparable to either a smaller-
sized proximal (M1) or distal (M2), segment of a human MCA or a normal-sized MCA 
branch.  
2. Blood clot size/volume comparable to what can be expected in proximal M1 or M2 
occlusions. 
3. A rabbit carotid artery provides a bifurcation (common-internal/external carotid 
artery), to mimic MCA branching, a preferred location for embolic occlusions.  
4. A rabbit carotid artery is in direct contact with FUS because no other tissues are 
involved and thus potential problems of US penetration are avoided. 
 Experimental set up 
The rabbit was anesthetized using a coctail of 500 mg of ketamine (100 mg/mL, 
Aveco, Ford Dodge, IA), 160 mg of xylazine (20 mg/mL, Loyd Laboratories, 
Shenandoah, IA) and 20 mg of acepromazine (10 mg/mL) at a dose of 1 mL/kg. The 
animal experiment protocol was approved by the national body in Cyprus responsible for 
animal studies (Ministry of Agriculture, Animal Services). The neck was shaved and 
through an incision of the overlying tissue layers by an experience veterinarian, the right 
common carotid artery was exposed. The anaesthetized rabbit was set in a decubitus 
position into a customized MR-compatible treatment platform, with its right carotid artery 
on the opening of platform. 
The 1.18 MHz MR compatible FUS transducer was attached on the arm of a 
custom made MR compatible robotic system and immersed into a tank of degassed water 
inside a 1.5T MR scanner (Signa 1.5 T; General Electric, Fairfield, CT). For beam 
targeting, the three axes robotic system positioned the transducer under the blocked artery 
and arranged it at such a distance in order to focus the US beam precisely on the clot.  
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A soft tissue mimicking material (TMM) was positioned between the rabbit’s 
neck and the opening of the treatment platform to improve acoustic coupling and thus, 
ensure US wave propagation. The set up for beam positioning is shown in figure 9.1. 
 
Figure 9.1: Beam positioning for MRgFUS treatment. 
A schematic diagram presenting the experimental set up for in vivo 
sonothrombolysis using a rabbit carotid artery model under MRI guidance, is shown in 
figure 9.2 below. 
 
Figure 9.2: Schematic diagram of experimental set up for MRgFUS sonothrombolysis in vivo using a rabbit 
carotid artery model. 
Rabbit 
Tissue mimicking material 
FUS transducer 
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 MR angiography 
To visualize flow within rabbit’s carotid artery, a 3D time of flight (TOF) MR 
angiography technique was applied, since it is the dominant non-contrast bright-blood 
method for imaging flow within vessel without the need for contrast administration. In 
MR, the signal from spins decreases as it expose to an increasing number of excitation 
pulses, until eventually a saturation value is reached. Consequently, the goal in TOF 
imaging, is to subject the spins of the flowing blood to only a very few excitation pulses 
and the spins of the surrounding stationary tissues to a large number of excitation pulses 
and thus, by manipulating the magnitude of the magnetization, a signal difference 
between blood flow and stationary tissues is achieved. This signal difference is large, 
since the magnitude of magnetization from the moving spins is very large as compared to 
the magnetization from the stationary spins. For maximum enhancement of flow, the 
imaging plane or slab is positioned perpendicular to the blood flow in order to minimize 
the TOF duration of blood through it. As a result, the moving spins enter the slab fully 
magnetized and experience only a few excitation pulses before flow out of this. This 
ensures that the signal from the blood will be relatively large, as it is continuously 
refreshed during image acquisition and hence, it will never experience enough excitation 
pulses to become saturated. In contrast, the stationary tissues remain in the slab during 
image acquisition, give rise to a diminished signal as the magnetization from them is 
saturated due to constant exposure to excitation pulses.  
 Mechanism of thrombus formation 
Although the pathogenesis of thrombus formation in the natural condition can be 
either due to an acute or due to a chronic process, in animals models an artificial method 
is required for in vivo experimental studies. These methods are related to the physiologic 
mechanisms of thrombus formation as described by Virchow [228]. In response to 
Virchow’s triad, thrombosis is the result of alterations in blood flow (stasis or turbulence), 
vascular endothelial injury, or alterations in the constitution of blood 
(hypercoagulability). In animal studies, thrombus formation can be resulted from 
endothelial injury (due to artificial vascular wall trauma), or from stagnant flow (due to 
vessel ligation).  
According to literature, clot preparation methods vary widely, since there is no 
common agreement of how experimental thrombi used for in vivo sonothrombolysis 
studies, should be formed. In this study, the clot preparation technique applied to the 
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rabbit carotid artery model, was accomplished by causing a direct mechanical trauma to 
the vessel’s wall. A 10 mm segment of the right common carotid artery of the rabbit was 
subjected to external compression with a forceps, in order to induce the release of tissue 
factor III, which is necessary for the initiation of thrombin formation. The blockage in 
blood flow due to clot formation at the segment of injury was monitored using a 3D TOF 
images. The signal from inflowing blood appears bright compared to background tissue 
(figure 9.3). On the other hand, the complete absence of signal indicated that there is no 
through plane flow, i.e. the carotid artery was fully occluded.  
 
Figure 9.3: Blood flow produces bright signal in TOF images. 
 Treatment protocol 
The optimized therapeutic protocol established in vitro for the treatment of a MCA 
occlusion occurred superficially, was translated in vivo using a rabbit carotid artery 
model. The low magnetic susceptibility FUS transducer with 1.18 MHz centre frequency, 
was driven in a pulsed mode with a DF of 10 % and a PRF of 100 Hz. Each sonication 
set included a pulse “ON” period (1 ms) followed by a pulse “OFF” period (9 ms) and 
both the “ON” and “OFF” pulses were repeated in succession for the duration of a 30 min 
treatment (i.e., 3000 pulses). 
The main prerequisite of the treatment protocol was to avoid the production of 
excess thermal heating at the target during the sonication period. Since AP is the operating 
parameter that mainly controls thermal heating, the AP was set at same level with that 
used in the corresponding in vitro experimental study, in order to maintain a temperature 
Right common carotid artery 
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change in the clot that does not exceed 1 0C (called safe temperature). Taking into 
consideration that MRgFUS sonothrombolysis relies on non-thermal mechanisms to 
achieve clot lysis, thermometry is not useful for temperature monitoring during the 
procedure.  
Since it is well established that thrombolytic drugs are associated with an 
increased risk of bleeding complications which limit their use, among the goals of this 
animal study was the dose of the thrombolytic TNK-tPA injected to the rabbit to be as 
safe as possible. A Pilot Dose-Escalation Safety Study, was designed to test the 
hypothesis that TNK-PA could be administered safely to patients with AIS within 3 hours 
of onset at doses that may be associated with improvement in clinical neurological 
outcome [177]. The study included dose tiers starting at 0.1 mg/kg to a maximum of 0.5 
mg/kg. The results showed that doses of 0.1 to 0.4 mg/kg are safe, since no sICH occurred, 
while at a dose of 0.5 mg/kg, sICH was observed in 15 % of the patients and the study 
was halted. Based on the results of the above mentioned study, the amount of TNK-tPA 
administered to the rabbit was selected to be as low as 50 % of the final tier and hence, a 
single bolus of 0.25 mg/kg was injected in the jugular vein prior sonication. 
Regarding the safety of MBs dose, a clinical trial performed by Molina et al. [93], 
demonstrated that although the use of low doses of MBs (1.4 mL) in sonothrombolysis 
may be safe, higher doses (2.8 mL) when administered with rt-PA may increase sICH 
rate. Based on the recommended clinical dose in humans for US imaging, which is 0.03 
mL/kg [229] and by comparing blood volume of humans with rabbits, a bolus of 0.02 
mL/kg was calculated to be injected iv through the ear vein prior to sonication. Every 5 
min a bolus of the same dose of MBs was administered to the rabbit, in order to replace 
the bubbles that were destroyed in the process and sustain cavitation. 
 MRI parameters 
The flow of right common artery of the rabbit was monitored using a 3D TOF 
SPGR sequence acquired by the GPFLEX flexible surface imaging coil. The 3D volume 
was covered by a single slab consisting of 88 locations (slices). To minimize the TOF 
duration of blood through the slab and hence to minimize as little as possible the 
saturation of the flowing spins signal, the 3D TOF slab was positioned perpendicularly to 
the expected flow direction.  
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The acquisition parameters used were the following: TR = 26 ms, TE = 6.9 ms, 
Echo Train Length (ETL) = 1, Matrix size = 256 x 128, DFOV = 13.3 x 10.6 cm, Slice 
Thickness = 2.4 mm and Interslice Spacing = 1.2 mm. 
Figure 9.4 shows sonothrombolysis procedure in the carotid artery due to the 
application of FUS waves in synergy with MBs and TNK-tPA. Initially, it is clearly seen 
the complete absence of TOF flow signal, verifying the complete blockage of the artery 
(figure 9.4 A, B and C). During recanalization procedure the TOF flow signal was 
increasing gradually (figure 9.4 D and E), until it was fully recovered, indicating complete 
recanalization (figure 9.4 F). 
 
Figure 9.4: A-C) The complete absence of TOF flow signal confirmed the blockage in blood flow.  D-E) 
The TOF flow signal is gradually increasing during recanalization procedure. F) The TOF signal is fully 
recovered indicating that the artery was completely opened.  
 Discussion 
This experimental study demonstrated the ability of MRgFUS as an adjunct to 
thrombolytic TNK-tPA and in combination with MBs to dissolve a blood clot in vivo, 
using a carotid artery model.  Since this proposed novel technique can be applied 
potentially for the treatment of stroke patients due to MCA occlusion, the carotid artery 
of a rabbit was the preferred in vivo sonothrombolysis model because it has arterial 
dimensions that are comparable to human MCA.  
Using an artificial method, a blood clot was formed into the right carotid artery of 
the rabbit. The artery was in direct contact with FUS beam (no other tissues were 
involved) and hence, penetration problems due to US attenuation, were avoided. The clot 
A B C 
D E F 
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was artificially formed due to a mechanical trauma on artery’s wall, which completely 
blocked the blood flow. Using a 3D TOF MR angiography, which is based on the 
phenomenon of flow-related enhancement, both the capability of the clot model to block 
the carotid artery as well as the ability of therapeutic FUS in synergy with MBs to enhance 
TNK-tPA mediated thrombolysis and hence to accelerate the recanalization rate, were 
monitored. MR angiography provided the opportunity to assess vessel occlusion and 
recanalization, since it is considered as the gold standard in MR imaging. 
 The optimized therapeutic protocol obtained in vitro for the treatment of a MCA 
occlusion occurred superficially, was employed in vivo to unblock the carotid artery of 
the rabbit. The goal was to achieve the maximum thrombolytic efficacy of TNK-tPA for 
fast and complete artery recanalization, without the production of unwanted thermal 
heating.  
The proposed treatment protocol, provided a localized temperature increase at 
beam focus that never exceeded 1˚C and kept the surrounding temperature constant. As a 
result, no excessive heating was produced in the clot and the surrounding tissue. This 
temperature increase at beam focus, was insufficient to account for the increase in clot 
lysis rate, indicating that the accelerated rate of recanalization observed in the study, 
occurred primarily through non-thermal effects such as ARF and cavitation mechanisms 
[53]. 
The enhancement of clot dissolution by non-thermal mechanisms, was mainly 
achieved due to accelerated enzymatic action, which is consistent with prior observations 
from other studies, demonstrating that US at 1 MHz can potentially be applied and 
tolerated in vivo to accelerate therapeutic fibrinolysis [129], [176]. 
Study showed that for the complete opening of the artery, lower doses of 
thrombolytic and MBs were used, compared to the recommended doses. Since one of the 
major problems of thrombolytic therapy is that it is associated with an increased risk of 
intracranial hemorrhage, a potential benefit from the application of the proposed 
technique, is that without affecting the functionality of the treatment, lower doses of 
thrombolytic drug and MBs were used, minimizing the risk to cause hemorrhage. 
The main limitations of this model was the lack of artery and surrounding tissue 
histology, in order to evaluate with care whether biological side effects might be caused 
due to this pulsed FUS regimen. Therefore, more in-depth investigation is required to 
confirm that this technique does not cause irreversible tissue damage, before applied to 
clinical trials. 
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Another limitation of the model was that the proposed therapeutic protocol was 
applied to a superficial target. In future clinical trials such as the treatment of stroke 
patients, tissue penetration may be a crucial factor, since occluded cerebral arteries 
intended as targets for this technology, occurred at depths of about 3 to 10 cm from skull’s 
surface [175]. In such a case, because the US beam will be highly attenuated due to tissue 
absorption, the AP should be significantly increased in order the output at the target to be 
the same with that used in this in vivo model (superficial target). Taking into 
consideration that the acoustic parameters that mainly control heating are AP and DF, a 
significant increase of the AP might cause unwanted local tissue heating. Therefore, to 
avoid excess tissue heating, the DF should be decreased. Since studies by Suchkova et al 
[115] and Holland et al [59] have shown that statistically significant enhancement of the 
fibrinolysis rate was achieved even with a DF of 1 %, extensive parametric studies 
(including AP, DF, exposure time etc.) are needed before this technology apply in 
humans. 
 Conclusions 
In conclusion, the use of a rabbit carotid artery model for sonothrombolysis 
research is feasible and mimics an arterial thrombosis, which is close to MCA occlusion 
in humans. 
This model, clearly demonstrated that 1.18 MHz FUS waves in combination with 
MBs, has the potential to strongly accelerate the action of thrombolytic drug TNK-tPA 
and hence reducing the treatment time needed for opening a vascular occlusion, which is 
a critical factor for future clinical studies.  
In addition, it is important to note that enzymatic clot dissolution occurred through 
non-thermal mechanisms that maximized the penetration and binding of the drug into the 
clot, leading to complete clot dissolution. 
Although the proposed treatment protocol lead to fast and complete recanalization 
of the carotid artery, further research in to the mechanisms, safety and reproducibility of 
this technique are required before applied for future clinical trials, including treatment of 
arterial thrombosis and ischemic stroke. 
 Summary 
A summary table with the treatment protocol applied for the complete opening of a 
fully occluded common right carotid artery of a rabbit is provided below: 
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Table 11: Recommended therapeutic protocol for the treatment of a fully 
occluded carotid artery of a rabbit under MR guidance and monitoring 
Experimental Parameters Values 
Mode MR compatible FUS transducer 
Frequency 1.18 MHz 
Acoustic Power 60 W 
Duty Factor 10 % 
Pulse length  1 ms 
Pulse Repetition Period 10 ms 
Pulse Repetition Frequency 100 Hz 
Treatment time 19 min 
MR angiography technique 3 D time of flight (TOF) 
TNK-tPA concentration 0.25 mg/kg  
MBs dose 0.02 mL/kg prior sonication and every 5 min  
Treatment’s outcome Complete artery recanalization 
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 Conclusions and future directions 
 Conclusions 
In this research, the 3rd generation thrombolytic agent TNK-tPA was used. Using an 
in vitro clot model, its lytic efficacy was determined. Fully retracted porcine clots were 
treated with different concentrations of TNK-tPA in the range between 0.1-1 mg/mL for 
two hours. Even though study results showed that the thrombolytic efficacy of TNK-tPA 
increases with dose, none of the TNK-tPA concentrations used, has led to full clot lysis. 
Therefore, it is confirmed that due to the low efficacy of thrombolytic therapy, the use of 
thrombolytic drug alone is not an effective lytic treatment and hence, should be enhanced 
in order to increase the degree of thrombolysis. The experimental study to measure the 
clot lysis activity of TNK-tPA is presented in appendix 2. 
This research demonstrated that temperature has a significant impact on thrombolytic 
efficacy in clots exposed to TNK-tPA, with the relative reduction in mass of the clot being 
higher at 37 °C compared to 39 °C and 41 °C respectively. According to the experimental 
results, the fibrinolytic activity of TNK-tPA decreases 4 % / 0C increase in temperature 
above the body baseline temperature of 37 °C, where the peak fibrinolytic activity of 
TNK-tPA was observed. Based on this observation, it is recommended that all 
sonothrombolysis studies with TNK-tPA, should be performed at a baseline temperature 
of around 37 °C, in order to take advantage of the peak thrombolytic activity of the drug 
and also to avoid unwanted thermal heating. 
The low and incomplete clot lysis achieved by thrombolytic therapy, has created the 
need to use FUS energy in order to improve efficacy. The use of FUS pulses for clots 
destruction has received attention lately, since it can deposit high amount of energy into 
millimeter sized focal volumes with a low risk of damaging the surrounding healthy 
tissue. Our experimental studies exhibited that FUS as a stand-alone method for clot lysis 
is not effective and should be always applied as an adjunct to thrombolytic agent TNK-
tPA, in order to increase the degree of thrombolysis. Experimental results clearly 
demonstrated that the use of pulsed FUS waves, strongly enhanced enzymatic fibrinolysis 
induced by thrombolytic TNK-tPA. 
Moreover, using in vitro flow clot models, the effect of flow on clot lysis was also 
investigated. Taking into consideration that experimental results confirmed the beneficial 
effect of flow on the speed of fibrinolysis, we can easily come to the conclusion that the 
combination of FUS waves and flow strongly enhanced fibrinolysis acceleration, since 
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both of them are directly responsible for increased transport and penetration of PAs into 
blood clots, leading to enhanced thrombolysis. 
It is of great importance to note that in all experimental studies, clot lysis occurred 
through non-thermal mechanisms, since the main aspect of all proposed treatment 
protocols was to maintain temperature elevation at the target that never exceeded 1 0C. 
Taking into consideration that the contribution of thermal effects on clot lysis was 
negligible, it is reasonable to assume that ARF is the primary non-thermal mechanism 
that dominantly appears in the propagation of pulsed FUS waves through a blood clot and 
contribute to thrombolysis enhancement. 
In addition, study’s outcome exhibited that a frequency of 1.18 MHz produced more 
thrombolysis compared to 0.6 MHz. Bearing in mind that for intracranial occlusion, low-
frequency US has the potential to cause intracerebral hemorrhage, in association with our 
experimental results, a frequency of 1.18 MHz seems to be the best trade-off between the 
sharpness of focus and the depth of penetration and hence, should be employed as the 
optimum choice for transcranial applications such as the treatment of stroke patients. 
Using 1.18 MHz FUS pulses, a linear increasing dependence between transmitted AP 
and thrombolysis efficacy in the range of 20-60 W was observed, verifying that ARF is 
the mechanism of action that is directly responsible for increasing the thrombolysis rate. 
In view of our findings, it is not unreasonable to suggest that ARF created structural 
changes in clots that increased the uptake, penetration, and binding of thrombolytic agent 
into the clot, leading to enhanced thrombolysis. 
The largest thrombolysis enhancement was assessed when clots were treated with 
FUS in synergy with TNK-tPA and MBs, establishing that the administration of MBs on 
a constant rate, is as a way to further accelerate FUS enhanced TNK-tPA mediated 
thrombolysis. Consequently, MBs mediated sonothrombolysis may offer a new approach 
to improve outcomes. Although cavitation activity was not detected in our experiments, 
the negligible contribution of thermal mechanisms on clot lysis, has lead us to make the 
hypothesis that MBs enhanced sonothrombolysis is directly related with cavitation based 
phenomena and most probably with stable cavitation since the physical conditions to 
support the onset of inertial cavitation (MI > 0.7), did not exist in our studies. 
In this research, the effect of operating parameters such as DF, PRF and pulse length 
on thrombolysis efficacy were investigated as well. Study findings have shown that pulse 
length and PRF are directly related with the degree of clot displacement and thus, the 
depth of penetration of the thrombolytic agent into the clot, leading to thrombolysis 
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enhancement. More specifically, our results demonstrated  that it is more effective to 
transmit shorter pulses more frequently, which keep the clot in constant motion, than to 
transmit longer pulses less frequently, which saturate clot’s displacement for an extended 
period of time. In addition, in order to avoid excessive heating, short DF values were 
applied (5 and 10 %). Study results exhibited a 7 % enhancement in thrombolysis 
efficiency using a DF of 5 % (AP = 40 W and pulse length = 0.5 ms) compared to that of 
10 % (AP = 20 W and pulse length = 1 ms). Although thrombolysis enhancement using 
a DF of 5 % might be due to the increased level of ARF (AP was doubled), further 
investigation is required to be done, since the difference in thrombolytic efficacy between 
the DFs examined, is within the statistical error. 
The main limitation of the proposed treatment protocol considers the effect of time 
on clot lysis, since our in vitro experimental studies showed that sonothrombolysis 
treatment is a time consuming procedure. Taking into account that after the incident of 
stroke only 3-6 hours are available to achieve a significant clinical benefit, thrombolysis 
enhancement due to FUS exposures even in the presence of MBs, may not be enough for 
timely recanalization of an occluded cerebral artery. 
Besides FUS studies, experimental studies with unfocused US were also conducted, 
using high frequency small planar rectangular transducers. The degree of clot lysis was 
explored at frequencies 3.7 and 5.2 MHz respectively and study findings showed that 
thrombolysis efficacy decreases with higher frequencies. Although experimental results 
demonstrated that intravascular sonothrombolysis using 3.7 MHz small planar ultrasonic 
transducers, seems to be a promising method for effective clot lysis, the employment of 
lower US frequencies might be more beneficial. Since the optimal frequency for 
endovascular treatment is a trade-off between depth of penetration and thrombolysis 
efficacy, US frequencies in the range between 2-2.5 MHz, potentially may offer a new 
approach for intravascular sonothrombolysis. 
Moreover, the thermal effects of such a transducer were monitored under MRI 
guidance. Using 4 MHz US frequency, a small planar rectangular transducer created 
within seconds thermal lesions with size sufficient enough to potentially shrink a vascular 
plaque and improve blood flow, without harming adjacent normal tissue (artery). Taking 
also into account that such a transducer is not expensive, we can easily come to the 
conclusion that in the future, a frequency of 4 MHz, may be a good choice for the 
treatment of atherosclerosis. 
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Finally, our in vivo study showed that the use of a rabbit carotid artery model for 
sonothrombolysis research is feasible and mimics an arterial thrombosis, which is close 
to MCA occlusion in humans. This novel model, clearly demonstrated that 1.18 MHz 
pulsed FUS waves in combination with MBs, has the potential through non-thermal 
mechanisms to strongly accelerate the enzymatic fibrinolysis induced by thrombolytic 
TNK-tPA, leading to fast and complete opening of the artery. This significant reduction 
in the treatment time needed for opening a vascular occlusion, is a critical factor for future 
clinical studies. 
To our knowledge, none of the animal sonothrombolysis studies so far has claimed 
complete artery recanalization in such a short period of time, through non-thermal 
mechanisms and based on enzymatic clot lysis using a low concentration of thrombolytic 
drug and a low dose of bubbles. In a similar in vivo study by Stone et al. [78], a rabbit 
marginal ear vein clot model was developed. This superficial target was treated with 1 
MHz pulsed FUS in synergy with rt-PA (no bubbles) for 15 min and complete vein 
recanalization was observed at 5 hours post treatment (relative clot size was measured at 
4 %). In some other animal studies, complete artery recanalization was claimed within 
seconds, using 1.5 MHz pulsed FUS alone [82], [86]. Taking into consideration that 
temperature elevation at beam focus is not stated in their studies, in association with the 
very high values of AP used, it is speculated that such a fast clot lysis occurred probably 
due to thermal mechanisms. 
 Future directions 
Concerning the in vitro applications of FUS enhanced TNK-tPA mediated 
thrombolysis in the presence of MBs the following steps should be done: 
1. Detailed investigation into the non-thermal mechanisms behind sonothrombolysis, 
such as ARF and cavitation phenomena. The understanding and identification of these 
mechanisms will allow us to further optimize our treatment protocol. 
2. Conduction of bench-top studies using a FUS transducer that produces a wider beam 
area at the target, in order to treat larger volumes of blood clot. More parametric studies 
are needed to establish a treatment protocol that through non-thermal mechanisms will 
maximize the thrombolytic activity of TNK-tPA. Thrombolysis efficacy in terms of mg 
of blood clot removed with 30 min of treatment should be evaluated. 
3. The use of a different 3rd generation thrombolytic drug with longer half-life and higher 
specificity than TNK-tPA, such as Desmoteplase Salivary PA (DSPA). Desmoteplase has 
  
142 
an extended half-life of 190 min and is more fibrin dependent and fibrin specific than 
TNK-tPA and thus it is of interest to be applied to stroke patients [230]. 
4. Further in vitro experimental studies using small rectangular planar transducers as an 
adjunct to thrombolytic TNK-tPA and in association with MBs are required. 
Thrombolysis efficacy at a wider frequency range should be explored in order to 
determine the optimal frequency for maximum thrombolytic enhancement. 
Concerning the in vivo applications of FUS enhanced TNK-tPA mediated 
thrombolysis in the presence of MBs, the following steps should be done: 
1. More animal models are needed to confirm the safety and reproducibility of this 
technique. 
2. Precise beam positioning using MR thermometry. By applying real-time MR 
thermometry, the location of the beam compared with the blocked artery will be identified 
quickly, ensuring accurate targeting.  
3. Careful evaluation of the biological side effects is required to confirm that this 
technique does not cause tissue damage, especially if cavitation (inertial) exists, which 
may be highly destructive. Therefore, after treatment, histological analysis of the vessel 
walls in the treated arteries and the surrounding tissues is needed, for any indications of 
damage in the endothelial cells or extravascular tissue. 
4. Experimental studies for deeper targets should be conducted, since occluded cerebral 
arteries intended as targets for this technology, occur at depths of about 3 to 10 cm from 
skull’s surface. In such a case, our treatment protocol established in vitro, reproducing 
the physiological situation of a MCA occlusion occurred 4 cm deep into a brain tissue 
mimicking phantom, should be translated in vivo.  
5. The therapeutic protocol should be applied directly to arteries in the brain such as the 
MCA. The main limitation of using a single element spherical transducer for transcranial 
application is the defocusing of the beam and the heating of the skull near the tissue/skull 
interface. To overcome these limitations, a phased arrays technology should be used. 
6. Intravascular sonothrombolysis studies, using an animal model. The small flat 
rectangular transducers will be attached on a catheter and inserted through the artery to 
the site of occlusion. The optimized treatment protocol obtained in vitro that maximized 
the mass clot removed with no excessive heating, will be applied in vivo. The time needed 
for complete recanalization of the occluded artery, in association with the safety of the 
technique will be evaluated. 
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Appendix 1 
Journals and conference publications 
  
Journal papers 
N. Papadopoulos and C. Damianou, “In Vitro Evaluation of Focused Ultrasound-
Enhanced TNK-Tissue Plasminogen Activator-Mediated Thrombolysis,” Journal of 
Stroke and Cerebrovascular Diseases, vol. 25, no. 8, pp. 1864–1877, 2016. 
N. Papadopoulos, C. Yiallouras, and C. Damianou, “The Enhancing Effect of Focused 
Ultrasound on TNK-Tissue Plasminogen Activator-Induced Thrombolysis Using an In 
Vitro Circulating Flow Model,” Journal of Stroke and Cerebrovascular Diseases, vol. 
25, no. 12, pp. 2891–2899, 2016. 
N. Papadopoulos, G. Menikou, M. Yiannakou, C. Yiallouras, K. Ioannides, and C. 
Damianou, “Evaluation of a small flat rectangular therapeutic ultrasonic transducer 
intended for intravascular use,” Ultrasonics, vol. 74, pp. 196–203, 2016. 
N. Papadopoulos, and C. Damianou, “Microbubble-based sonothrombolysis using a 
planar rectangular ultrasonic transducer,” Journal of Stroke and Cerebrovascular 
Diseases, 2017. 
Accepted for publication 
N. Papadopoulos, and C. Damianou, “Review of protocols used in ultrasound 
thrombolysis,” Journal of Stroke and Cerebrovascular Diseases. 
N. Papadopoulos and C. Damianou, “In vitro enzymatic clot lysis using focused 
ultrasound waves as an adjunct to thrombolytic drug tenecteplase and in combination with 
microbubbles,” Springer volume, “Translational Stroke Research.” 
 
Conference papers  
N. Papadopoulos and C. Damianou, “In Vitro Study using MR-Guided Focused   Pulsed    
Ultrasound for Destroying clots using thrombolytic Drugs,” ISTU  International 
Symposium on Therapeutic Ultrasound, March 14-16, Tel Aviv, Israel, 2016. 
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Appendix 2 
Development of an in vitro human clot model to study clot lysis      
activity of different doses of thrombolytic drug TNK-tPA  
To study the efficacy of TNK-tPA, an in-vitro clot lysis model was used. This 
model provides an easy to perform and effective method to measure in vitro the clot lysis 
activity of either newly developed or already known thrombolytic drug such as TNK-tPA.  
For this purpose fully retracted porcine blood clots were formed into various pre-
weighted sterile tubes, carefully numbered (figure 1A). Different concentrations of TNK-
tPA were added to each one of them. To measure the thrombolytic activity of each one of 
the concentrations used, a group of 5 clots was used. Also, a group of clots was served as 
the control, or untreated group. Clots no. 1-4, were treated with TNK-tPA concentrations 
of 0.01 mg/mL, 0.1 mg/mL, 0.5 mg/mL and 1.0 mg/mL respectively and clot no. 5, which 
was served as the control was treated only with saline (figure 1B).  
 
 
 
 
 
 
 
 
 
 
The lowest concentration used was equal to the average maximum TNK-tPA 
concentration in blood (Cmax = 11.6 μg/mL), following iv bolus administration of 50 mg 
(figure 4.1). The clot samples were immersed in a temperature controlled water bath and 
treated at a constant temperature of 37 0C (body’s baseline temperature) for 2 hours, since 
the treatment time for stroke is limited to around 2 hours.  After treatment’s termination, 
all tubes were taken out of the water and inverted for clot lysis observation. Clot 
dissolution and fluid along with the remnants of each one of the clots is clearly seen in 
figure 2A. Then, the clot dissolution and fluid obtained from each sample was carefully 
removed and the tubes were left to dry for 60 min (figure 2B). Percentage clot lysis was 
A B 
 
 
 Figure 1: A) Tubes 1-5 containing blood clot samples, B) Tubes 1-4 treated with different concentrations 
of TNK-tPA. Tube 5 is the control clot. 
Figure 1: A) Tubes 1-5 containing blood clot samples, B) Tubes 1-4 treated with different concentrations 
of TNK-tPA. Tube 5 is the control clot. 
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measured as the relative reduction in the mass of the clot before and after thrombolytic 
treatment.  
 
 
 
 
 
 
 
 
 
Figure 3 shows the percentage clot lysis obtained from each one of the TNK-tPA 
concentrations used. Maximum clot lysis (87%) was obtained when the clots were treated 
with 1.0 mg/mL of TNK-tPA and minimum clot lysis (45 %) was obtained when the clots 
were treated with 0.01 mg /mL of TNK-tPA. 
 
Figure 3: In vitro clot dissolution using various concentrations of TNK-tPA. 
Although study results have shown that thrombolysis efficacy increases with the dose 
of the thrombolytic drug, none of the TNK-tPA concentrations used, led to full clot lysis. 
Since the average concentration of TNK-tPA in blood during 2 hour thrombolytic 
treatment is between 1-11 μg/ml (figure 4.1), we come to the conclusion that the use of 
thrombolytic drug alone is not an effective lytic treatment for thrombotic diseases, due to 
slow and incomplete clot lysis. 
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Figure 2: A) After clots dissolution, fluids along with the remnants of clots. B) Clot dissolution in tubes 
1-4 with increasing order is clearly seen, whereas the control clot is intact. 
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Appendix 3 
Calculation of clot displacement in vitro initiated by FUS pulses 
 
The area of the focal spot size a, is related to the transducer area A (12.57 cm2) by: 
                                       a =
𝜆2𝑓2
𝐴
= 0.13 𝑐𝑚2                                                         (1) 
where, λ is the wavelength in water (0.13 cm), c the speed of sound in water at 37 °C 
(1527 
𝑚
𝑠
), f the focal distance (10 cm) and F the frequency of US waves (1.18 MHz). The 
intensity gain G in a lossless medium for longitudinal waves: 
                                      𝐺 (𝑙𝑜𝑠𝑠𝑙𝑒𝑠) =
 𝐴
a
= (
𝐴𝐹
𝑐𝑓
)2 = 97                                             (2) 
The attenuation loss after traversing a distance x (10 cm) in degassed water is:  
                     Attenuation (loss) = 10− 
𝑥𝑎𝐹
10 = 0.63                                                       (3) 
where, the attenuation coefficient of water α = -0.2 dB/MHz.cm [55].  
So, the net acoustic gain is the product of (2) and (3): 
                                   𝐺 = (
𝐴𝐹
𝑐𝑓
)2 10−
𝑥𝛼𝐹
10 = 61                                                          (4) 
For transmit AP = 60 W, the intensity on transducer’s surface: 𝐼 = 4.77
𝑊
𝑐𝑚2
. So, the 
intensity at beam focus: 𝐼𝑜 = 286 
𝑊
𝑐𝑚2
.  
To calculate the maximum clot displacement (ξmax), the following formula was used:  
                                       𝜉 max =
1
𝜋𝐹
√
𝐼0
2𝜌𝑏𝑐𝑏
= 256 𝑛𝑚                                               (5) 
Since, the values for mass density (ρ) and speed of sound (c) in clot at 37 °C are not 
available, the corresponding values in blood at the same temperature were used (𝜌𝑏 =
1060
𝑘𝑔
𝑚3
 and 𝑐𝑏 = 1530
𝑚
𝑠
) [55]. 
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